{"PMC7216672": [["BackgroundThe association between persistent high-risk human Papillomavirus (hrHPV), squamous cervical cancer (CC), and some vaginal and anal cancers has been well-established [1\u20133].", [["squamous cervical cancer", "ANATOMY", 85, 109], ["CC", "ANATOMY", 111, 113], ["vaginal", "ANATOMY", 125, 132], ["anal cancers", "ANATOMY", 137, 149], ["human Papillomavirus (hrHPV)", "DISEASE", 55, 83], ["squamous cervical cancer", "DISEASE", 85, 109], ["CC", "DISEASE", 111, 113], ["vaginal and anal cancers", "DISEASE", 125, 149], ["human", "ORGANISM", 55, 60], ["Papillomavirus", "ORGANISM", 61, 75], ["hrHPV", "ORGANISM", 77, 82], ["squamous cervical cancer", "CANCER", 85, 109], ["CC", "CANCER", 111, 113], ["vaginal", "ORGANISM_SUBDIVISION", 125, 132], ["anal cancers", "CANCER", 137, 149], ["human", "SPECIES", 55, 60], ["human Papillomavirus", "SPECIES", 55, 75], ["hrHPV", "SPECIES", 77, 82], ["persistent high-risk human Papillomavirus (hrHPV)", "PROBLEM", 34, 83], ["squamous cervical cancer (CC)", "PROBLEM", 85, 114], ["some vaginal and anal cancers", "PROBLEM", 120, 149], ["persistent", "OBSERVATION_MODIFIER", 34, 44], ["high", "OBSERVATION_MODIFIER", 45, 49], ["Papillomavirus", "OBSERVATION", 61, 75], ["squamous", "OBSERVATION_MODIFIER", 85, 93], ["cervical", "ANATOMY", 94, 102], ["cancer", "OBSERVATION", 103, 109], ["vaginal", "ANATOMY", 125, 132], ["anal", "ANATOMY", 137, 141], ["cancers", "OBSERVATION", 142, 149]]], ["Additionally, recent data demonstrated that HPV is also associated with a subset of head and neck cancers (HNCs), including a worldwide range ~20\u201380% of oropharyngeal cancers (OPCs) [4, 5].", [["head and neck cancers", "ANATOMY", 84, 105], ["HNCs", "ANATOMY", 107, 111], ["oropharyngeal cancers", "ANATOMY", 153, 174], ["OPCs", "ANATOMY", 176, 180], ["head and neck cancers", "DISEASE", 84, 105], ["HNCs", "DISEASE", 107, 111], ["oropharyngeal cancers", "DISEASE", 153, 174], ["HPV", "ORGANISM", 44, 47], ["head and neck cancers", "CANCER", 84, 105], ["HNCs", "CANCER", 107, 111], ["oropharyngeal cancers", "CANCER", 153, 174], ["OPCs", "CELL", 176, 180], ["HPV", "SPECIES", 44, 47], ["HPV", "PROBLEM", 44, 47], ["head and neck cancers", "PROBLEM", 84, 105], ["oropharyngeal cancers", "PROBLEM", 153, 174], ["HPV", "OBSERVATION", 44, 47], ["head", "ANATOMY", 84, 88], ["neck", "ANATOMY", 93, 97], ["cancers", "OBSERVATION", 98, 105], ["oropharyngeal", "ANATOMY", 153, 166], ["cancers", "OBSERVATION", 167, 174]]], ["Individuals living with human immunodeficiency virus (HIV+) are more susceptible to infection, less likely to clear the virus and have a higher risk of HPV-related cancers than HIV-negative (HIV-) individuals [6, 7].", [["cancers", "ANATOMY", 164, 171], ["human immunodeficiency virus", "DISEASE", 24, 52], ["infection", "DISEASE", 84, 93], ["cancers", "DISEASE", 164, 171], ["HIV-negative (HIV-)", "DISEASE", 177, 196], ["human immunodeficiency virus", "ORGANISM", 24, 52], ["HPV", "ORGANISM", 152, 155], ["cancers", "CANCER", 164, 171], ["HIV-negative (HIV-) individuals", "ORGANISM", 177, 208], ["human immunodeficiency virus", "SPECIES", 24, 52], ["HIV", "SPECIES", 177, 180], ["HIV", "SPECIES", 191, 194], ["human immunodeficiency virus", "SPECIES", 24, 52], ["HIV", "SPECIES", 54, 57], ["HPV", "SPECIES", 152, 155], ["HIV", "SPECIES", 177, 180], ["HIV", "SPECIES", 191, 194], ["human immunodeficiency virus", "PROBLEM", 24, 52], ["HIV", "PROBLEM", 54, 57], ["infection", "PROBLEM", 84, 93], ["the virus", "PROBLEM", 116, 125], ["HPV", "PROBLEM", 152, 155], ["related cancers", "PROBLEM", 156, 171], ["HIV", "TEST", 177, 180], ["infection", "OBSERVATION", 84, 93], ["cancers", "OBSERVATION", 164, 171]]], ["Although the incidence of overall cancer has decreased in HIV+ individuals with the advent of highly active antiretroviral therapy (HAART), HPV-related CC risk is higher among HIV+ individuals [8, 9].", [["cancer", "ANATOMY", 34, 40], ["cancer", "DISEASE", 34, 40], ["CC", "CHEMICAL", 152, 154], ["cancer", "CANCER", 34, 40], ["HPV", "ORGANISM", 140, 143], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 176, 179], ["overall cancer", "PROBLEM", 26, 40], ["highly active antiretroviral therapy", "TREATMENT", 94, 130], ["HAART", "TREATMENT", 132, 137], ["HPV", "PROBLEM", 140, 143], ["CC risk", "PROBLEM", 152, 159], ["overall", "OBSERVATION_MODIFIER", 26, 33], ["cancer", "OBSERVATION", 34, 40], ["decreased", "OBSERVATION_MODIFIER", 45, 54], ["active", "OBSERVATION_MODIFIER", 101, 107], ["antiretroviral therapy", "OBSERVATION", 108, 130]]], ["Moreover, in HIV+ women, CC tends to respond poorly to recommended therapies, becomes more aggressive, and may have a worse prognosis [6].", [["CC", "CHEMICAL", 25, 27], ["HIV+ women", "ORGANISM", 13, 23], ["CC", "CELL", 25, 27], ["HIV", "SPECIES", 13, 16], ["women", "SPECIES", 18, 23], ["HIV", "SPECIES", 13, 16], ["therapies", "TREATMENT", 67, 76]]], ["With the increase in survival of HIV+ women due to HAART, progression of oncogenic viral infection into malignancy may result in an increased incidence of HPV-associated oropharyngeal, genital, and anal cancers [8\u201310].BackgroundCurrently, the HIV/acquired immunodeficiency syndrome (AIDS) pandemic impacts the poorest and the youngest in low-resource settings [11].", [["malignancy", "ANATOMY", 104, 114], ["oropharyngeal", "ANATOMY", 170, 183], ["genital", "ANATOMY", 185, 192], ["anal cancers", "ANATOMY", 198, 210], ["viral infection", "DISEASE", 83, 98], ["malignancy", "DISEASE", 104, 114], ["oropharyngeal, genital, and anal cancers", "DISEASE", 170, 210], ["HIV/acquired immunodeficiency syndrome", "DISEASE", 243, 281], ["AIDS", "DISEASE", 283, 287], ["HIV+ women", "ORGANISM", 33, 43], ["malignancy", "CANCER", 104, 114], ["HPV", "ORGANISM", 155, 158], ["oropharyngeal", "ORGANISM_SUBDIVISION", 170, 183], ["genital", "ORGANISM_SUBDIVISION", 185, 192], ["anal cancers", "CANCER", 198, 210], ["women", "SPECIES", 38, 43], ["HIV", "SPECIES", 33, 36], ["HPV", "SPECIES", 155, 158], ["HIV+ women", "TREATMENT", 33, 43], ["HAART", "TREATMENT", 51, 56], ["oncogenic viral infection into malignancy", "PROBLEM", 73, 114], ["HPV", "PROBLEM", 155, 158], ["oropharyngeal, genital, and anal cancers", "PROBLEM", 170, 210], ["the HIV/acquired immunodeficiency syndrome", "PROBLEM", 239, 281], ["increase", "OBSERVATION_MODIFIER", 9, 17], ["oncogenic", "OBSERVATION_MODIFIER", 73, 82], ["viral infection", "OBSERVATION", 83, 98], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["HPV", "OBSERVATION", 155, 158], ["oropharyngeal", "ANATOMY", 170, 183], ["genital", "ANATOMY", 185, 192], ["anal", "ANATOMY", 198, 202], ["cancers", "OBSERVATION", 203, 210], ["immunodeficiency syndrome", "OBSERVATION", 256, 281]]], ["HIV+ young women are key populations at high risk for developing HPV-related cancers, particularly in low- and middle-income countries such as Brazil [12, 13].", [["cancers", "ANATOMY", 77, 84], ["cancers", "DISEASE", 77, 84], ["HIV", "ORGANISM", 0, 3], ["women", "ORGANISM", 11, 16], ["cancers", "CANCER", 77, 84], ["HIV", "SPECIES", 0, 3], ["women", "SPECIES", 11, 16], ["HIV", "SPECIES", 0, 3], ["HPV", "SPECIES", 65, 68], ["developing HPV", "PROBLEM", 54, 68], ["related cancers", "PROBLEM", 69, 84], ["HPV", "OBSERVATION", 65, 68], ["cancers", "OBSERVATION", 77, 84]]], ["With the recent approval of the 9-valent HPV vaccine, the risks of persistent HPV infection and HPV-related cervical precancerous lesions and malignancies are expected to decrease significantly [14].", [["cervical precancerous lesions", "ANATOMY", 108, 137], ["malignancies", "ANATOMY", 142, 154], ["HPV infection", "DISEASE", 78, 91], ["cervical precancerous lesions", "DISEASE", 108, 137], ["malignancies", "DISEASE", 142, 154], ["HPV", "ORGANISM", 41, 44], ["HPV", "ORGANISM", 78, 81], ["HPV", "ORGANISM", 96, 99], ["cervical precancerous lesions", "PATHOLOGICAL_FORMATION", 108, 137], ["malignancies", "CANCER", 142, 154], ["HPV", "SPECIES", 41, 44], ["HPV", "SPECIES", 78, 81], ["HPV", "SPECIES", 96, 99], ["the 9-valent HPV vaccine", "TREATMENT", 28, 52], ["persistent HPV infection", "PROBLEM", 67, 91], ["HPV", "PROBLEM", 96, 99], ["cervical precancerous lesions", "PROBLEM", 108, 137], ["malignancies", "PROBLEM", 142, 154], ["persistent", "OBSERVATION_MODIFIER", 67, 77], ["HPV", "OBSERVATION_MODIFIER", 78, 81], ["infection", "OBSERVATION", 82, 91], ["cervical", "ANATOMY", 108, 116], ["precancerous", "OBSERVATION_MODIFIER", 117, 129], ["lesions", "OBSERVATION", 130, 137], ["malignancies", "OBSERVATION", 142, 154]]], ["With the appropriate vaccination rate thresholds, this vaccine provides a logical rationale for increasing screening intervals considering the anticipated decrease in the burden of disease [15].", [["the appropriate vaccination rate thresholds", "TREATMENT", 5, 48], ["this vaccine", "TREATMENT", 50, 62], ["increasing screening intervals", "TREATMENT", 96, 126], ["the burden of disease", "PROBLEM", 167, 188], ["decrease", "OBSERVATION_MODIFIER", 155, 163]]], ["Therefore, understanding the specific prevalence, distribution and concordance of cervical and oral HPV in at-risk women in specific geographic locations will provide further insight into the effectiveness of this new vaccine against oral HPV infection, which has not been proven yet.", [["cervical", "ANATOMY", 82, 90], ["oral", "ANATOMY", 95, 99], ["oral", "ANATOMY", 234, 238], ["HPV infection", "DISEASE", 239, 252], ["cervical", "ORGANISM_SUBDIVISION", 82, 90], ["oral", "ORGANISM_SUBDIVISION", 95, 99], ["HPV", "ORGANISM", 100, 103], ["women", "ORGANISM", 115, 120], ["oral HPV", "ORGANISM", 234, 242], ["women", "SPECIES", 115, 120], ["HPV", "SPECIES", 239, 242], ["cervical and oral HPV", "PROBLEM", 82, 103], ["this new vaccine", "TREATMENT", 209, 225], ["oral HPV infection", "PROBLEM", 234, 252], ["cervical", "ANATOMY", 82, 90], ["infection", "OBSERVATION", 243, 252]]], ["Considering the high burden of HPV-related cancers among HIV+ women and the possible effectiveness of a 9-valent HPV vaccine [16], it is critical to understand the prevalence and types of HPV infections in oral and cervical mucosa in HIV+ women (and matched controls).", [["cancers", "ANATOMY", 43, 50], ["oral", "ANATOMY", 206, 210], ["cervical mucosa", "ANATOMY", 215, 230], ["cancers", "DISEASE", 43, 50], ["HPV infections", "DISEASE", 188, 202], ["HPV", "ORGANISM", 31, 34], ["cancers", "CANCER", 43, 50], ["HIV+ women", "ORGANISM", 57, 67], ["HPV", "ORGANISM", 113, 116], ["HPV", "ORGANISM", 188, 191], ["oral", "ORGANISM_SUBDIVISION", 206, 210], ["cervical mucosa", "MULTI-TISSUE_STRUCTURE", 215, 230], ["women", "ORGANISM", 239, 244], ["HIV", "SPECIES", 57, 60], ["women", "SPECIES", 62, 67], ["HIV", "SPECIES", 234, 237], ["women", "SPECIES", 239, 244], ["HIV", "SPECIES", 57, 60], ["HPV", "SPECIES", 113, 116], ["HPV", "SPECIES", 188, 191], ["HIV", "SPECIES", 234, 237], ["HPV", "PROBLEM", 31, 34], ["related cancers", "PROBLEM", 35, 50], ["HIV+ women", "PROBLEM", 57, 67], ["a 9-valent HPV vaccine", "TREATMENT", 102, 124], ["HPV infections in oral and cervical mucosa", "PROBLEM", 188, 230], ["HPV", "OBSERVATION", 31, 34], ["cancers", "OBSERVATION", 43, 50], ["HPV infections", "OBSERVATION", 188, 202], ["cervical mucosa", "ANATOMY", 215, 230]]], ["However, while several studies on HIV+ women have reported cervical, oral, or anal HPV type distribution [17\u201323], only a few studies have addressed concurrent cervical and oral HPV prevalence [24\u201326].", [["cervical", "ANATOMY", 59, 67], ["oral", "ANATOMY", 69, 73], ["anal", "ANATOMY", 78, 82], ["cervical", "ANATOMY", 159, 167], ["oral", "ANATOMY", 172, 176], ["HIV+ women", "ORGANISM", 34, 44], ["cervical", "ORGANISM_SUBDIVISION", 59, 67], ["oral", "ORGANISM_SUBDIVISION", 69, 73], ["cervical", "ORGANISM_SUBDIVISION", 159, 167], ["oral", "ORGANISM_SUBDIVISION", 172, 176], ["HPV", "ORGANISM", 177, 180], ["HIV", "SPECIES", 34, 37], ["women", "SPECIES", 39, 44], ["HIV", "SPECIES", 34, 37], ["HIV", "TEST", 34, 37], ["cervical, oral, or anal HPV type distribution", "PROBLEM", 59, 104], ["a few studies", "TEST", 119, 132], ["concurrent cervical and oral HPV prevalence", "PROBLEM", 148, 191], ["cervical", "ANATOMY", 59, 67], ["oral", "ANATOMY", 69, 73], ["anal HPV", "ANATOMY", 78, 86], ["cervical", "ANATOMY", 159, 167]]], ["Despite the demonstrated role of HPV in the etiology of CC and the strong evidence suggesting the importance of HPV in the development of OPC [27\u201330], several aspects of the interrelationship between oral and cervical infections remain unknown, specifically in HIV+ female patients.BackgroundThe present study aimed to assess the prevalence, distribution, and concordance of cervical and oral HPV in HIV+ women and matched HIV- controls in the southern region of Brazil, a geographic area with a high incidence of HIV and CC.Study population ::: MethodsParticipants included 115 HIV+ women receiving HAART and 139 HIV- aged 19 to 66 years who attended the Specialized Assistance Service (SAE) for sexually transmitted diseases (STD/AIDS in Maring\u00e1, southern Brazil) from September 2017 to May 2018.", [["oral", "ANATOMY", 200, 204], ["cervical", "ANATOMY", 209, 217], ["cervical", "ANATOMY", 375, 383], ["oral", "ANATOMY", 388, 392], ["CC", "CHEMICAL", 56, 58], ["OPC", "DISEASE", 138, 141], ["oral and cervical infections", "DISEASE", 200, 228], ["CC", "CHEMICAL", 522, 524], ["sexually transmitted diseases", "DISEASE", 697, 726], ["STD", "DISEASE", 728, 731], ["AIDS", "DISEASE", 732, 736], ["HPV", "ORGANISM", 33, 36], ["CC", "CANCER", 56, 58], ["HPV", "ORGANISM", 112, 115], ["oral", "ORGANISM_SUBDIVISION", 200, 204], ["cervical", "ORGAN", 209, 217], ["HIV", "ORGANISM", 261, 264], ["patients", "ORGANISM", 273, 281], ["cervical", "ORGANISM_SUBDIVISION", 375, 383], ["oral", "ORGANISM_SUBDIVISION", 388, 392], ["HPV", "ORGANISM", 393, 396], ["HIV", "ORGANISM", 400, 403], ["women", "ORGANISM", 405, 410], ["HIV", "ORGANISM", 514, 517], ["HIV", "ORGANISM", 579, 582], ["women", "ORGANISM", 584, 589], ["HIV", "SPECIES", 261, 264], ["patients", "SPECIES", 273, 281], ["HIV", "SPECIES", 400, 403], ["women", "SPECIES", 405, 410], ["HIV", "SPECIES", 423, 426], ["HIV", "SPECIES", 514, 517], ["HIV", "SPECIES", 579, 582], ["women", "SPECIES", 584, 589], ["HIV", "SPECIES", 614, 617], ["HPV", "SPECIES", 33, 36], ["HPV", "SPECIES", 112, 115], ["HIV", "SPECIES", 261, 264], ["HIV", "SPECIES", 400, 403], ["HIV", "SPECIES", 423, 426], ["HIV", "SPECIES", 514, 517], ["HIV", "SPECIES", 579, 582], ["HIV", "SPECIES", 614, 617], ["HPV", "PROBLEM", 33, 36], ["HPV", "PROBLEM", 112, 115], ["OPC", "TEST", 138, 141], ["oral and cervical infections", "PROBLEM", 200, 228], ["The present study", "TEST", 292, 309], ["cervical and oral HPV", "PROBLEM", 375, 396], ["HIV and CC", "TREATMENT", 514, 524], ["HAART", "TREATMENT", 600, 605], ["sexually transmitted diseases", "PROBLEM", 697, 726], ["cervical", "ANATOMY", 209, 217], ["infections", "OBSERVATION", 218, 228], ["cervical", "ANATOMY", 375, 383], ["HIV", "OBSERVATION", 514, 517]]], ["Women with the following characteristics were included in this study: women with confirmed HIV/AIDS diagnosis using two different methods were included in the HIV+ group and women with two HIV/AIDS negative results using two different methods were included in the HIV- group.", [["HIV/AIDS", "DISEASE", 91, 99], ["HIV/AIDS", "DISEASE", 189, 197], ["Women", "ORGANISM", 0, 5], ["women", "ORGANISM", 70, 75], ["women", "ORGANISM", 174, 179], ["Women", "SPECIES", 0, 5], ["women", "SPECIES", 70, 75], ["HIV", "SPECIES", 91, 94], ["women", "SPECIES", 174, 179], ["HIV", "SPECIES", 189, 192], ["HIV", "SPECIES", 91, 94], ["HIV", "SPECIES", 159, 162], ["HIV", "SPECIES", 189, 192], ["HIV", "SPECIES", 264, 267], ["this study", "TEST", 58, 68]]], ["Exclusion criteria include: women with previous hysterectomy, pregnant, younger than 19 years, and women with no history of sexual intercourse.Study population ::: MethodsOf the 778 HIV+ women enrolled in the SAE, 324 were eligible for the study.", [["sexual intercourse", "DISEASE", 124, 142], ["SAE", "DISEASE", 209, 212], ["women", "ORGANISM", 28, 33], ["women", "ORGANISM", 99, 104], ["HIV", "ORGANISM", 182, 185], ["women", "ORGANISM", 187, 192], ["women", "SPECIES", 28, 33], ["women", "SPECIES", 99, 104], ["HIV", "SPECIES", 182, 185], ["women", "SPECIES", 187, 192], ["HIV", "SPECIES", 182, 185], ["previous hysterectomy", "TREATMENT", 39, 60], ["MethodsOf", "TEST", 164, 173], ["the study", "TEST", 236, 245], ["hysterectomy", "OBSERVATION", 48, 60]]], ["The sample size was calculated with a HPV cervical prevalence of 50% in HIV+ women [19], a 95% confidence interval (CI), and an error estimate of 5%.", [["cervical", "ANATOMY", 42, 50], ["cervical", "ORGANISM_SUBDIVISION", 42, 50], ["women", "ORGANISM", 77, 82], ["HIV", "SPECIES", 72, 75], ["women", "SPECIES", 77, 82], ["HIV", "SPECIES", 72, 75], ["The sample size", "TEST", 0, 15], ["a HPV cervical prevalence", "TEST", 36, 61], ["CI", "TEST", 116, 118], ["an error estimate", "TEST", 125, 142], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["With an increase of 10% for possible participant losses, the total sample size was fixed at 138 randomly selected women.", [["women", "ORGANISM", 114, 119], ["women", "SPECIES", 114, 119], ["participant losses", "PROBLEM", 37, 55], ["the total sample size", "TEST", 57, 78], ["increase", "OBSERVATION_MODIFIER", 8, 16], ["size", "OBSERVATION_MODIFIER", 74, 78]]], ["SAE also provides other services and HIV screening.", [["SAE", "DISEASE", 0, 3], ["HIV", "SPECIES", 37, 40], ["HIV screening", "TEST", 37, 50]]], ["Therefore, to obtain a comparable sample, 138 matched controls from the list of patients served by the SAE were identified.", [["SAE", "DISEASE", 103, 106], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["a comparable sample", "TEST", 21, 40]]], ["Written informed consent was obtained from 254 women, and based on their HIV serology status, participants were assigned to the HIV+ (n = 115) or HIV- group (n = 139).", [["women", "ORGANISM", 47, 52], ["HIV", "ORGANISM", 73, 76], ["participants", "ORGANISM", 94, 106], ["women", "SPECIES", 47, 52], ["HIV", "SPECIES", 73, 76], ["participants", "SPECIES", 94, 106], ["HIV", "SPECIES", 146, 149], ["HIV", "SPECIES", 73, 76], ["HIV", "SPECIES", 128, 131], ["HIV", "SPECIES", 146, 149], ["the HIV", "TEST", 124, 131], ["HIV", "PROBLEM", 146, 149]]], ["Participants were interviewed using a standardized questionnaire to obtain demographic information (e.g., age, educational attainment, household income, race/ethnicity); tobacco and alcohol use/abuse; obstetric and gynecologic history (e.g., age at menarche, contraceptive use, number of pregnancies); CC screening, and sexual behaviors (e.g., age at first intercourse, number of sexual partners).", [["alcohol", "CHEMICAL", 182, 189], ["CC", "CHEMICAL", 302, 304], ["sexual behaviors", "DISEASE", 320, 336], ["alcohol", "CHEMICAL", 182, 189], ["tobacco", "ORGANISM", 170, 177], ["Participants", "SPECIES", 0, 12], ["tobacco", "SPECIES", 170, 177], ["obstetric and gynecologic history", "PROBLEM", 201, 234], ["pregnancies)", "PROBLEM", 288, 300], ["CC screening", "TEST", 302, 314]]], ["Data regarding HIV infection and adherence to HAART were obtained from SAE medical records.Sample collection ::: MethodsNursing staff contacted all women, administered the questionnaire, and collected the cervical and oropharyngeal samples.", [["cervical", "ANATOMY", 205, 213], ["oropharyngeal samples", "ANATOMY", 218, 239], ["HIV infection", "DISEASE", 15, 28], ["HIV", "ORGANISM", 15, 18], ["women", "ORGANISM", 148, 153], ["cervical", "ORGANISM_SUBDIVISION", 205, 213], ["oropharyngeal samples", "CANCER", 218, 239], ["HIV", "SPECIES", 15, 18], ["women", "SPECIES", 148, 153], ["HIV", "SPECIES", 15, 18], ["HIV infection", "PROBLEM", 15, 28], ["HAART", "TREATMENT", 46, 51], ["infection", "OBSERVATION", 19, 28], ["cervical", "ANATOMY", 205, 213], ["oropharyngeal", "ANATOMY", 218, 231]]], ["Ecto\u2212/endocervical samples were collected using an Ayre\u2019s spatula and cytobrush for cervical cytology and polymerase chain reaction (PCR) for HPV; the samples for HPV testing were stored in ThinPrep\u00ae Pap Test solution.", [["endocervical samples", "ANATOMY", 6, 26], ["cytobrush", "ANATOMY", 70, 79], ["cervical", "ANATOMY", 84, 92], ["samples", "ANATOMY", 151, 158], ["endocervical samples", "CANCER", 6, 26], ["cervical", "ORGAN", 84, 92], ["HPV", "ORGANISM", 142, 145], ["HPV", "ORGANISM", 163, 166], ["HPV", "SPECIES", 142, 145], ["HPV", "SPECIES", 163, 166], ["endocervical samples", "TEST", 6, 26], ["an Ayre\u2019s spatula", "TEST", 48, 65], ["cytobrush", "TEST", 70, 79], ["cervical cytology", "TEST", 84, 101], ["polymerase chain reaction", "TEST", 106, 131], ["PCR", "TEST", 133, 136], ["HPV", "PROBLEM", 142, 145], ["the samples", "TEST", 147, 158], ["HPV testing", "TEST", 163, 174], ["endocervical", "ANATOMY", 6, 18], ["cervical", "ANATOMY", 84, 92]]], ["The conventional cytological smears were sent to the Clinical Cytology Laboratory at State University of Maring\u00e1 (UEM) and were graded according to the Bethesda System [31].Sample collection ::: MethodsFull-mouth oral/oropharyngeal scraping, including the cheeks, tongue, palate, tonsils, and oropharynx, was performed using a sterile brush with soft bristles; samples were stored in ThinPrep\u00ae Pap Test solution.", [["oral", "ANATOMY", 213, 217], ["oropharyngeal", "ANATOMY", 218, 231], ["cheeks", "ANATOMY", 256, 262], ["tongue", "ANATOMY", 264, 270], ["palate", "ANATOMY", 272, 278], ["tonsils", "ANATOMY", 280, 287], ["oropharynx", "ANATOMY", 293, 303], ["brush", "ANATOMY", 335, 340], ["bristles", "ANATOMY", 351, 359], ["samples", "ANATOMY", 361, 368], ["oral", "ORGANISM_SUBDIVISION", 213, 217], ["oropharyngeal", "ORGANISM_SUBDIVISION", 218, 231], ["cheeks", "ORGANISM_SUBDIVISION", 256, 262], ["tongue", "ORGAN", 264, 270], ["palate", "ORGAN", 272, 278], ["tonsils", "ORGAN", 280, 287], ["oropharynx", "ORGAN", 293, 303], ["The conventional cytological smears", "TEST", 0, 35], ["MethodsFull", "TREATMENT", 195, 206], ["oropharyngeal scraping", "TREATMENT", 218, 240], ["a sterile brush with soft bristles", "TREATMENT", 325, 359], ["mouth", "ANATOMY", 207, 212], ["oropharyngeal", "ANATOMY", 218, 231], ["scraping", "OBSERVATION", 232, 240], ["cheeks", "ANATOMY", 256, 262], ["tongue", "ANATOMY", 264, 270], ["palate", "ANATOMY", 272, 278], ["tonsils", "ANATOMY", 280, 287], ["oropharynx", "ANATOMY", 293, 303], ["soft bristles", "OBSERVATION_MODIFIER", 346, 359]]], ["Moreover, a gargle sample was obtained by having the participant gargle with 10 mL of 0.9% sterile saline for a total of 30 s (10s, rinse; 5 s, gargle; 10s rinse; 5 s, gargle), collected in a sterile cup and stored at \u2212 4 \u00b0C [20, 32].", [["gargle sample", "ANATOMY", 12, 25], ["cup", "ANATOMY", 200, 203], ["saline", "SIMPLE_CHEMICAL", 99, 105], ["participant", "SPECIES", 53, 64], ["a gargle sample", "TEST", 10, 25], ["0.9% sterile saline", "TREATMENT", 86, 105], ["rinse", "TREATMENT", 132, 137], ["a sterile cup", "TREATMENT", 190, 203]]], ["All oral/oropharyngeal samples will be referred as \u201coral samples.\u201dHPV DNA testing ::: MethodsDetection and typing of HPV were performed using the Kit Multiplex XGEN MULTI HPV CHIP HS12 (Mobius Life Science), following the manufacturer\u2019s instructions.", [["oral", "ANATOMY", 4, 8], ["oropharyngeal samples", "ANATOMY", 9, 30], ["oral samples", "ANATOMY", 52, 64], ["oral", "ORGANISM_SUBDIVISION", 4, 8], ["oropharyngeal samples", "CANCER", 9, 30], ["oral samples", "CANCER", 52, 64], ["HPV", "ORGANISM", 66, 69], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["HPV", "ORGANISM", 117, 120], ["HPV", "SPECIES", 66, 69], ["HPV", "SPECIES", 117, 120], ["All oral/oropharyngeal samples", "TREATMENT", 0, 30], ["MethodsDetection", "TEST", 86, 102], ["typing of HPV", "TEST", 107, 120], ["the Kit Multiplex XGEN MULTI HPV CHIP HS12", "TREATMENT", 142, 184], ["oropharyngeal", "ANATOMY", 9, 22]]], ["The multiplex detected the following 36 HPV types: 18 hrHPV (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 e 82) and 18 low-risk HPV (lrHPV) (6, 11, 40, 42, 43, 44, 54, 55, 61, 62, 67, 69, 70, 71, 72, 81, 84 e 89).", [["hrHPV", "ORGANISM", 54, 59], ["HPV", "ORGANISM", 150, 153], ["The multiplex", "TEST", 0, 13], ["HPV types", "TEST", 40, 49], ["hrHPV", "TEST", 54, 59]]], ["An additional HPV universal probe was used to detect other, non-specified types of HPV.", [["HPV", "ORGANISM", 83, 86], ["HPV", "SPECIES", 14, 17], ["HPV", "SPECIES", 83, 86], ["An additional HPV universal probe", "TREATMENT", 0, 33], ["HPV", "PROBLEM", 83, 86], ["HPV", "OBSERVATION", 83, 86]]], ["Samples with invalid outcomes were retested, and the second result was considered definitive.", [["Samples", "ANATOMY", 0, 7]]], ["Women were considered positive for oropharyngeal HPV if one of the samples, oral and/or scraping, was positive for HPV.", [["samples", "ANATOMY", 67, 74], ["oral", "ANATOMY", 76, 80], ["oropharyngeal HPV", "DISEASE", 35, 52], ["Women", "ORGANISM", 0, 5], ["oropharyngeal HPV", "ORGANISM", 35, 52], ["oral", "ORGANISM_SUBDIVISION", 76, 80], ["HPV", "ORGANISM", 115, 118], ["Women", "SPECIES", 0, 5], ["HPV", "SPECIES", 49, 52], ["HPV", "SPECIES", 115, 118], ["oropharyngeal HPV", "PROBLEM", 35, 52], ["the samples", "TEST", 63, 74], ["oral and/or scraping", "TEST", 76, 96], ["HPV", "PROBLEM", 115, 118]]], ["Furthermore, women were considered negative for oropharyngeal HPV if their oral and scraping samples were negative for HPV.Statistical analysis ::: MethodsStatistical analyses were performed using the GraphPad Prism 6.0 (San Diego, California, USA) software.", [["oropharyngeal", "ANATOMY", 48, 61], ["oral", "ANATOMY", 75, 79], ["samples", "ANATOMY", 93, 100], ["women", "ORGANISM", 13, 18], ["HPV", "ORGANISM", 62, 65], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["HPV", "ORGANISM", 119, 122], ["women", "SPECIES", 13, 18], ["HPV", "SPECIES", 62, 65], ["HPV", "SPECIES", 119, 122], ["oropharyngeal HPV", "PROBLEM", 48, 65], ["their oral and scraping samples", "TEST", 69, 100], ["HPV", "PROBLEM", 119, 122], ["MethodsStatistical analyses", "TEST", 148, 175], ["the GraphPad Prism", "TEST", 197, 215]]], ["For univariate analysis (unadjusted odds ratios [ORs]), categorical variables were compared with HPV infection using the chi-squared and Fisher\u2019s exact test.", [["HPV infection", "DISEASE", 97, 110], ["HPV", "ORGANISM", 97, 100], ["HPV", "SPECIES", 97, 100], ["univariate analysis", "TEST", 4, 23], ["categorical variables", "TEST", 56, 77], ["HPV infection", "PROBLEM", 97, 110], ["exact test", "TEST", 146, 156]]], ["Crude ORs and 95% confidence intervals (CIs) were calculated.", [["CIs", "TEST", 40, 43]]], ["A P-value < 0.05 was considered significant.ResultsA total of 254 (115 HIV+ and 139 HIV-) women were included in the study, with all 254 cervical and 508 oral samples (oral scraping and gargle) having sufficient DNA for HPV assessment.", [["cervical", "ANATOMY", 137, 145], ["oral samples", "ANATOMY", 154, 166], ["oral", "ANATOMY", 168, 172], ["gargle", "ANATOMY", 186, 192], ["women", "ORGANISM", 90, 95], ["cervical", "CANCER", 137, 145], ["oral samples", "TISSUE", 154, 166], ["oral", "ORGANISM_SUBDIVISION", 168, 172], ["DNA", "CELLULAR_COMPONENT", 212, 215], ["HIV", "SPECIES", 71, 74], ["HIV", "SPECIES", 84, 87], ["women", "SPECIES", 90, 95], ["HIV", "SPECIES", 71, 74], ["HIV", "SPECIES", 84, 87], ["HPV", "SPECIES", 220, 223], ["A P-value", "TEST", 0, 9], ["ResultsA total", "TEST", 44, 58], ["HIV", "TEST", 71, 74], ["the study", "TEST", 113, 122], ["oral scraping", "TREATMENT", 168, 181], ["HPV assessment", "TEST", 220, 234], ["cervical", "ANATOMY", 137, 145]]], ["All 254 (100%) participants had conclusive HPV test results from both anatomical sites.ResultsDemographic and clinical characteristics of the two groups of patients are presented in Table 1.", [["participants", "ORGANISM", 15, 27], ["HPV", "ORGANISM", 43, 46], ["patients", "ORGANISM", 156, 164], ["participants", "SPECIES", 15, 27], ["patients", "SPECIES", 156, 164], ["HPV", "SPECIES", 43, 46], ["conclusive HPV test", "TEST", 32, 51]]], ["The median age was 42.17 \u00b1 10.18 years old for HIV+ women and 41.4 \u00b1 12.31 years old for HIV- women.", [["women", "ORGANISM", 52, 57], ["HIV", "ORGANISM", 89, 92], ["women", "ORGANISM", 94, 99], ["HIV", "SPECIES", 47, 50], ["women", "SPECIES", 52, 57], ["HIV", "SPECIES", 89, 92], ["women", "SPECIES", 94, 99], ["HIV", "SPECIES", 47, 50], ["HIV", "SPECIES", 89, 92], ["HIV", "PROBLEM", 47, 50], ["HIV", "PROBLEM", 89, 92]]], ["Compared to HIV- women, HIV+ women were significantly more likely to have less than 8 years of schooling (P = 0.0003), non-white skin color (P = 0.009), their first sexual intercourse at < 18 years old (P = 0.04), more than two sexual partners (P = 0.004 for 2\u20137 partners and P = 0.007 for > 7 partners), and a higher number of parities (P = 0.0006 for 1\u20132 parities and P 0.0001 for \u22653 parities), and were less likely to report screening for CC within the past three years (P = 0.01).", [["skin", "ANATOMY", 129, 133], ["CC", "CHEMICAL", 442, 444], ["HIV- women", "ORGANISM", 12, 22], ["HIV+ women", "ORGANISM", 24, 34], ["skin", "ORGAN", 129, 133], ["HIV", "SPECIES", 12, 15], ["women", "SPECIES", 17, 22], ["HIV", "SPECIES", 24, 27], ["women", "SPECIES", 29, 34], ["HIV", "SPECIES", 12, 15], ["HIV", "SPECIES", 24, 27], ["HIV+ women", "PROBLEM", 24, 34], ["non-white skin color", "TEST", 119, 139], ["skin", "ANATOMY", 129, 133]]], ["HIV- women were, however, more likely to be a widowed (P = 0.004).", [["HIV", "ORGANISM", 0, 3], ["women", "ORGANISM", 5, 10], ["HIV-", "SPECIES", 0, 4], ["women", "SPECIES", 5, 10], ["HIV", "SPECIES", 0, 3]]]], "fd4af40a080312187195d0dadb13f73de0e06508": [["IntroductionNovel coronavirus disease 2019 (COVID- 19) was first reported in Wuhan, Hubei province, and rapidly spread to other provinces/regions of China and other countries [1] .", [["coronavirus disease", "DISEASE", 18, 37], ["COVID- 19", "CHEMICAL", 44, 53], ["Novel coronavirus disease", "PROBLEM", 12, 37], ["COVID", "TEST", 44, 49], ["coronavirus disease", "OBSERVATION", 18, 37]]], ["At the time of writing this article, COVID-19 has affected 74,680 people.", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72], ["COVID", "TEST", 37, 42]]], ["The epidemiological, clinical, laboratory, and radiologic (thinsection computed tomography [CT]) characteristics have been published recently [2] [3] [4] [5] .", [["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 142, 157], ["radiologic (thinsection computed tomography", "TEST", 47, 90]]], ["The radiographic features at presentation included peripheral and bilateral ground-glass opacities (GGO), which progressed with consolidation in most of COVID-19 patients [6] [7] [8] [9] .IntroductionThe alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were reportedly increasing 23-100% and 70-78% in severe acute respiratory syndrome (SARS) patients, respectively [10] [11] [12] [13] [14] .", [["GGO", "DISEASE", 100, 103], ["alanine", "CHEMICAL", 204, 211], ["aspartate", "CHEMICAL", 239, 248], ["acute respiratory syndrome", "DISEASE", 335, 361], ["SARS", "DISEASE", 363, 367], ["alanine", "CHEMICAL", 204, 211], ["aspartate", "CHEMICAL", 239, 248], ["patients", "ORGANISM", 162, 170], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 204, 228], ["ALT", "SIMPLE_CHEMICAL", 230, 233], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 239, 265], ["AST", "SIMPLE_CHEMICAL", 267, 270], ["patients", "ORGANISM", 369, 377], ["alanine aminotransferase", "PROTEIN", 204, 228], ["ALT", "PROTEIN", 230, 233], ["aspartate aminotransferase", "PROTEIN", 239, 265], ["AST", "PROTEIN", 267, 270], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 369, 377], ["peripheral and bilateral ground-glass opacities", "PROBLEM", 51, 98], ["consolidation", "PROBLEM", 128, 141], ["COVID", "TEST", 153, 158], ["The alanine aminotransferase", "TEST", 200, 228], ["ALT", "TEST", 230, 233], ["aspartate aminotransferase", "TEST", 239, 265], ["AST) levels", "TEST", 267, 278], ["severe acute respiratory syndrome", "PROBLEM", 328, 361], ["peripheral", "ANATOMY_MODIFIER", 51, 61], ["bilateral", "ANATOMY_MODIFIER", 66, 75], ["ground-glass opacities", "OBSERVATION", 76, 98], ["GGO", "OBSERVATION_MODIFIER", 100, 103], ["consolidation", "OBSERVATION", 128, 141], ["severe", "OBSERVATION_MODIFIER", 328, 334], ["acute", "OBSERVATION_MODIFIER", 335, 340], ["respiratory syndrome", "OBSERVATION", 341, 361]]], ["A recent study took biopsy samples from the lung, liver, and heart tissue of a patient Bin Zhang and Jue Zhang contributed equally to this work.IntroductionThis article is part of the Topical Collection on Infection and Inflammation * Ke Yang tmyangke2019@sina.com * Shuixing Zhang shui7515@126.com who died of COVID-19 [15] .", [["biopsy samples", "ANATOMY", 20, 34], ["lung", "ANATOMY", 44, 48], ["liver", "ANATOMY", 50, 55], ["heart tissue", "ANATOMY", 61, 73], ["Infection", "DISEASE", 206, 215], ["Inflammation", "DISEASE", 220, 232], ["COVID-19", "CHEMICAL", 311, 319], ["biopsy samples", "CANCER", 20, 34], ["lung", "ORGAN", 44, 48], ["liver", "ORGAN", 50, 55], ["heart tissue", "TISSUE", 61, 73], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["A recent study", "TEST", 0, 14], ["biopsy samples", "TEST", 20, 34], ["the Topical Collection", "TREATMENT", 180, 202], ["Infection", "PROBLEM", 206, 215], ["Inflammation", "PROBLEM", 220, 232], ["COVID", "TEST", 311, 316], ["lung", "ANATOMY", 44, 48], ["liver", "ANATOMY", 50, 55], ["heart", "ANATOMY", 61, 66], ["tissue", "ANATOMY_MODIFIER", 67, 73], ["Infection", "OBSERVATION", 206, 215]]], ["The pathological findings of the lung showed bilateral diffuse alveolar damage with cellular fibromyxoid exudates and interstitial mononuclear inflammatory infiltrates (mainly lymphocytes).", [["lung", "ANATOMY", 33, 37], ["alveolar", "ANATOMY", 63, 71], ["cellular", "ANATOMY", 84, 92], ["interstitial mononuclear inflammatory infiltrates", "ANATOMY", 118, 167], ["lymphocytes", "ANATOMY", 176, 187], ["alveolar damage", "DISEASE", 63, 78], ["lung", "ORGAN", 33, 37], ["alveolar", "TISSUE", 63, 71], ["cellular", "CELL", 84, 92], ["interstitial mononuclear inflammatory infiltrates", "PATHOLOGICAL_FORMATION", 118, 167], ["lymphocytes", "CELL", 176, 187], ["interstitial mononuclear inflammatory infiltrates", "CELL_TYPE", 118, 167], ["lymphocytes", "CELL_TYPE", 176, 187], ["bilateral diffuse alveolar damage", "PROBLEM", 45, 78], ["cellular fibromyxoid exudates", "PROBLEM", 84, 113], ["interstitial mononuclear inflammatory infiltrates", "PROBLEM", 118, 167], ["lung", "ANATOMY", 33, 37], ["bilateral", "ANATOMY_MODIFIER", 45, 54], ["diffuse", "OBSERVATION_MODIFIER", 55, 62], ["alveolar", "ANATOMY_MODIFIER", 63, 71], ["damage", "OBSERVATION", 72, 78], ["cellular", "OBSERVATION_MODIFIER", 84, 92], ["fibromyxoid exudates", "OBSERVATION", 93, 113], ["interstitial", "ANATOMY_MODIFIER", 118, 130], ["mononuclear", "OBSERVATION_MODIFIER", 131, 142], ["inflammatory", "OBSERVATION_MODIFIER", 143, 155], ["infiltrates", "OBSERVATION", 156, 167]]], ["The biopsy specimens of the liver showed moderate microvascular steatosis and mild lobular and portal activity, suggesting the injury maybe induced by novel coronavirus or drugs.", [["biopsy specimens", "ANATOMY", 4, 20], ["liver", "ANATOMY", 28, 33], ["microvascular", "ANATOMY", 50, 63], ["lobular", "ANATOMY", 83, 90], ["portal", "ANATOMY", 95, 101], ["steatosis", "DISEASE", 64, 73], ["biopsy specimens", "CANCER", 4, 20], ["liver", "ORGAN", 28, 33], ["microvascular", "TISSUE", 50, 63], ["lobular", "PATHOLOGICAL_FORMATION", 83, 90], ["portal", "MULTI-TISSUE_STRUCTURE", 95, 101], ["coronavirus", "ORGANISM", 157, 168], ["The biopsy specimens of the liver", "TEST", 0, 33], ["moderate microvascular steatosis", "PROBLEM", 41, 73], ["mild lobular and portal activity", "PROBLEM", 78, 110], ["the injury", "PROBLEM", 123, 133], ["novel coronavirus", "PROBLEM", 151, 168], ["liver", "ANATOMY", 28, 33], ["moderate", "OBSERVATION_MODIFIER", 41, 49], ["microvascular", "ANATOMY", 50, 63], ["steatosis", "OBSERVATION", 64, 73], ["mild", "OBSERVATION_MODIFIER", 78, 82], ["lobular", "OBSERVATION", 83, 90], ["portal activity", "ANATOMY", 95, 110], ["injury", "OBSERVATION", 127, 133]]], ["No obvious histological changes were seen in the heart specimens, suggesting coronavirus infection may not directly damage the heart.", [["heart specimens", "ANATOMY", 49, 64], ["heart", "ANATOMY", 127, 132], ["coronavirus infection", "DISEASE", 77, 98], ["heart", "ORGAN", 49, 54], ["coronavirus", "ORGANISM", 77, 88], ["heart", "ORGAN", 127, 132], ["coronavirus", "SPECIES", 77, 88], ["obvious histological changes", "PROBLEM", 3, 31], ["the heart specimens", "TEST", 45, 64], ["coronavirus infection", "PROBLEM", 77, 98], ["obvious", "OBSERVATION_MODIFIER", 3, 10], ["histological", "OBSERVATION", 11, 23], ["heart", "ANATOMY", 49, 54], ["suggesting", "UNCERTAINTY", 66, 76], ["coronavirus", "OBSERVATION_MODIFIER", 77, 88], ["infection", "OBSERVATION", 89, 98], ["heart", "ANATOMY", 127, 132]]], ["Although we already knew the pathological changes of multiple organs in a critically ill patient with COVID-19, little is known about the potential association between the temporal dynamic changes of the lung and other organs.", [["organs", "ANATOMY", 62, 68], ["lung", "ANATOMY", 204, 208], ["organs", "ANATOMY", 219, 225], ["critically ill", "DISEASE", 74, 88], ["COVID-19", "CHEMICAL", 102, 110], ["organs", "ORGAN", 62, 68], ["patient", "ORGANISM", 89, 96], ["lung", "ORGAN", 204, 208], ["organs", "ORGAN", 219, 225], ["patient", "SPECIES", 89, 96], ["COVID", "TEST", 102, 107], ["the temporal dynamic changes of the lung and other organs", "PROBLEM", 168, 225], ["multiple", "OBSERVATION_MODIFIER", 53, 61], ["organs", "ANATOMY", 62, 68], ["temporal", "ANATOMY_MODIFIER", 172, 180], ["dynamic", "OBSERVATION", 181, 188], ["lung", "ANATOMY", 204, 208], ["organs", "ANATOMY", 219, 225]]], ["The aim of this study, therefore, was to quantify the severity of lung involvement on chest CT and to determine the relationship between lung severity and laboratory parameters of infection and organ function in different disease stages, which might benefit patient care.Materials and methodsThe retrospective study was approved by the ethics committee of the First Affiliated Hospital of Jinan University, with a waiver of informed consent.", [["lung", "ANATOMY", 66, 70], ["chest", "ANATOMY", 86, 91], ["lung", "ANATOMY", 137, 141], ["organ", "ANATOMY", 194, 199], ["infection", "DISEASE", 180, 189], ["lung", "ORGAN", 66, 70], ["chest", "ORGAN", 86, 91], ["lung", "ORGAN", 137, 141], ["organ", "ORGAN", 194, 199], ["patient", "ORGANISM", 258, 265], ["patient", "SPECIES", 258, 265], ["this study", "TEST", 11, 21], ["lung involvement", "PROBLEM", 66, 82], ["chest CT", "TEST", 86, 94], ["lung severity", "PROBLEM", 137, 150], ["laboratory parameters", "TEST", 155, 176], ["infection", "PROBLEM", 180, 189], ["organ function", "PROBLEM", 194, 208], ["different disease stages", "PROBLEM", 212, 236], ["The retrospective study", "TEST", 292, 315], ["lung", "ANATOMY", 66, 70], ["involvement", "OBSERVATION", 71, 82], ["chest", "ANATOMY", 86, 91], ["lung", "ANATOMY", 137, 141], ["severity", "OBSERVATION", 142, 150], ["infection", "OBSERVATION", 180, 189]]], ["From January 01 to February 18, 2020, a total of 103 COVID-19 patients were admitted to The First People's Hospital of Tianmen City, Hubei Province.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["All the patients were positive for COVID-19 via real-time fluorescence polymerase chain reaction (RT-PCR) for COVID-19 nucleic acid by bronchoalveolar lavage, endotracheal aspirate, nasopharyngeal swab, or oropharyngeal swab.", [["bronchoalveolar lavage", "ANATOMY", 135, 157], ["endotracheal", "ANATOMY", 159, 171], ["nasopharyngeal swab", "ANATOMY", 182, 201], ["oropharyngeal swab", "ANATOMY", 206, 224], ["COVID-19 nucleic acid", "CHEMICAL", 110, 131], ["patients", "ORGANISM", 8, 16], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 135, 157], ["endotracheal aspirate", "MULTI-TISSUE_STRUCTURE", 159, 180], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 182, 201], ["oropharyngeal", "ORGANISM_SUBDIVISION", 206, 219], ["swab", "ORGANISM_SUBSTANCE", 220, 224], ["COVID-19", "DNA", 35, 43], ["patients", "SPECIES", 8, 16], ["COVID", "TEST", 35, 40], ["chain reaction", "TEST", 82, 96], ["RT-PCR", "TEST", 98, 104], ["COVID", "TEST", 110, 115], ["nucleic acid", "TEST", 119, 131], ["bronchoalveolar lavage", "TEST", 135, 157], ["endotracheal aspirate", "TEST", 159, 180], ["nasopharyngeal swab", "TEST", 182, 201], ["oropharyngeal swab", "TEST", 206, 224], ["bronchoalveolar lavage", "OBSERVATION", 135, 157], ["endotracheal", "ANATOMY", 159, 171], ["nasopharyngeal", "ANATOMY", 182, 196], ["oropharyngeal", "ANATOMY", 206, 219]]], ["Critically ill patients (n = 13) and patients with consistently normal chest CT (n = 6) were excluded.", [["chest", "ANATOMY", 71, 76], ["Critically ill", "DISEASE", 0, 14], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 37, 45], ["chest", "ORGANISM_SUBDIVISION", 71, 76], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 37, 45], ["Critically ill", "PROBLEM", 0, 14], ["chest", "ANATOMY", 71, 76]]], ["Critically ill patients were defined as having one of the following conditions [16] : (1) respiratory failure occurs and requires mechanical ventilation; (2) septic shock; (3) complicated with other organ failures requiring intensive care unit management.", [["respiratory", "ANATOMY", 90, 101], ["organ", "ANATOMY", 199, 204], ["Critically ill", "DISEASE", 0, 14], ["respiratory failure", "DISEASE", 90, 109], ["septic shock", "DISEASE", 158, 170], ["patients", "ORGANISM", 15, 23], ["organ", "ORGAN", 199, 204], ["patients", "SPECIES", 15, 23], ["respiratory failure", "PROBLEM", 90, 109], ["mechanical ventilation", "TREATMENT", 130, 152], ["septic shock", "PROBLEM", 158, 170], ["other organ failures", "PROBLEM", 193, 213], ["intensive care unit management", "TREATMENT", 224, 254], ["respiratory", "ANATOMY", 90, 101], ["failure", "OBSERVATION", 102, 109], ["mechanical ventilation", "OBSERVATION", 130, 152], ["septic shock", "OBSERVATION", 158, 170], ["organ", "ANATOMY", 199, 204], ["failures", "OBSERVATION", 205, 213]]], ["The patients underwent chest CT by a CT 64 scanner (GE Medical System), Siemens Emotion 16 scanner (Siemens Healthineers; Erlangen, Germany), and ICT 128 scanner (Philips Healthcare, Netherlands), with images indicating a 1-or 1.25-mm slice thickness.", [["slice", "ANATOMY", 235, 240], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["chest CT", "TEST", 23, 31], ["a CT", "TEST", 35, 39], ["images", "TEST", 202, 208], ["chest", "ANATOMY", 23, 28]]], ["We obtained patients' laboratory parameters from medical records, including lymphocyte count (normal range, 1.1-3.2 \u00d7 10 9 /L), neutrophil count (normal range, 1.8-6.3 \u00d7 10 9 /L), white blood cell (WBC) count (normal range, 3.5-9.5 \u00d7 10 9 /L), hemoglobin (normal range, 130-175 g/L), platelet count (125-350 \u00d7 10 9 /L), C-reactive protein (CRP) (normal range, \u2264 6 mg/L), procalcitonin (normal range, 0-0.046 ng/mL), lactose dehydrogenase (LDH) (normal range, 120-250 U/L), alanine aminotransferase (ALT) (normal range, 7-40 U/L), aspartate aminotransferase (AST) (normal range, 13-35 U/ L), creatine kinase (CK) (normal range, 40-200 U/L), creatine kinase isoenzyme (CK-MB) (normal range, 0-24 U/L), activated partial thromboplastin time (APTT) (normal range, 22-38 s), prothrombin time (PT) (normal range, 10-14 s), and creatinine (normal range, 57-111 \u03bcmol/L).", [["lymphocyte", "ANATOMY", 76, 86], ["neutrophil", "ANATOMY", 128, 138], ["white blood cell", "ANATOMY", 180, 196], ["WBC", "ANATOMY", 198, 201], ["platelet", "ANATOMY", 284, 292], ["lactose", "CHEMICAL", 416, 423], ["alanine", "CHEMICAL", 473, 480], ["aspartate", "CHEMICAL", 530, 539], ["creatine", "CHEMICAL", 591, 599], ["creatine", "CHEMICAL", 640, 648], ["creatinine", "CHEMICAL", 821, 831], ["lactose", "CHEMICAL", 416, 423], ["alanine", "CHEMICAL", 473, 480], ["aspartate", "CHEMICAL", 530, 539], ["creatine", "CHEMICAL", 591, 599], ["creatine", "CHEMICAL", 640, 648], ["creatinine", "CHEMICAL", 821, 831], ["patients", "ORGANISM", 12, 20], ["lymphocyte", "CELL", 76, 86], ["neutrophil", "CELL", 128, 138], ["white blood cell", "CELL", 180, 196], ["WBC", "CELL", 198, 201], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 244, 254], ["platelet", "CELL", 284, 292], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 320, 338], ["CRP", "GENE_OR_GENE_PRODUCT", 340, 343], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 371, 384], ["lactose dehydrogenase", "GENE_OR_GENE_PRODUCT", 416, 437], ["LDH", "GENE_OR_GENE_PRODUCT", 439, 442], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 473, 497], ["ALT", "SIMPLE_CHEMICAL", 499, 502], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 530, 556], ["AST", "SIMPLE_CHEMICAL", 558, 561], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 591, 606], ["CK", "GENE_OR_GENE_PRODUCT", 608, 610], ["creatine kinase isoenzyme", "GENE_OR_GENE_PRODUCT", 640, 665], ["CK-MB", "GENE_OR_GENE_PRODUCT", 667, 672], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 718, 732], ["prothrombin", "GENE_OR_GENE_PRODUCT", 770, 781], ["creatinine", "SIMPLE_CHEMICAL", 821, 831], ["hemoglobin", "PROTEIN", 244, 254], ["C-reactive protein", "PROTEIN", 320, 338], ["CRP", "PROTEIN", 340, 343], ["procalcitonin", "PROTEIN", 371, 384], ["lactose dehydrogenase", "PROTEIN", 416, 437], ["LDH", "PROTEIN", 439, 442], ["alanine aminotransferase", "PROTEIN", 473, 497], ["ALT", "PROTEIN", 499, 502], ["aspartate aminotransferase", "PROTEIN", 530, 556], ["AST", "PROTEIN", 558, 561], ["creatine kinase", "PROTEIN", 591, 606], ["CK", "PROTEIN", 608, 610], ["creatine kinase isoenzyme", "PROTEIN", 640, 665], ["CK", "PROTEIN", 667, 669], ["APTT", "PROTEIN", 739, 743], ["patients", "SPECIES", 12, 20], ["lymphocyte count", "TEST", 76, 92], ["neutrophil count", "TEST", 128, 144], ["white blood cell", "TEST", 180, 196], ["WBC", "TEST", 198, 201], ["count", "TEST", 203, 208], ["hemoglobin", "TEST", 244, 254], ["platelet count", "TEST", 284, 298], ["C-reactive protein", "TEST", 320, 338], ["CRP", "TEST", 340, 343], ["\u2264", "TEST", 360, 361], ["procalcitonin", "TEST", 371, 384], ["lactose dehydrogenase", "TEST", 416, 437], ["LDH", "TEST", 439, 442], ["U/L", "TEST", 467, 470], ["alanine aminotransferase", "TEST", 473, 497], ["ALT", "TEST", 499, 502], ["U/L)", "TEST", 524, 528], ["aspartate aminotransferase", "TEST", 530, 556], ["AST", "TEST", 558, 561], ["U/ L", "TEST", 584, 588], ["creatine kinase", "TEST", 591, 606], ["CK", "TEST", 608, 610], ["U/L)", "TEST", 634, 638], ["creatine kinase isoenzyme", "TEST", 640, 665], ["CK-MB", "TEST", 667, 672], ["activated partial thromboplastin time", "TEST", 700, 737], ["APTT", "TEST", 739, 743], ["prothrombin time", "TEST", 770, 786], ["PT", "TEST", 788, 790], ["creatinine", "TEST", 821, 831]]], ["All the patients received antiviral drugs (e.g., oseltamivir, arbidol, interferon, Yanhuning, or kaletra) and antii n f l a m m a t o r y d r u g s ( e . g . , m o x i f l o x a c i n a n d / o r cefoperazone sodium and tazobactam), and most severe patients received methylprednisolone.", [["oseltamivir", "CHEMICAL", 49, 60], ["arbidol", "CHEMICAL", 62, 69], ["interferon", "CHEMICAL", 71, 81], ["Yanhuning", "CHEMICAL", 83, 92], ["cefoperazone sodium", "CHEMICAL", 196, 215], ["tazobactam", "CHEMICAL", 220, 230], ["methylprednisolone", "CHEMICAL", 267, 285], ["oseltamivir", "CHEMICAL", 49, 60], ["arbidol", "CHEMICAL", 62, 69], ["cefoperazone sodium", "CHEMICAL", 196, 215], ["tazobactam", "CHEMICAL", 220, 230], ["methylprednisolone", "CHEMICAL", 267, 285], ["patients", "ORGANISM", 8, 16], ["oseltamivir", "SIMPLE_CHEMICAL", 49, 60], ["arbidol", "SIMPLE_CHEMICAL", 62, 69], ["Yanhuning", "SIMPLE_CHEMICAL", 83, 92], ["kaletra", "SIMPLE_CHEMICAL", 97, 104], ["cefoperazone sodium", "SIMPLE_CHEMICAL", 196, 215], ["tazobactam", "SIMPLE_CHEMICAL", 220, 230], ["patients", "ORGANISM", 249, 257], ["methylprednisolone", "SIMPLE_CHEMICAL", 267, 285], ["interferon", "PROTEIN", 71, 81], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 249, 257], ["antiviral drugs", "TREATMENT", 26, 41], ["oseltamivir", "TREATMENT", 49, 60], ["arbidol", "TREATMENT", 62, 69], ["interferon", "TREATMENT", 71, 81], ["Yanhuning", "TREATMENT", 83, 92], ["kaletra", "TREATMENT", 97, 104], ["g", "TEST", 154, 155], ["a c i", "TEST", 176, 181], ["a", "TEST", 184, 185], ["d", "TEST", 188, 189], ["cefoperazone sodium", "TREATMENT", 196, 215], ["tazobactam", "TREATMENT", 220, 230], ["methylprednisolone", "TREATMENT", 267, 285]]], ["All the patients were followed up by chest CT, which could be classified into four stages: early, progressive, peak, and absorption stages [17] .", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["chest CT", "TEST", 37, 45], ["progressive, peak, and absorption stages", "PROBLEM", 98, 138], ["chest", "ANATOMY", 37, 42], ["progressive", "OBSERVATION_MODIFIER", 98, 109], ["peak", "OBSERVATION_MODIFIER", 111, 115]]], ["The dates of chest CT and laboratory examination were wellmatched.", [["chest", "ANATOMY", 13, 18], ["chest", "ORGAN", 13, 18], ["chest CT", "TEST", 13, 21], ["laboratory examination", "TEST", 26, 48], ["chest", "ANATOMY", 13, 18]]], ["An overall lung total severity score (CT score) (range 0-20 points) was assigned according to Chung et al. [6] .", [["lung", "ANATOMY", 11, 15], ["lung", "ORGAN", 11, 15], ["An overall lung total severity score", "PROBLEM", 0, 36], ["CT score", "TEST", 38, 46], ["overall", "OBSERVATION_MODIFIER", 3, 10], ["lung", "ANATOMY", 11, 15], ["total", "OBSERVATION_MODIFIER", 16, 21], ["severity", "OBSERVATION_MODIFIER", 22, 30]]], ["All chest CT images were reviewed independently by two cardiothoracic radiologists with more than 10 years of experience.", [["chest", "ANATOMY", 4, 9], ["All chest CT images", "TEST", 0, 19], ["chest", "ANATOMY", 4, 9]]], ["Final decisions were reached by consensus.Statistical analysisAll chest CT scores were correlated with laboratory parameters at days of early, progressive, peak, and absorption stages using the Spearman rank correlation.", [["chest", "ANATOMY", 66, 71], ["Statistical analysis", "TEST", 42, 62], ["All chest CT scores", "TEST", 62, 81], ["laboratory parameters", "TEST", 103, 124], ["chest", "ANATOMY", 66, 71], ["progressive", "OBSERVATION_MODIFIER", 143, 154]]], ["Difference between laboratory and radiographic data was obtained at early, progressive, peak, and absorption stages using one-way analysis of variance (ANOVA) with post hoc Tukey's multiple comparison tests at a level of significance P < 0.05.", [["radiographic data", "TEST", 34, 51], ["comparison tests", "TEST", 190, 206]]], ["The peak stage was used as the reference stage.Clinical characteristicsThe mean age of the 84 patients was 47.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["The mean age", "TEST", 71, 83], ["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["8Imaging featuresThe major CT findings were compared at early, progressive, peak, and absorption stages ( Table 2 ).", [["The major CT findings", "TEST", 17, 38], ["progressive", "OBSERVATION_MODIFIER", 63, 74], ["peak", "OBSERVATION_MODIFIER", 76, 80]]], ["In the early stage, the most frequent CT appearance was bilateral GGO with peripheral distribution (Fig. 1a ).", [["GGO", "DISEASE", 66, 69], ["bilateral GGO", "PROBLEM", 56, 69], ["early stage", "OBSERVATION_MODIFIER", 7, 18], ["bilateral", "ANATOMY_MODIFIER", 56, 65], ["GGO", "OBSERVATION", 66, 69], ["peripheral", "ANATOMY_MODIFIER", 75, 85], ["distribution", "OBSERVATION_MODIFIER", 86, 98]]], ["In addition, consolidation, crazypaving pattern, bronchiectasis, and reverse halo sign could Values are the mean \u00b1 SD or median and interquartile range # One-way ANOVA analysis with post hoc tests was used to test the differences between data at the early, progressive, peak, and absorption stages + P < 0.05, comparison between data at the early, progressive, absorption, and peak stages ++ P < 0.001, comparison between data at the early, progressive, absorption, and peak stages *P < 0.05 **P < 0.001Imaging featuresCT computed tomography; WBC white blood cell; CRP C-reactive protein; LDH lactose dehydrogenase; ALT alanine aminotransferase; AST aspartate aminotransferase; CK creatine kinase; CK-MB creatine kinase isoenzyme; APTT activated partial thromboplastin time; PT prothrombin time be found in some patients.", [["white blood cell", "ANATOMY", 547, 563], ["bronchiectasis", "DISEASE", 49, 63], ["alanine", "CHEMICAL", 620, 627], ["aspartate", "CHEMICAL", 650, 659], ["creatine", "CHEMICAL", 681, 689], ["creatine", "CHEMICAL", 704, 712], ["lactose", "CHEMICAL", 593, 600], ["alanine", "CHEMICAL", 620, 627], ["aspartate", "CHEMICAL", 650, 659], ["creatine", "CHEMICAL", 681, 689], ["creatine", "CHEMICAL", 704, 712], ["blood cell", "CELL", 553, 563], ["CRP", "GENE_OR_GENE_PRODUCT", 565, 568], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 569, 587], ["LDH lactose dehydrogenase", "GENE_OR_GENE_PRODUCT", 589, 614], ["ALT alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 616, 644], ["AST", "SIMPLE_CHEMICAL", 646, 649], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 650, 676], ["CK creatine kinase", "GENE_OR_GENE_PRODUCT", 678, 696], ["CK-MB creatine kinase isoenzyme", "GENE_OR_GENE_PRODUCT", 698, 729], ["APTT activated partial thromboplastin", "GENE_OR_GENE_PRODUCT", 731, 768], ["PT", "GENE_OR_GENE_PRODUCT", 775, 777], ["prothrombin", "GENE_OR_GENE_PRODUCT", 778, 789], ["patients", "ORGANISM", 812, 820], ["CRP C-reactive protein", "PROTEIN", 565, 587], ["LDH lactose dehydrogenase", "PROTEIN", 589, 614], ["ALT alanine aminotransferase", "PROTEIN", 616, 644], ["AST aspartate aminotransferase", "PROTEIN", 646, 676], ["CK creatine kinase", "PROTEIN", 678, 696], ["CK-MB creatine kinase isoenzyme", "PROTEIN", 698, 729], ["APTT", "PROTEIN", 731, 735], ["patients", "SPECIES", 812, 820], ["consolidation", "PROBLEM", 13, 26], ["crazypaving pattern", "PROBLEM", 28, 47], ["bronchiectasis", "PROBLEM", 49, 63], ["reverse halo sign", "PROBLEM", 69, 86], ["ANOVA analysis", "TEST", 162, 176], ["post hoc tests", "TEST", 182, 196], ["absorption stages", "TEST", 280, 297], ["peak stages", "TEST", 377, 388], ["P", "TEST", 483, 484], ["Imaging featuresCT computed tomography", "TEST", 503, 541], ["WBC white blood cell", "TEST", 543, 563], ["CRP", "TEST", 565, 568], ["C", "TEST", 569, 570], ["reactive protein", "TEST", 571, 587], ["LDH", "TEST", 589, 592], ["lactose dehydrogenase", "TEST", 593, 614], ["ALT alanine aminotransferase", "TEST", 616, 644], ["AST", "TEST", 646, 649], ["aspartate aminotransferase", "TEST", 650, 676], ["CK", "TEST", 678, 680], ["creatine kinase", "TEST", 681, 696], ["CK", "TEST", 698, 700], ["MB creatine kinase isoenzyme", "TEST", 701, 729], ["APTT", "TEST", 731, 735], ["partial thromboplastin time", "TEST", 746, 773], ["PT prothrombin time", "TEST", 775, 794], ["consolidation", "OBSERVATION", 13, 26], ["bronchiectasis", "OBSERVATION", 49, 63]]], ["In the progressive stage, extensive GGO with consolidation, crazy-paving pattern, and traction bronchiectasis was often observed (Fig. 1b) .", [["GGO", "DISEASE", 36, 39], ["bronchiectasis", "DISEASE", 95, 109], ["extensive GGO", "PROBLEM", 26, 39], ["consolidation", "PROBLEM", 45, 58], ["crazy", "PROBLEM", 60, 65], ["traction bronchiectasis", "PROBLEM", 86, 109], ["progressive", "OBSERVATION_MODIFIER", 7, 18], ["stage", "OBSERVATION_MODIFIER", 19, 24], ["extensive", "OBSERVATION_MODIFIER", 26, 35], ["GGO", "OBSERVATION", 36, 39], ["consolidation", "OBSERVATION", 45, 58], ["crazy", "OBSERVATION_MODIFIER", 60, 65], ["traction", "OBSERVATION_MODIFIER", 86, 94], ["bronchiectasis", "OBSERVATION", 95, 109]]], ["In a small proportion of cases, pleural effusion and cavitation could be seen.Imaging featuresIn the peak stage, the diffuse GGO further extended to peak, with consolidation becoming denser (Fig. 1c) .", [["pleural", "ANATOMY", 32, 39], ["pleural effusion", "DISEASE", 32, 48], ["cavitation", "DISEASE", 53, 63], ["pleural", "PATHOLOGICAL_FORMATION", 32, 39], ["pleural effusion", "PROBLEM", 32, 48], ["cavitation", "PROBLEM", 53, 63], ["Imaging features", "TEST", 78, 94], ["the diffuse GGO", "PROBLEM", 113, 128], ["consolidation", "PROBLEM", 160, 173], ["small", "OBSERVATION_MODIFIER", 5, 10], ["pleural", "ANATOMY", 32, 39], ["effusion", "OBSERVATION", 40, 48], ["cavitation", "OBSERVATION", 53, 63], ["peak stage", "OBSERVATION_MODIFIER", 101, 111], ["diffuse", "OBSERVATION_MODIFIER", 117, 124], ["GGO", "OBSERVATION", 125, 128], ["peak", "OBSERVATION_MODIFIER", 149, 153], ["consolidation", "OBSERVATION", 160, 173], ["denser", "OBSERVATION_MODIFIER", 183, 189]]], ["In the absorption stage, the consolidation was gradually absorbed with residual parenchymal bands (Fig. 1d) .", [["parenchymal", "ANATOMY", 80, 91], ["the consolidation", "PROBLEM", 25, 42], ["residual parenchymal bands", "PROBLEM", 71, 97], ["absorption stage", "OBSERVATION_MODIFIER", 7, 23], ["consolidation", "OBSERVATION", 29, 42], ["parenchymal", "ANATOMY_MODIFIER", 80, 91], ["bands", "OBSERVATION", 92, 97]]], ["Few cases presented crazy-paving pattern.", [["crazy", "OBSERVATION_MODIFIER", 20, 25]]], ["Figure 2 shows the progression pattern or stage of the disease as of February 18, 2020.", [["the progression pattern", "PROBLEM", 15, 38], ["the disease", "PROBLEM", 51, 62], ["progression", "OBSERVATION_MODIFIER", 19, 30], ["pattern", "OBSERVATION_MODIFIER", 31, 38], ["stage", "OBSERVATION_MODIFIER", 42, 47], ["disease", "OBSERVATION", 55, 62]]], ["At admission, 5 (6.0%) patients' chest CT scans were normal, 51 (60.7%) were at early stage, and 28 (33.3%) were at progressive stage.", [["patients", "ORGANISM", 23, 31], ["chest CT", "CANCER", 33, 41], ["patients", "SPECIES", 23, 31], ["patients' chest CT scans", "TEST", 23, 47], ["chest", "ANATOMY", 33, 38]]], ["Early-progressive-absorption stage was the most frequent (34.5%) pattern.", [["progressive-absorption stage", "PROBLEM", 6, 34], ["progressive", "OBSERVATION_MODIFIER", 6, 17], ["absorption stage", "OBSERVATION_MODIFIER", 18, 34], ["most frequent", "OBSERVATION_MODIFIER", 43, 56]]], ["Only 11 (13%) patients experienced peak stage of the disease.Relationship between the CT scores and laboratory parametersThe mean CT scores of the early, progressive, peak, and absorption stages were 4.8 \u00b1 2.0, 7.1 \u00b1 2.8, 13.1 \u00b1 2.1, and 7.1 \u00b1 2.8, respectively, with significant difference among the four stages (P < 0.001).", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["the disease", "PROBLEM", 49, 60], ["the CT scores", "TEST", 82, 95], ["laboratory parameters", "TEST", 100, 121], ["The mean CT scores", "TEST", 121, 139], ["absorption stages", "TEST", 177, 194], ["disease", "OBSERVATION", 53, 60], ["progressive", "OBSERVATION_MODIFIER", 154, 165], ["peak", "OBSERVATION_MODIFIER", 167, 171], ["significant", "OBSERVATION_MODIFIER", 268, 279], ["difference", "OBSERVATION_MODIFIER", 280, 290], ["four", "OBSERVATION_MODIFIER", 301, 305], ["stages", "OBSERVATION_MODIFIER", 306, 312]]], ["Median chest CT scores peaked at 4 days after the beginning of treatment and then declined.", [["chest", "ANATOMY", 7, 12], ["Median chest CT scores", "TEST", 0, 22], ["treatment", "TREATMENT", 63, 72], ["chest", "ANATOMY", 7, 12]]], ["The early stage CT score was correlated with neutrophil count (r = 0.531, P = 0.011).", [["neutrophil", "ANATOMY", 45, 55], ["neutrophil", "CELL", 45, 55], ["The early stage CT score", "TEST", 0, 24], ["neutrophil count", "TEST", 45, 61], ["r", "TEST", 63, 64], ["P", "TEST", 74, 75]]], ["The progressive stage CT score was correlated with neutrophil count (r = 0.502, P < 0.001), WBC count (r = 0.414, P = 0.001), CRP (r = 0.511, P < 0.001), procalcitonin (r = 0.423, P = 0.004), and LDH (r = 0.369, P = 0.010).", [["neutrophil", "ANATOMY", 51, 61], ["WBC", "ANATOMY", 92, 95], ["neutrophil", "CELL", 51, 61], ["CRP", "GENE_OR_GENE_PRODUCT", 126, 129], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 154, 167], ["LDH", "GENE_OR_GENE_PRODUCT", 196, 199], ["CRP", "PROTEIN", 126, 129], ["procalcitonin", "PROTEIN", 154, 167], ["LDH", "PROTEIN", 196, 199], ["The progressive stage CT score", "PROBLEM", 0, 30], ["neutrophil count", "TEST", 51, 67], ["P", "TEST", 80, 81], ["WBC count", "TEST", 92, 101], ["r", "TEST", 103, 104], ["P", "TEST", 114, 115], ["CRP", "TEST", 126, 129], ["r", "TEST", 131, 132], ["P", "TEST", 142, 143], ["procalcitonin", "TEST", 154, 167], ["P", "TEST", 180, 181], ["LDH", "TEST", 196, 199], ["P", "TEST", 212, 213], ["progressive", "OBSERVATION_MODIFIER", 4, 15], ["LDH", "ANATOMY", 196, 199]]], ["However, there were no relationship between CT scores of peak and absorption stages and all laboratory parameters (P > 0.0125).", [["CT scores", "TEST", 44, 53], ["peak and absorption stages", "PROBLEM", 57, 83], ["all laboratory parameters", "TEST", 88, 113], ["P", "TEST", 115, 116]]], ["While patients were stratified according to sex, there was no significant difference with respect to CT score (P > 0.05).", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["significant difference", "PROBLEM", 62, 84], ["CT score", "TEST", 101, 109], ["P", "TEST", 111, 112], ["no", "UNCERTAINTY", 59, 61], ["significant", "OBSERVATION_MODIFIER", 62, 73]]], ["Significant difference was observed in CRP (P = 0.010 in the early stage), CK (P = 0.007 in the early stage), AST (P = 0.005 in the early stage), neutrophil count (P = 0.046 in the absorption stage), platelet count (P = 0.034 in the absorption stage), WBC count (P = 0.016 in the progressive stage and 0.041 in the absorption stage), procalcitonin (P = 0.003 in the progressive stage), ALT (P < 0.05 in the early, progressive, and absorption stages), hemoglobin (P < 0.001 in all stages), and creatinine (P \u2264 0.001 in all stages).DiscussionThe findings of this clinical and radiological study in a cohort of patients with COVID-19 infection showed that the severity of lung abnormalities quantified on chest CT was positively correlated with laboratory parameters in the early and progressive stages.", [["neutrophil", "ANATOMY", 146, 156], ["platelet", "ANATOMY", 200, 208], ["WBC", "ANATOMY", 252, 255], ["lung", "ANATOMY", 669, 673], ["chest", "ANATOMY", 702, 707], ["creatinine", "CHEMICAL", 493, 503], ["infection", "DISEASE", 631, 640], ["lung abnormalities", "DISEASE", 669, 687], ["creatinine", "CHEMICAL", 493, 503], ["CRP", "GENE_OR_GENE_PRODUCT", 39, 42], ["neutrophil", "CELL", 146, 156], ["platelet", "CELL", 200, 208], ["ALT", "SIMPLE_CHEMICAL", 386, 389], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 451, 461], ["creatinine", "SIMPLE_CHEMICAL", 493, 503], ["patients", "ORGANISM", 608, 616], ["lung", "ORGAN", 669, 673], ["chest", "ORGAN", 702, 707], ["CRP", "PROTEIN", 39, 42], ["CK", "PROTEIN", 75, 77], ["AST", "PROTEIN", 110, 113], ["procalcitonin", "PROTEIN", 334, 347], ["hemoglobin", "PROTEIN", 451, 461], ["patients", "SPECIES", 608, 616], ["CRP", "TEST", 39, 42], ["P", "TEST", 44, 45], ["CK", "TEST", 75, 77], ["P", "TEST", 79, 80], ["AST", "TEST", 110, 113], ["P", "TEST", 115, 116], ["neutrophil count", "TEST", 146, 162], ["P", "TEST", 164, 165], ["the absorption stage", "TEST", 177, 197], ["platelet count", "TEST", 200, 214], ["P", "TEST", 216, 217], ["the absorption stage", "TEST", 229, 249], ["WBC count", "TEST", 252, 261], ["P", "TEST", 263, 264], ["the absorption stage", "TEST", 311, 331], ["procalcitonin", "TEST", 334, 347], ["ALT", "TEST", 386, 389], ["P", "TEST", 391, 392], ["absorption stages", "TEST", 431, 448], ["hemoglobin", "TEST", 451, 461], ["P", "TEST", 463, 464], ["creatinine", "TEST", 493, 503], ["radiological study", "TEST", 574, 592], ["COVID", "TEST", 622, 627], ["infection", "PROBLEM", 631, 640], ["lung abnormalities", "PROBLEM", 669, 687], ["chest CT", "TEST", 702, 710], ["laboratory parameters", "TEST", 742, 763], ["neutrophil count", "OBSERVATION", 146, 162], ["progressive", "OBSERVATION_MODIFIER", 414, 425], ["lung", "ANATOMY", 669, 673], ["abnormalities", "OBSERVATION", 674, 687], ["chest", "ANATOMY", 702, 707], ["progressive", "OBSERVATION_MODIFIER", 781, 792]]], ["CT scores peaked at about 4 days after the beginning of treatment and then declined, which generally reflected temporal changes in laboratory parameters after the start of treatment.", [["CT scores", "TEST", 0, 9], ["treatment", "TREATMENT", 56, 65], ["temporal changes in laboratory parameters", "PROBLEM", 111, 152], ["treatment", "TREATMENT", 172, 181], ["temporal", "OBSERVATION_MODIFIER", 111, 119], ["changes", "OBSERVATION", 120, 127]]], ["In the absence of more specific disease biomarkers, chest CT, therefore, appears to be a useful and effective tool for patient assessment.DiscussionIn the early stage, the relationship between neutrophil count and CT score indicated the early inflammatory response Fig. 1 Typical evolution of CT findings in a 46-year-old female presenting with fever for 4 days. a Axial chest CT obtained at presentation shows subpleural ground-glass opacities (GGO) in the right upper and lower lobes. b Axial chest CT obtained at day 5 of treatment shows enlarged region of GGO with interlobular septal thickening (crazy-paving pattern) and partial consolidation. c Axial chest CT obtained at day 9 of treatment shows increased consolidation. d Axial chest CT obtained at day 13 shows significant absorption of consolidation with residual parenchymal bands Fig. 2 The progression pattern or stage of COVID-19 on chest CT as of February 18, 2020 caused by pneumonias.", [["chest", "ANATOMY", 52, 57], ["neutrophil", "ANATOMY", 193, 203], ["chest", "ANATOMY", 371, 376], ["right upper", "ANATOMY", 458, 469], ["lower lobes", "ANATOMY", 474, 485], ["chest", "ANATOMY", 495, 500], ["interlobular septal", "ANATOMY", 569, 588], ["parenchymal", "ANATOMY", 825, 836], ["fever", "DISEASE", 345, 350], ["GGO", "DISEASE", 446, 449], ["GGO", "DISEASE", 560, 563], ["pneumonias", "DISEASE", 941, 951], ["chest", "ORGAN", 52, 57], ["patient", "ORGANISM", 119, 126], ["neutrophil", "CELL", 193, 203], ["female", "ORGANISM", 322, 328], ["right upper", "ORGANISM_SUBDIVISION", 458, 469], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 474, 485], ["interlobular septal", "TISSUE", 569, 588], ["chest", "ORGAN", 898, 903], ["patient", "SPECIES", 119, 126], ["more specific disease biomarkers", "PROBLEM", 18, 50], ["chest CT", "TEST", 52, 60], ["patient assessment", "TEST", 119, 137], ["neutrophil count", "TEST", 193, 209], ["CT score", "TEST", 214, 222], ["the early inflammatory response Fig", "PROBLEM", 233, 268], ["CT findings", "TEST", 293, 304], ["fever", "PROBLEM", 345, 350], ["a Axial chest CT", "TEST", 363, 379], ["subpleural ground-glass opacities", "PROBLEM", 411, 444], ["Axial chest CT", "TEST", 489, 503], ["treatment", "TREATMENT", 525, 534], ["enlarged region of GGO", "PROBLEM", 541, 563], ["interlobular septal thickening", "PROBLEM", 569, 599], ["partial consolidation", "PROBLEM", 627, 648], ["Axial chest CT", "TEST", 652, 666], ["treatment", "TREATMENT", 688, 697], ["increased consolidation", "PROBLEM", 704, 727], ["d Axial chest CT", "TEST", 729, 745], ["significant absorption of consolidation", "PROBLEM", 771, 810], ["residual parenchymal bands Fig", "PROBLEM", 816, 846], ["COVID", "TEST", 886, 891], ["chest CT", "TEST", 898, 906], ["pneumonias", "PROBLEM", 941, 951], ["chest", "ANATOMY", 52, 57], ["early", "OBSERVATION_MODIFIER", 237, 242], ["inflammatory", "OBSERVATION_MODIFIER", 243, 255], ["response Fig", "OBSERVATION", 256, 268], ["fever", "OBSERVATION", 345, 350], ["chest", "ANATOMY", 371, 376], ["subpleural", "ANATOMY", 411, 421], ["glass opacities", "OBSERVATION", 429, 444], ["GGO", "OBSERVATION_MODIFIER", 446, 449], ["right upper", "ANATOMY_MODIFIER", 458, 469], ["lower lobes", "ANATOMY", 474, 485], ["chest", "ANATOMY", 495, 500], ["enlarged", "OBSERVATION", 541, 549], ["GGO", "OBSERVATION", 560, 563], ["interlobular", "ANATOMY_MODIFIER", 569, 581], ["septal", "ANATOMY_MODIFIER", 582, 588], ["thickening", "OBSERVATION", 589, 599], ["crazy", "OBSERVATION_MODIFIER", 601, 606], ["partial", "OBSERVATION_MODIFIER", 627, 634], ["consolidation", "OBSERVATION", 635, 648], ["chest", "ANATOMY", 658, 663], ["increased", "OBSERVATION_MODIFIER", 704, 713], ["consolidation", "OBSERVATION", 714, 727], ["chest", "ANATOMY", 737, 742], ["significant", "OBSERVATION_MODIFIER", 771, 782], ["absorption", "OBSERVATION_MODIFIER", 783, 793], ["consolidation", "OBSERVATION", 797, 810], ["residual", "OBSERVATION_MODIFIER", 816, 824], ["parenchymal", "ANATOMY_MODIFIER", 825, 836], ["bands Fig", "OBSERVATION", 837, 846], ["chest", "ANATOMY", 898, 903], ["pneumonias", "OBSERVATION", 941, 951]]], ["Neutrophilia is one of the hallmarks of acute infection.", [["Neutrophilia", "DISEASE", 0, 12], ["infection", "DISEASE", 46, 55], ["Neutrophilia", "PROBLEM", 0, 12], ["acute infection", "PROBLEM", 40, 55], ["one of the hallmarks", "OBSERVATION_MODIFIER", 16, 36], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 46, 55]]], ["Neutrophils are recruited early to sites of infection where they kill pathogens (bacteria, fungi, and viruses) by oxidative burst and phagocytosis [18] .", [["Neutrophils", "ANATOMY", 0, 11], ["sites", "ANATOMY", 35, 40], ["infection", "DISEASE", 44, 53], ["Neutrophils", "CELL", 0, 11], ["Neutrophils", "CELL_TYPE", 0, 11], ["Neutrophils", "PROBLEM", 0, 11], ["infection", "PROBLEM", 44, 53], ["bacteria", "PROBLEM", 81, 89], ["fungi", "PROBLEM", 91, 96], ["viruses", "PROBLEM", 102, 109], ["oxidative burst", "TEST", 114, 129], ["phagocytosis", "TEST", 134, 146], ["infection", "OBSERVATION", 44, 53]]], ["Some literature supported the hypothesis that a little known yet powerful function of neutrophils-the ability to form neutrophil extracellular traps-may contribute to organ damage and death in COVID-19 [19] .", [["neutrophils", "ANATOMY", 86, 97], ["neutrophil extracellular", "ANATOMY", 118, 142], ["organ", "ANATOMY", 167, 172], ["organ damage", "DISEASE", 167, 179], ["death", "DISEASE", 184, 189], ["neutrophils", "CELL", 86, 97], ["neutrophil", "CELL", 118, 128], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 129, 142], ["organ", "ORGAN", 167, 172], ["neutrophils", "CELL_TYPE", 86, 97], ["neutrophils", "TEST", 86, 97], ["neutrophil extracellular traps", "TREATMENT", 118, 148], ["organ damage", "PROBLEM", 167, 179], ["death", "PROBLEM", 184, 189], ["COVID", "TEST", 193, 198]]], ["Previous studies showed neutrophil count was notably related to disease severity [20, 21] .", [["neutrophil", "ANATOMY", 24, 34], ["neutrophil", "CELL", 24, 34], ["Previous studies", "TEST", 0, 16], ["neutrophil count", "TEST", 24, 40], ["disease severity", "PROBLEM", 64, 80], ["neutrophil count", "OBSERVATION", 24, 40]]], ["Neutrophil infiltration was noted in two recent reports on the pathological findings from autopsied COVID-19 patients [22, 23] .", [["Neutrophil", "ANATOMY", 0, 10], ["Neutrophil", "CELL", 0, 10], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["Neutrophil infiltration", "PROBLEM", 0, 23], ["autopsied COVID", "TEST", 90, 105], ["infiltration", "OBSERVATION", 11, 23]]], ["In the progressive stage, infection-related biomarkers included neutrophil count, WBC, CRP, and procalcitonin elevated.", [["neutrophil", "ANATOMY", 64, 74], ["WBC", "ANATOMY", 82, 85], ["infection", "DISEASE", 26, 35], ["neutrophil", "CELL", 64, 74], ["WBC", "CELL", 82, 85], ["CRP", "GENE_OR_GENE_PRODUCT", 87, 90], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 96, 109], ["WBC", "CELL_TYPE", 82, 85], ["CRP", "PROTEIN", 87, 90], ["procalcitonin", "PROTEIN", 96, 109], ["infection", "PROBLEM", 26, 35], ["biomarkers", "TEST", 44, 54], ["neutrophil count", "TEST", 64, 80], ["WBC", "TEST", 82, 85], ["CRP", "TEST", 87, 90], ["procalcitonin elevated", "PROBLEM", 96, 118], ["progressive", "OBSERVATION_MODIFIER", 7, 18], ["stage", "OBSERVATION_MODIFIER", 19, 24], ["infection", "OBSERVATION", 26, 35], ["neutrophil count", "OBSERVATION", 64, 80]]], ["Pathological findings showed diffuse alveolar damage with inflammatory cell infiltration in this stage.", [["alveolar", "ANATOMY", 37, 45], ["inflammatory cell", "ANATOMY", 58, 75], ["alveolar damage", "DISEASE", 37, 52], ["alveolar", "TISSUE", 37, 45], ["inflammatory cell", "CELL", 58, 75], ["Pathological findings", "TEST", 0, 21], ["diffuse alveolar damage", "PROBLEM", 29, 52], ["inflammatory cell infiltration", "PROBLEM", 58, 88], ["diffuse", "OBSERVATION_MODIFIER", 29, 36], ["alveolar damage", "OBSERVATION", 37, 52], ["inflammatory cell infiltration", "OBSERVATION", 58, 88]]], ["Accordingly, chest CT showed diffuse GGO with consolidation.", [["chest", "ANATOMY", 13, 18], ["GGO", "DISEASE", 37, 40], ["chest CT", "TEST", 13, 21], ["diffuse GGO", "PROBLEM", 29, 40], ["consolidation", "PROBLEM", 46, 59], ["chest", "ANATOMY", 13, 18], ["diffuse", "OBSERVATION_MODIFIER", 29, 36], ["GGO", "OBSERVATION", 37, 40], ["consolidation", "OBSERVATION", 46, 59]]], ["Patients with severe virus infection are more likely to be co-infected with bacteria due to low immune functions [24] .", [["infection", "DISEASE", 27, 36], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["severe virus infection", "PROBLEM", 14, 36], ["bacteria", "PROBLEM", 76, 84], ["low immune functions", "PROBLEM", 92, 112], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["virus", "OBSERVATION_MODIFIER", 21, 26], ["infection", "OBSERVATION", 27, 36], ["more likely", "UNCERTAINTY", 41, 52], ["low immune", "OBSERVATION_MODIFIER", 92, 102]]], ["Cytokine storm in severe and critically ill patients with COVID-19 might be associated with the activity of these infection-related biomarkers regulated by inflammatory cytokine.DiscussionIn the peak stage, we found no linkage between CT scores and laboratory parameters, which might be due to the treatment effect of antiviral and antibacterial drugs as well as the small sample size.", [["critically ill", "DISEASE", 29, 43], ["COVID-19", "CHEMICAL", 58, 66], ["infection", "DISEASE", 114, 123], ["COVID-19", "CHEMICAL", 58, 66], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 44, 52], ["Cytokine", "PROTEIN", 0, 8], ["inflammatory cytokine", "PROTEIN", 156, 177], ["patients", "SPECIES", 44, 52], ["Cytokine storm", "PROBLEM", 0, 14], ["COVID", "TEST", 58, 63], ["these infection", "PROBLEM", 108, 123], ["inflammatory cytokine", "PROBLEM", 156, 177], ["CT scores", "TEST", 235, 244], ["laboratory parameters", "TEST", 249, 270], ["antiviral and antibacterial drugs", "TREATMENT", 318, 351], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["infection", "OBSERVATION", 114, 123], ["inflammatory", "OBSERVATION_MODIFIER", 156, 168], ["small", "OBSERVATION_MODIFIER", 367, 372], ["sample", "OBSERVATION_MODIFIER", 373, 379], ["size", "OBSERVATION_MODIFIER", 380, 384]]], ["The changes of CT images might lag behind the changes of laboratory parameters.", [["CT images", "TEST", 15, 24], ["laboratory parameters", "TEST", 57, 78]]], ["In the absorption stage, the laboratory parameters did not correlate with CT scores, which might be due to the mismatch between CT scores and inflammatory clearance.", [["the laboratory parameters", "TEST", 25, 50], ["CT scores", "TEST", 74, 83], ["the mismatch", "PROBLEM", 107, 119], ["CT scores", "TEST", 128, 137], ["inflammatory clearance", "PROBLEM", 142, 164], ["absorption stage", "OBSERVATION_MODIFIER", 7, 23], ["mismatch", "OBSERVATION", 111, 119], ["inflammatory", "OBSERVATION_MODIFIER", 142, 154]]], ["The CT scores in the absorption stage were not significantly reduced compared with those in progressive stage because consolidation generally dissipated into GGO and extensive GGO was noted after consolidation absorption.", [["GGO", "DISEASE", 158, 161], ["GGO", "DISEASE", 176, 179], ["The CT scores", "TEST", 0, 13], ["the absorption stage", "PROBLEM", 17, 37], ["consolidation", "PROBLEM", 118, 131], ["GGO", "PROBLEM", 158, 161], ["extensive GGO", "PROBLEM", 166, 179], ["consolidation absorption", "PROBLEM", 196, 220], ["not", "UNCERTAINTY", 43, 46], ["significantly", "OBSERVATION_MODIFIER", 47, 60], ["reduced", "OBSERVATION_MODIFIER", 61, 68], ["consolidation", "OBSERVATION", 118, 131], ["GGO", "OBSERVATION", 158, 161], ["extensive", "OBSERVATION_MODIFIER", 166, 175], ["GGO", "OBSERVATION", 176, 179], ["consolidation", "OBSERVATION", 196, 209]]], ["Another explanation might be the changes of chest CT lagged behind the changes of laboratory indexes.DiscussionThe limitations of this study should be acknowledged.", [["chest", "ANATOMY", 44, 49], ["chest", "ORGAN", 44, 49], ["chest CT", "TEST", 44, 52], ["laboratory indexes", "TEST", 82, 100], ["this study", "TEST", 130, 140], ["chest", "ANATOMY", 44, 49]]], ["Firstly, this was a retrospective study and the sample size was relatively small, especially for the peak stage.", [["a retrospective study", "TEST", 18, 39], ["the sample size", "TEST", 44, 59], ["the peak stage", "PROBLEM", 97, 111], ["size", "OBSERVATION_MODIFIER", 55, 59], ["relatively", "OBSERVATION_MODIFIER", 64, 74], ["small", "OBSERVATION_MODIFIER", 75, 80]]], ["Secondly, there was a selection bias due to the exclusion of critically ill patients.", [["critically ill", "DISEASE", 61, 75], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["a selection bias", "TEST", 20, 36]]], ["Hence, the findings of this study could only be applied to patients with moderate and severe COVID-19.DiscussionIn conclusion, the results of this study indicated that disease severity on chest CT peaked at about 4 days after the beginning of treatment, followed by a general decline.", [["chest", "ANATOMY", 188, 193], ["patients", "ORGANISM", 59, 67], ["chest", "ORGAN", 188, 193], ["patients", "SPECIES", 59, 67], ["this study", "TEST", 23, 33], ["moderate and severe COVID", "PROBLEM", 73, 98], ["this study", "TEST", 142, 152], ["disease severity", "PROBLEM", 168, 184], ["chest CT", "TEST", 188, 196], ["treatment", "TREATMENT", 243, 252], ["a general decline", "PROBLEM", 266, 283], ["moderate", "OBSERVATION_MODIFIER", 73, 81], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["disease", "OBSERVATION", 168, 175], ["chest", "ANATOMY", 188, 193]]], ["Our findings showed the severity of abnormalities quantified on the chest CT might positively correlate with laboratory parameters in the early and progressive stages.", [["chest", "ANATOMY", 68, 73], ["chest", "ORGAN", 68, 73], ["Our findings", "TEST", 0, 12], ["the severity of abnormalities", "PROBLEM", 20, 49], ["the chest CT", "TEST", 64, 76], ["laboratory parameters", "TEST", 109, 130], ["abnormalities", "OBSERVATION", 36, 49], ["chest", "ANATOMY", 68, 73]]], ["However, larger cohort studies are needed to confirm these findings.", [["larger cohort studies", "TEST", 9, 30]]], ["This study might provide an insight into the appropriate follow-up interval of chest CT to reduce radiation and also indicate the indispensable role of chest CT in monitoring disease progression and therapeutic effect.", [["chest", "ANATOMY", 79, 84], ["chest", "ANATOMY", 152, 157], ["chest", "ORGAN", 79, 84], ["chest", "ORGAN", 152, 157], ["This study", "TEST", 0, 10], ["chest CT", "TEST", 79, 87], ["radiation", "TREATMENT", 98, 107], ["chest CT", "TEST", 152, 160], ["monitoring disease progression", "PROBLEM", 164, 194], ["chest", "ANATOMY", 79, 84], ["chest", "ANATOMY", 152, 157], ["therapeutic effect", "OBSERVATION", 199, 217]]]], "PMC7298444": [["Emergency departments (EDs), in most countries, have been on the frontline, meeting the undifferentiated patients presenting with a variety of complaints that represent the disease.", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["the disease", "PROBLEM", 169, 180], ["disease", "OBSERVATION", 173, 180]]], ["Serving an essential function in identifying likely patients with the infection and isolating them early, this pandemic has reinforced the critical role played by Emergency Medicine in public health.BackgroundWe document the measures taken by a busy ED in Singapore in managing the outbreak; outline the reasons for these various measures, their limitations, and details of implementation; and suggest approaches for the long-term role of Emergency Medicine in the community management of the COVID-19 pandemic and future communicable public health emergencies.BackgroundIn reviewing these measures, we take a step-by-step approach using the patient\u2019s pathway through the ED as a guide.", [["infection", "DISEASE", 70, 79], ["patients", "ORGANISM", 52, 60], ["patient", "ORGANISM", 642, 649], ["patients", "SPECIES", 52, 60], ["patient", "SPECIES", 642, 649], ["the infection", "PROBLEM", 66, 79], ["infection", "OBSERVATION", 70, 79]]], ["Subsequently, we begin with the reception of patients and discuss screening procedures, triage, isolation, medical care in resuscitation, critical trolley areas, ambulatory patients, and the role of observation.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 173, 181], ["screening procedures", "TEST", 66, 86], ["triage", "TEST", 88, 94], ["isolation", "TREATMENT", 96, 105], ["medical care", "TREATMENT", 107, 119], ["resuscitation", "TREATMENT", 123, 136], ["ambulatory patients", "TREATMENT", 162, 181]]], ["Finally, we elaborate on the need for Emergency Medicine to take the lead in addressing screening of clusters of these infections and the role of surveillance research.The environmentSingapore is one of the smallest countries in the world.", [["infections", "DISEASE", 119, 129], ["Emergency Medicine", "TREATMENT", 38, 56], ["these infections", "PROBLEM", 113, 129], ["surveillance research", "TEST", 146, 167], ["infections", "OBSERVATION", 119, 129]]], ["This tropical island country of 721.5 km2 had a population of 5.70 million people in 2019.", [["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81]]], ["About 85% of the residents live in modern high-rise apartments scattered all over the island and the remaining 15% in landed properties [2].", [["scattered", "OBSERVATION_MODIFIER", 63, 72], ["all", "OBSERVATION_MODIFIER", 73, 76]]], ["Of the non-resident population, the labour force commands approximately 1.41 million persons, of whom around 323,000 are employed principally in the construction industry, living in crowded dormitories built by employers with financial assistance provided by the government [3].The environmentSingapore\u2019s healthcare system was ranked sixth in the World Health Organization\u2019s (WHO) ranking of world health systems in 2000 and first by Bloomberg for the most efficient in the world in 2014 [4, 5].", [["persons", "ORGANISM", 85, 92], ["persons", "SPECIES", 85, 92]]], ["It is also the largest, with 1785 beds in total.", [["largest", "OBSERVATION_MODIFIER", 15, 22]]], ["Its ED was established 72 years ago and manages approximately 130,000 patients annually.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["The ED has 70 medical staff (25 emergency physicians and 45 residents) and 200 registered nurses.The environmentThe first indication of the COVID-19 disease outbreak was in the city of Wuhan, Hubei Province, on 31 December 2019 when the Chinese government informed the WHO China country office about a cluster of 41 patients with a new respiratory infection.", [["respiratory", "ANATOMY", 336, 347], ["respiratory infection", "DISEASE", 336, 357], ["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 316, 324], ["the COVID-19 disease outbreak", "PROBLEM", 136, 165], ["a new respiratory infection", "PROBLEM", 330, 357], ["new", "OBSERVATION_MODIFIER", 332, 335], ["respiratory", "ANATOMY", 336, 347], ["infection", "OBSERVATION", 348, 357]]], ["On 2 January, the Ministry of Health (MOH) in Singapore issued a health advisory and implemented temperature checks for passengers arriving at her international airport from Wuhan [6].", [["temperature checks", "TEST", 97, 115]]], ["On 11 January 2020, the Chinese authorities informed the WHO that this infection was due to a novel coronavirus [7].The environmentThe first case of the illness in Singapore was in a tourist from Wuhan who presented to the ED at SGH on 22 January 2020.", [["infection", "DISEASE", 71, 80], ["coronavirus", "DISEASE", 100, 111], ["illness", "DISEASE", 153, 160], ["this infection", "PROBLEM", 66, 80], ["a novel coronavirus", "PROBLEM", 92, 111]]], ["DORSCON is a colour-coded framework that shows the current infectious disease situation and provides guidelines on what can be done to prevent transmission and reduce the impact of infections.", [["infections", "DISEASE", 181, 191], ["the current infectious disease situation", "PROBLEM", 47, 87], ["infections", "PROBLEM", 181, 191], ["infectious", "OBSERVATION", 59, 69], ["infections", "OBSERVATION", 181, 191]]], ["The colour codes vary from green (mild) to yellow (severe and minimal community spread), orange (severe and contained spread) and red (severe and spreading widely) [8].", [["green (mild) to yellow (severe and minimal community spread", "PROBLEM", 27, 86], ["red (severe and spreading widely)", "PROBLEM", 130, 163], ["colour codes", "OBSERVATION", 4, 16], ["vary", "OBSERVATION_MODIFIER", 17, 21], ["green", "OBSERVATION_MODIFIER", 27, 32], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["yellow", "OBSERVATION_MODIFIER", 43, 49], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["minimal", "OBSERVATION_MODIFIER", 62, 69], ["community", "OBSERVATION_MODIFIER", 70, 79], ["spread", "OBSERVATION_MODIFIER", 80, 86], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["severe", "OBSERVATION_MODIFIER", 135, 141]]], ["The first COVID-19 death in Singapore was recorded on 24 March 2020.", [["death", "DISEASE", 19, 24]]], ["The first instances of foreign workers from the dormitories with the infection were on 30 March 2020 when 16 positive cases were identified.", [["infection", "DISEASE", 69, 78], ["the infection", "PROBLEM", 65, 78], ["16 positive cases", "PROBLEM", 106, 123], ["foreign workers", "OBSERVATION", 23, 38], ["infection", "OBSERVATION", 69, 78]]], ["Just prior to that, Singapore had 844 COVID-19 cases, of whom all were either imported or from local transmission.", [["COVID", "TEST", 38, 43]]], ["Over the next few weeks, the number of COVID-19-positive cases amongst the foreign workers in the crowded dormitories surged to more than 700 a day and became a significant contributor to the national case tally (Fig. 1) On 7 April 2020, the government announced a state-wide lockdown (referred to as circuit breaker in Singapore) which has since been extended to 1 June 2020.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 39, 47], ["COVID", "TEST", 39, 44]]]], "PMC7235311": [["Social distancing and a shelter-in-place order are among the measures implemented to effectively prevent the spread of coronavirus disease\u20132019 (COVID-19).1 The shutdown of all nonessential services and restriction of restaurants to takeout service, in response to the social distancing measures, spark surge in food delivery service.", [["coronavirus disease\u2013", "DISEASE", 119, 139], ["coronavirus", "ORGANISM", 119, 130], ["coronavirus disease\u2013", "PROBLEM", 119, 139], ["COVID", "TEST", 145, 150]]], ["Such a service has been touted as being a useful, convenient, and safe means to reduce the risk of exposure to infection sources of the novel coronavirus.", [["infection", "DISEASE", 111, 120], ["coronavirus", "DISEASE", 142, 153], ["coronavirus", "ORGANISM", 142, 153], ["infection sources", "PROBLEM", 111, 128], ["the novel coronavirus", "PROBLEM", 132, 153], ["infection", "OBSERVATION", 111, 120]]], ["Nevertheless, this distribution method may still pose a potential risk of spreading the disease.", [["spreading the disease", "PROBLEM", 74, 95], ["disease", "OBSERVATION", 88, 95]]]], "01c25f9838ef8e005bf720c4f76e67a9f1038ff0": [["BackgroundViral zoonosis, the transmission of a virus from its primary vertebrate reservoir species to humans, requires ubiquitous cellular proteins known as receptor proteins [1] .", [["cellular", "ANATOMY", 131, 139], ["BackgroundViral zoonosis", "DISEASE", 0, 24], ["humans", "ORGANISM", 103, 109], ["cellular", "CELL", 131, 139], ["ubiquitous cellular proteins", "PROTEIN", 120, 148], ["receptor proteins", "PROTEIN", 158, 175], ["humans", "SPECIES", 103, 109], ["humans", "SPECIES", 103, 109], ["BackgroundViral zoonosis", "PROBLEM", 0, 24], ["a virus", "PROBLEM", 46, 53], ["ubiquitous cellular proteins", "PROBLEM", 120, 148], ["zoonosis", "OBSERVATION", 16, 24], ["reservoir species", "OBSERVATION", 82, 99]]], ["Zoonosis can occur not only through direct transmission, but also through intermediate reservoirs or other environmental factors [2] [3] [4] .", [["Zoonosis", "DISEASE", 0, 8]]], ["The zoonotic viruses can be categorized according to genotype; of the various classes of viruses, the RNA viruses exhibit the highest mutation rates [5] .", [["zoonotic viruses", "DISEASE", 4, 20], ["The zoonotic viruses", "PROBLEM", 0, 20], ["viruses", "PROBLEM", 89, 96], ["the RNA viruses", "PROBLEM", 98, 113], ["viruses", "OBSERVATION", 89, 96]]], ["Most zoonotic viruses are RNA viruses that change their envelope proteins to facilitate binding to various receptors of host species [6, 7] .", [["zoonotic viruses", "DISEASE", 5, 21], ["envelope proteins", "PROTEIN", 56, 73], ["Most zoonotic viruses", "PROBLEM", 0, 21], ["RNA viruses", "PROBLEM", 26, 37], ["their envelope proteins", "PROBLEM", 50, 73], ["viruses", "OBSERVATION", 14, 21], ["RNA viruses", "OBSERVATION", 26, 37]]], ["The high mutation rate of envelope proteins [5] hinders the development of accurate vaccines, as does the great ability of the RNA viruses to infect host species in order to exploit host proteins for viral reproduction [8] .BackgroundLacking the ability to self-replicate, viruses must utilize the replication apparatus of their host cells [9] .", [["cells", "ANATOMY", 334, 339], ["host cells", "CELL", 329, 339], ["envelope proteins", "PROTEIN", 26, 43], ["host cells", "CELL_TYPE", 329, 339], ["The high mutation rate of envelope proteins", "PROBLEM", 0, 43], ["accurate vaccines", "TREATMENT", 75, 92], ["the RNA viruses", "PROBLEM", 123, 138], ["host species", "PROBLEM", 149, 161], ["viral reproduction", "PROBLEM", 200, 218], ["viruses", "PROBLEM", 273, 280]]], ["Viral infection of a cell begins with attachment of the virus to the cell surface [6, 10, 11] .", [["cell", "ANATOMY", 21, 25], ["cell surface", "ANATOMY", 69, 81], ["Viral infection", "DISEASE", 0, 15], ["cell", "CELL", 21, 25], ["cell surface", "CELLULAR_COMPONENT", 69, 81], ["Viral infection", "PROBLEM", 0, 15], ["a cell", "PROBLEM", 19, 25], ["the virus", "PROBLEM", 52, 61], ["infection", "OBSERVATION", 6, 15], ["cell", "OBSERVATION", 21, 25], ["virus", "OBSERVATION", 56, 61], ["cell", "OBSERVATION_MODIFIER", 69, 73], ["surface", "OBSERVATION_MODIFIER", 74, 81]]], ["During attachment to the cell membrane, the viral envelope protein (a structural protein) interacts with the host-cell receptor protein(s) [12] .", [["cell membrane", "ANATOMY", 25, 38], ["cell", "ANATOMY", 114, 118], ["cell membrane", "CELLULAR_COMPONENT", 25, 38], ["host-cell receptor", "GENE_OR_GENE_PRODUCT", 109, 127], ["viral envelope protein", "PROTEIN", 44, 66], ["structural protein", "PROTEIN", 70, 88], ["host-cell receptor protein", "PROTEIN", 109, 135], ["the viral envelope protein", "TEST", 40, 66], ["cell membrane", "OBSERVATION", 25, 38]]], ["In non-envelope viruses, the capsid plays this role.", [["non-envelope viruses", "PROBLEM", 3, 23], ["non-envelope viruses", "OBSERVATION", 3, 23]]], ["The cell receptors that play a major role in viral attachment are predominantly membrane proteins of the immunoglobin superfamily [13] [14] [15] .", [["cell", "ANATOMY", 4, 8], ["membrane", "ANATOMY", 80, 88], ["cell", "CELL", 4, 8], ["membrane", "CELLULAR_COMPONENT", 80, 88], ["cell receptors", "PROTEIN", 4, 18], ["membrane proteins", "PROTEIN", 80, 97], ["immunoglobin superfamily", "PROTEIN", 105, 129], ["The cell receptors", "TREATMENT", 0, 18], ["viral attachment", "PROBLEM", 45, 61], ["the immunoglobin superfamily", "TEST", 101, 129], ["cell receptors", "OBSERVATION", 4, 18], ["viral attachment", "OBSERVATION", 45, 61]]], ["The identification of virusbinding cellular receptors was rapidly accelerated in the late 1980s owing to developments in the use of monoclonal antibodies and molecular cloning techniques [15] .", [["cellular", "ANATOMY", 35, 43], ["cellular", "CELL", 35, 43], ["virusbinding cellular receptors", "PROTEIN", 22, 53], ["monoclonal antibodies", "PROTEIN", 132, 153], ["virusbinding cellular receptors", "PROBLEM", 22, 53], ["monoclonal antibodies", "TREATMENT", 132, 153], ["cellular receptors", "OBSERVATION", 35, 53]]], ["The various receptors that have been found are surface matrix structures containing carbohydrate, lipid, and protein moieties [1, 16, 17] .", [["surface matrix structures", "ANATOMY", 47, 72], ["carbohydrate", "CHEMICAL", 84, 96], ["surface", "CELLULAR_COMPONENT", 47, 54], ["matrix structures", "CELLULAR_COMPONENT", 55, 72], ["carbohydrate", "SIMPLE_CHEMICAL", 84, 96], ["lipid", "SIMPLE_CHEMICAL", 98, 103], ["carbohydrate, lipid, and protein moieties", "TEST", 84, 125], ["surface", "OBSERVATION_MODIFIER", 47, 54], ["protein moieties", "OBSERVATION", 109, 125]]], ["In some cases, viral attachment also exploits co-receptors.", [["co-receptors", "PROTEIN", 46, 58], ["viral attachment", "PROBLEM", 15, 31], ["viral attachment", "OBSERVATION", 15, 31]]], ["For example, HIV, which uses the CD4 molecule as its receptor, uses the CXCR4 and CCR5 co-receptors to strengthen the effectiveness of infection [1, 14, 18, 19] .", [["infection", "DISEASE", 135, 144], ["HIV", "ORGANISM", 13, 16], ["CD4", "GENE_OR_GENE_PRODUCT", 33, 36], ["CXCR4", "GENE_OR_GENE_PRODUCT", 72, 77], ["CCR5", "GENE_OR_GENE_PRODUCT", 82, 86], ["CD4 molecule", "PROTEIN", 33, 45], ["CXCR4", "PROTEIN", 72, 77], ["CCR5 co-receptors", "PROTEIN", 82, 99], ["HIV", "SPECIES", 13, 16], ["HIV", "SPECIES", 13, 16], ["HIV", "PROBLEM", 13, 16], ["the CD4 molecule", "TREATMENT", 29, 45], ["the CXCR4 and CCR5 co-receptors", "TREATMENT", 68, 99], ["infection", "PROBLEM", 135, 144], ["HIV", "OBSERVATION", 13, 16], ["infection", "OBSERVATION", 135, 144]]], ["Similarly, hepatitis C virus utilizes CD81 as a receptor and LDLR as a coreceptor [20] .BackgroundSince the host-cell range of a specific virus is predetermined by its ability to recognize specific receptors, the similarities between the receptors of its primary reservoir host cell and the potential human host cell play a major role in determining the likelihood of viral zoonosis.", [["cell", "ANATOMY", 113, 117], ["cell", "ANATOMY", 278, 282], ["cell", "ANATOMY", 312, 316], ["hepatitis C", "DISEASE", 11, 22], ["viral zoonosis", "DISEASE", 368, 382], ["hepatitis C virus", "ORGANISM", 11, 28], ["CD81", "GENE_OR_GENE_PRODUCT", 38, 42], ["LDLR", "GENE_OR_GENE_PRODUCT", 61, 65], ["cell", "CELL", 113, 117], ["host cell", "CELL", 273, 282], ["human", "ORGANISM", 301, 306], ["host cell", "CELL", 307, 316], ["CD81", "PROTEIN", 38, 42], ["LDLR", "PROTEIN", 61, 65], ["hepatitis C virus", "SPECIES", 11, 28], ["human", "SPECIES", 301, 306], ["hepatitis C virus", "SPECIES", 11, 28], ["human", "SPECIES", 301, 306], ["hepatitis C virus", "PROBLEM", 11, 28], ["a specific virus", "PROBLEM", 127, 143], ["viral zoonosis", "PROBLEM", 368, 382], ["hepatitis", "OBSERVATION", 11, 20], ["primary", "OBSERVATION_MODIFIER", 255, 262], ["reservoir host cell", "OBSERVATION", 263, 282], ["human host cell", "OBSERVATION", 301, 316], ["viral zoonosis", "OBSERVATION", 368, 382]]], ["Here, we analysed zoonotic and non-zoonotic RNA viruses along with their cellular receptors in human and (non-human) primary reservoir species to extract the receptor characteristics common to zoonosis.", [["cellular", "ANATOMY", 73, 81], ["zoonosis", "DISEASE", 193, 201], ["cellular", "CELL", 73, 81], ["human", "ORGANISM", 95, 100], ["non-human", "ORGANISM", 106, 115], ["cellular receptors", "PROTEIN", 73, 91], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["non-zoonotic RNA viruses", "PROBLEM", 31, 55], ["their cellular receptors in human and (non-human) primary reservoir species", "TREATMENT", 67, 142], ["zoonosis", "OBSERVATION", 193, 201]]], ["Viruses not previously reported to infect humans were classified as non-zoonotic viruses.", [["humans", "ORGANISM", 42, 48], ["humans", "SPECIES", 42, 48], ["humans", "SPECIES", 42, 48], ["Viruses", "PROBLEM", 0, 7]]], ["We excluded all viruses known to utilize co-receptors; i.e., only virus-receptor interactions occurring through virus tropism and pathogenesis were considered [5, 21] .", [["co-receptors", "PROTEIN", 41, 53], ["all viruses", "PROBLEM", 12, 23], ["virus", "PROBLEM", 66, 71], ["receptor interactions", "PROBLEM", 72, 93], ["virus tropism", "PROBLEM", 112, 125], ["pathogenesis", "PROBLEM", 130, 142], ["viruses", "OBSERVATION", 16, 23]]], ["The receptors and viruses examined in this study are listed in Table 1 .", [["this study", "TEST", 38, 48], ["viruses", "OBSERVATION", 18, 25]]], ["We hypothesized that the major barrier to the transmission of viruses between species is the difference in cellular receptor sequences.", [["cellular", "ANATOMY", 107, 115], ["cellular", "CELL", 107, 115], ["cellular receptor sequences", "DNA", 107, 134], ["viruses between species", "PROBLEM", 62, 85], ["viruses", "OBSERVATION", 62, 69]]], ["In other words, the specific amino acid sequence of the receptor should be the major determinant of the ability of the viral envelope protein to attach to the cell.", [["cell", "ANATOMY", 159, 163], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "AMINO_ACID", 29, 39], ["cell", "CELL", 159, 163], ["amino acid sequence", "PROTEIN", 29, 48], ["viral envelope protein", "PROTEIN", 119, 141], ["the specific amino acid sequence", "TEST", 16, 48], ["the viral envelope protein", "TREATMENT", 115, 141]]], ["Ordinary sequence alignment protocol tells us overall sequence similarity which we thought useful but insufficient because most receptors are membrane proteins and membrane proteins consist of distinctive hydrophobic and hydrophilic parts.", [["membrane", "ANATOMY", 142, 150], ["membrane", "ANATOMY", 164, 172], ["membrane", "CELLULAR_COMPONENT", 142, 150], ["membrane", "CELLULAR_COMPONENT", 164, 172], ["membrane proteins", "PROTEIN", 142, 159], ["membrane proteins", "PROTEIN", 164, 181], ["Ordinary sequence alignment protocol", "TEST", 0, 36], ["membrane proteins", "TEST", 142, 159], ["membrane proteins", "TEST", 164, 181], ["distinctive hydrophobic and hydrophilic parts", "PROBLEM", 193, 238], ["distinctive", "OBSERVATION_MODIFIER", 193, 204], ["hydrophobic", "OBSERVATION_MODIFIER", 205, 216], ["hydrophilic parts", "OBSERVATION", 221, 238]]], ["Therefore, we analysed host-cell receptor sequences for their hydrophobicity/hydrophilicity characteristics.", [["cell", "ANATOMY", 28, 32], ["cell", "CELL", 28, 32], ["host-cell receptor sequences", "DNA", 23, 51], ["their hydrophobicity/hydrophilicity characteristics", "PROBLEM", 56, 107], ["hydrophilicity characteristics", "OBSERVATION", 77, 107]]], ["We then analysed these properties for similarities among receptors of different species to predict the likelihood of transmission across species, including humans.", [["humans", "ORGANISM", 156, 162], ["humans", "SPECIES", 156, 162], ["humans", "SPECIES", 156, 162], ["different species", "PROBLEM", 70, 87], ["transmission across species", "PROBLEM", 117, 144]]], ["To our best knowledge, this study is the first attempt to predict zoonosis through a simple analysis of receptor sequence similarities and differences.", [["zoonosis", "DISEASE", 66, 74], ["this study", "TEST", 23, 33], ["a simple analysis", "TEST", 83, 100]]], ["This method may be useful in predicting the zoonotic potential of newly discovered viral strains.Results and DiscussionThe pair-wise receptor sequence similarities ( g S i,1 , g S i,2 , and g S i,3 ) between host-species pairs for each virus family are shown in Table 1 .", [["newly discovered viral strains", "PROBLEM", 66, 96], ["The pair-wise receptor sequence similarities", "TEST", 119, 163], ["g S i", "TEST", 166, 171], ["g S i", "TEST", 176, 181], ["g S i", "TEST", 190, 195], ["viral strains", "OBSERVATION", 83, 96]]], ["For logical comparisons, each virus contains at least one infected host (the primary reservoir, designated as \"#\" in Table 1 ).", [["each virus", "PROBLEM", 25, 35], ["infected", "OBSERVATION", 58, 66]]], ["As shown in Table 1 , the similarity scores for the infected group (g = 1) were high, ranging from 0.790 to 0.988 for 1 S i,1 , from 0.841 to 0.996 for 1 S i,2 , and 0.794 to 0.962 for 1 S i,3 .", [["infected", "OBSERVATION", 52, 60]]], ["All pair-wise comparisons in group 1 (human vs. primary reservoir, primary reservoir vs. host, and human vs. host) yielded high similarity scores, indicating a high similarity among receptor sequences.", [["human", "ORGANISM", 38, 43], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 99, 104], ["primary reservoir", "TREATMENT", 48, 65], ["primary reservoir", "TREATMENT", 67, 84], ["high similarity scores", "PROBLEM", 123, 145], ["a high similarity among receptor sequences", "PROBLEM", 158, 200]]], ["The similarity scores were comparatively low in the non-infection group (g = 2), ranging from 0.092 to 0.440 for 2 S i,1 , from 0.108 to 0.432 for 2 S i,2 , and from 0.130 to 0.416 for 2 S i,3 .", [["non-infection", "DISEASE", 52, 65], ["The similarity scores", "TEST", 0, 21], ["low", "OBSERVATION_MODIFIER", 41, 44]]], ["For group 2, both the primary host species and non-infected species are listed to illustrate the differences in similarity.", [["non-infected species", "PROBLEM", 47, 67], ["host species", "OBSERVATION", 30, 42], ["non-infected species", "OBSERVATION", 47, 67]]], ["In pair-wise comparisons, all the non-infection cases yielded low similarity values, i.e., the receptor sequences differed significantly from each other.Results and DiscussionWe assume that a low similarity in receptor sequences disfavors infection despite the existence of a common receptor.", [["infection", "DISEASE", 239, 248], ["all the non-infection cases", "TEST", 26, 53], ["low similarity values", "PROBLEM", 62, 83], ["the receptor sequences", "TEST", 91, 113], ["a low similarity in receptor sequences disfavors infection", "PROBLEM", 190, 248], ["low similarity", "OBSERVATION_MODIFIER", 62, 76], ["infection", "OBSERVATION", 239, 248]]], ["For example, enterovirus infects only Sus scrofa (pig); it does not infect Rattus norvegicus (rat) or Homo sapiens (human) because of the high transmission barrier.", [["enterovirus", "ORGANISM", 13, 24], ["Sus scrofa", "ORGANISM", 38, 48], ["pig", "ORGANISM", 50, 53], ["Rattus norvegicus", "ORGANISM", 75, 92], ["rat", "ORGANISM", 94, 97], ["Homo sapiens", "ORGANISM", 102, 114], ["human", "ORGANISM", 116, 121], ["Sus scrofa", "SPECIES", 38, 48], ["pig", "SPECIES", 50, 53], ["Rattus norvegicus", "SPECIES", 75, 92], ["rat", "SPECIES", 94, 97], ["Homo sapiens", "SPECIES", 102, 114], ["human", "SPECIES", 116, 121], ["Sus scrofa", "SPECIES", 38, 48], ["pig", "SPECIES", 50, 53], ["Rattus norvegicus", "SPECIES", 75, 92], ["rat", "SPECIES", 94, 97], ["Homo sapiens", "SPECIES", 102, 114], ["human", "SPECIES", 116, 121], ["enterovirus infects", "PROBLEM", 13, 32], ["enterovirus infects", "OBSERVATION", 13, 32]]], ["Similarly, for leukovirus, only Gallus gallus (chicken) is infected as a primary reservoir; because of the high transmission barrier, R. norvegicus and H. sapiens are not infected.", [["Gallus gallus", "ORGANISM", 32, 45], ["chicken", "ORGANISM", 47, 54], ["R. norvegicus", "ORGANISM", 134, 147], ["H. sapiens", "ORGANISM", 152, 162], ["Gallus gallus", "SPECIES", 32, 45], ["chicken", "SPECIES", 47, 54], ["R. norvegicus", "SPECIES", 134, 147], ["H. sapiens", "SPECIES", 152, 162], ["Gallus gallus", "SPECIES", 32, 45], ["chicken", "SPECIES", 47, 54], ["R. norvegicus", "SPECIES", 134, 147], ["H. sapiens", "SPECIES", 152, 162], ["leukovirus", "TEST", 15, 25], ["Gallus gallus", "PROBLEM", 32, 45], ["a primary reservoir", "TREATMENT", 71, 90], ["the high transmission barrier", "TREATMENT", 103, 132], ["H. sapiens", "PROBLEM", 152, 162], ["infected", "PROBLEM", 171, 179], ["Gallus gallus", "ANATOMY", 32, 45], ["infected", "OBSERVATION_MODIFIER", 59, 67], ["H. sapiens", "OBSERVATION", 152, 162], ["not", "UNCERTAINTY", 167, 170], ["infected", "OBSERVATION", 171, 179]]], ["These results imply that for non-infection cases, species barriers exist, and the propensity to cross the barrier is determined by the sequence similarity between the potential and primary host receptors.Results and DiscussionSimilarity scores for rabies virus were low between Canis lupus familiaris (domestic dog) and Bos Taurus (domestic cow) ( 2 S i,1 = 0.280, 2 S i,2 = 0.373, and 2 S i,3 = 0.366) and also between B. taurus and H. sapiens ( 2 S i,1 = 0.267, 2 S i,2 = 0.371, and 2 S i,3 = 0.416) but were high between C. l. familiaris and H. sapiens ( 1 S i,1 = 0.947, 1 S i,2 = 0.985, and 1 S i,3 = 0.962).", [["rabies virus", "DISEASE", 248, 260], ["lupus familiaris", "DISEASE", 284, 300], ["rabies virus", "ORGANISM", 248, 260], ["Canis lupus familiaris", "ORGANISM", 278, 300], ["domestic dog", "ORGANISM", 302, 314], ["Bos Taurus", "ORGANISM", 320, 330], ["cow", "ORGANISM_SUBDIVISION", 341, 344], ["B. taurus", "ORGANISM", 420, 429], ["H. sapiens", "ORGANISM", 434, 444], ["C.", "ORGANISM", 524, 526], ["l. familiaris", "ORGANISM", 527, 540], ["H. sapiens", "ORGANISM", 545, 555], ["primary host receptors", "PROTEIN", 181, 203], ["Canis lupus familiaris", "SPECIES", 278, 300], ["dog", "SPECIES", 311, 314], ["Bos Taurus", "SPECIES", 320, 330], ["cow", "SPECIES", 341, 344], ["B. taurus", "SPECIES", 420, 429], ["H. sapiens", "SPECIES", 434, 444], ["C.", "SPECIES", 524, 526], ["l. familiaris", "SPECIES", 527, 540], ["H. sapiens", "SPECIES", 545, 555], ["rabies virus", "SPECIES", 248, 260], ["Canis lupus familiaris", "SPECIES", 278, 300], ["Bos Taurus", "SPECIES", 320, 330], ["B. taurus", "SPECIES", 420, 429], ["H. sapiens", "SPECIES", 434, 444], ["C. l. familiaris", "SPECIES", 524, 540], ["H. sapiens", "SPECIES", 545, 555], ["non-infection cases", "PROBLEM", 29, 48], ["DiscussionSimilarity scores", "TEST", 216, 243], ["rabies virus", "PROBLEM", 248, 260], ["Canis lupus familiaris", "PROBLEM", 278, 300], ["B. taurus", "TEST", 420, 429], ["H. sapiens", "TEST", 434, 444], ["S i", "TEST", 449, 452], ["S", "TEST", 466, 467], ["S i", "TEST", 487, 490], ["H. sapiens", "TEST", 545, 555], ["S", "TEST", 577, 578], ["H. sapiens", "OBSERVATION", 434, 444]]], ["Clearly, C. l. familiaris is the primary reservoir, and transmission of the disease to H. sapiens is possible only because of the high human/ dog receptor similarity.", [["H. sapiens", "DISEASE", 87, 97], ["C. l. familiaris", "ORGANISM", 9, 25], ["H. sapiens", "ORGANISM", 87, 97], ["human", "ORGANISM", 135, 140], ["dog", "ORGANISM", 142, 145], ["C.", "SPECIES", 9, 11], ["l. familiaris", "SPECIES", 12, 25], ["H. sapiens", "SPECIES", 87, 97], ["human", "SPECIES", 135, 140], ["C. l. familiaris", "SPECIES", 9, 25], ["H. sapiens", "SPECIES", 87, 97], ["human", "SPECIES", 135, 140], ["the disease", "PROBLEM", 72, 83], ["H. sapiens", "PROBLEM", 87, 97]]], ["Thus, for particular viruses, transmission of disease may be species-selective, although common receptors exist among species.", [["particular viruses", "PROBLEM", 10, 28], ["disease", "PROBLEM", 46, 53], ["disease", "OBSERVATION", 46, 53]]], ["Furthermore, infection specificity may be determined by the species barrier, which results from receptor differences.Results and DiscussionThe values in Table 1 are plotted in Figure 1 to illustrate the differences among groups.", [["infection", "DISEASE", 13, 22], ["infection", "PROBLEM", 13, 22], ["infection", "OBSERVATION", 13, 22]]], ["The x-and y-axes denote g S i,1 and g S i,2 , respectively, where \"g\" is the group classification.", [["The x-and y-axes", "TEST", 0, 16], ["g S i", "TEST", 24, 29]]], ["The results provide clear evidence that the receptor sequences from cases of cross-species infection are well separated from those of other infection cases.", [["infection", "DISEASE", 91, 100], ["infection", "DISEASE", 140, 149], ["the receptor sequences", "TEST", 40, 62], ["cross-species infection", "PROBLEM", 77, 100], ["other infection cases", "PROBLEM", 134, 155], ["infection", "OBSERVATION", 91, 100], ["infection", "OBSERVATION", 140, 149]]], ["From these observations, we conclude that receptor differences are a major contributing factor to the potential of a specific viral strain to cross species barriers for transmission.", [["a specific viral strain", "PROBLEM", 115, 138]]], ["In other words, the species dependence of infection is indirectly related to the receptor sequence similarity.", [["infection", "DISEASE", 42, 51], ["infection", "PROBLEM", 42, 51], ["infection", "OBSERVATION", 42, 51]]], ["This finding implies that once the receptor sequences of the primary reservoir and possible hosts are known, we might be able to predict the likelihood of viral disease transmission.", [["viral disease transmission", "DISEASE", 155, 181], ["viral disease transmission", "PROBLEM", 155, 181], ["viral disease", "OBSERVATION", 155, 168]]], ["Three kinds of pairwise similarity scores ( g S i,1 , g S i,2 , g S i,3 ) are plotted in two dimensional space to show clear differences among groups.", [["pairwise similarity scores", "TEST", 15, 41], ["g S i", "TEST", 44, 49], ["g S i", "TEST", 54, 59], ["g S i", "TEST", 64, 69], ["clear differences among groups", "PROBLEM", 119, 149], ["clear", "OBSERVATION", 119, 124]]], ["Groups 1, 2 and 3 are each well separated; the results show clearly that the receptor sequences from cases of cross-species infection are well distinguished from those of other infection cases.Results and Discussionby subsequent assessment of cases of actual zoonotic transmission to humans.Results and DiscussionOur analysis revealed significant differences in receptor similarity between infection and non-infection cases.Results and DiscussionThe similarity values, and the experimentally determined group categories were fed into a statistical discriminant analysis to logically predict infection (or zoonosis, in the case of human infection).", [["infection", "DISEASE", 124, 133], ["infection", "DISEASE", 177, 186], ["infection", "DISEASE", 390, 399], ["non-infection", "DISEASE", 404, 417], ["infection", "DISEASE", 591, 600], ["zoonosis", "DISEASE", 605, 613], ["infection", "DISEASE", 636, 645], ["3", "GENE_OR_GENE_PRODUCT", 16, 17], ["humans", "ORGANISM", 284, 290], ["human", "ORGANISM", 630, 635], ["humans", "SPECIES", 284, 290], ["human", "SPECIES", 630, 635], ["humans", "SPECIES", 284, 290], ["human", "SPECIES", 630, 635], ["the receptor sequences", "TEST", 73, 95], ["cross-species infection", "PROBLEM", 110, 133], ["other infection cases", "PROBLEM", 171, 192], ["subsequent assessment", "TEST", 218, 239], ["DiscussionOur analysis", "TEST", 303, 325], ["significant differences in receptor similarity between infection and non-infection cases", "PROBLEM", 335, 423], ["The similarity values", "TEST", 446, 467], ["infection", "PROBLEM", 591, 600], ["zoonosis", "PROBLEM", 605, 613], ["human infection", "PROBLEM", 630, 645], ["infection", "OBSERVATION", 124, 133], ["infection", "OBSERVATION", 177, 186], ["significant", "OBSERVATION_MODIFIER", 335, 346], ["infection", "OBSERVATION", 390, 399], ["infection", "OBSERVATION", 636, 645]]], ["As described in the Materials and Methods section, the values D i 2 (i = 1, 2, 3) were calculated from the data in the Table 1 to yield results of a specific discriminant analysis.Results and DiscussionThe statistical discriminant analysis was verified using a test set of four viruses that were deliberately excluded from the training set.", [["Methods section", "TEST", 34, 49], ["the values D i", "TEST", 51, 65], ["a specific discriminant analysis", "TEST", 147, 179], ["The statistical discriminant analysis", "TEST", 202, 239], ["four viruses", "PROBLEM", 273, 285]]], ["The viruses whose groups were predicted using the discriminant analysis are shown in Table 2 .", [["the discriminant analysis", "TEST", 46, 71], ["viruses", "OBSERVATION", 4, 11]]], ["The first virus, feline immunodeficiency virus (FIV), uses Felis catus (domestic cat) as its primary host and CD4 as its receptor.", [["feline immunodeficiency virus", "DISEASE", 17, 46], ["feline immunodeficiency virus", "ORGANISM", 17, 46], ["FIV", "ORGANISM", 48, 51], ["Felis catus", "ORGANISM", 59, 70], ["domestic cat", "ORGANISM", 72, 84], ["CD4", "GENE_OR_GENE_PRODUCT", 110, 113], ["CD4", "PROTEIN", 110, 113], ["feline immunodeficiency virus", "SPECIES", 17, 46], ["Felis catus", "SPECIES", 59, 70], ["feline immunodeficiency virus", "SPECIES", 17, 46], ["FIV", "SPECIES", 48, 51], ["Felis catus", "SPECIES", 59, 70], ["The first virus", "PROBLEM", 0, 15], ["feline immunodeficiency virus", "PROBLEM", 17, 46], ["Felis catus", "TREATMENT", 59, 70]]], ["According to the literature [22, 23] , FIV infection of humans is rare but has been reported.", [["FIV infection", "DISEASE", 39, 52], ["FIV", "ORGANISM", 39, 42], ["humans", "ORGANISM", 56, 62], ["humans", "SPECIES", 56, 62], ["humans", "SPECIES", 56, 62], ["FIV infection of humans", "PROBLEM", 39, 62], ["infection", "OBSERVATION", 43, 52]]], ["The second virus, classical swine fever virus, is known to be non-zoonotic and was classified as such by our method (G = 2).", [["swine fever", "DISEASE", 28, 39], ["classical swine fever virus", "ORGANISM", 18, 45], ["swine fever virus", "SPECIES", 28, 45], ["swine fever virus", "SPECIES", 28, 45], ["The second virus", "PROBLEM", 0, 16], ["classical swine fever virus", "PROBLEM", 18, 45]]], ["Thirdly, the encephalomyocarditis virus infects S. scrofa but has been known to cause sporadic infections in H. sapiens; it was classified as group 1 (G = 1) by our method.", [["encephalomyocarditis virus", "DISEASE", 13, 39], ["infections", "DISEASE", 95, 105], ["encephalomyocarditis virus", "ORGANISM", 13, 39], ["S. scrofa", "ORGANISM", 48, 57], ["H. sapiens", "ORGANISM", 109, 119], ["encephalomyocarditis virus", "SPECIES", 13, 39], ["S. scrofa", "SPECIES", 48, 57], ["H. sapiens", "SPECIES", 109, 119], ["encephalomyocarditis virus", "SPECIES", 13, 39], ["S. scrofa", "SPECIES", 48, 57], ["H. sapiens", "SPECIES", 109, 119], ["the encephalomyocarditis virus", "PROBLEM", 9, 39], ["sporadic infections in H. sapiens", "PROBLEM", 86, 119], ["encephalomyocarditis virus", "OBSERVATION", 13, 39], ["sporadic", "OBSERVATION_MODIFIER", 86, 94], ["infections", "OBSERVATION", 95, 105], ["H. sapiens", "OBSERVATION_MODIFIER", 109, 119]]], ["Finally, the Lass virus is known to be zoonotic and was classified as group 1 (G = 1) by our method.Results and DiscussionIn Table 2 , the hydrophilic similarity scores (S 1 ) show less consistency, comparing to the hydrophobic scores (S2), with the predictive values (G).", [["Lass virus", "ORGANISM", 13, 23], ["Lass virus", "SPECIES", 13, 23], ["the Lass virus", "PROBLEM", 9, 23], ["the hydrophilic similarity scores", "TEST", 135, 168], ["less consistency", "OBSERVATION_MODIFIER", 181, 197]]], ["From the result, it could be said that the hydrophobic characteristics of receptor sequence might be the key contributor to the prediction.", [["the hydrophobic characteristics of receptor sequence", "PROBLEM", 39, 91]]], ["However, this observation should only be carefully interpreted because the variables (S1, S2, S3) are complementary in the statistical process.ConclusionsOur analysis of viral receptor sequences shows that the likelihood of viral infection correlates with the similarity in sequence of the primary and host receptors.", [["viral infection", "DISEASE", 224, 239], ["viral receptor sequences", "DNA", 170, 194], ["primary and host receptors", "PROTEIN", 290, 316], ["this observation", "TEST", 9, 25], ["the variables (S1, S2, S3)", "PROBLEM", 71, 97], ["Our analysis", "TEST", 154, 166], ["viral receptor sequences", "TEST", 170, 194], ["viral infection", "PROBLEM", 224, 239], ["viral", "OBSERVATION_MODIFIER", 224, 229], ["infection", "OBSERVATION", 230, 239]]], ["This result is not surprising, because viral infection also inversely correlates with the inhibition of viral coat protein binding to the receptors.", [["viral infection", "DISEASE", 39, 54], ["viral coat protein", "PROTEIN", 104, 122], ["viral infection", "PROBLEM", 39, 54], ["viral coat protein binding", "PROBLEM", 104, 130], ["not surprising", "UNCERTAINTY", 15, 29], ["infection", "OBSERVATION", 45, 54]]], ["Importantly, we were able to establish this relationship at the amino acid sequence level, allowing for the prediction of possible human infection at an early stage of a viral outbreak, before the structures of viral coat proteins and receptors are known.", [["amino acid", "CHEMICAL", 64, 74], ["infection", "DISEASE", 137, 146], ["amino acid", "CHEMICAL", 64, 74], ["amino acid", "AMINO_ACID", 64, 74], ["human", "ORGANISM", 131, 136], ["viral coat proteins", "PROTEIN", 211, 230], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["the amino acid sequence level", "TEST", 60, 89], ["human infection", "PROBLEM", 131, 146], ["a viral outbreak", "PROBLEM", 168, 184], ["viral coat proteins", "PROBLEM", 211, 230], ["infection", "OBSERVATION", 137, 146], ["viral outbreak", "OBSERVATION", 170, 184], ["viral coat proteins", "OBSERVATION", 211, 230]]], ["Therefore, once the receptor sequences of primary reservoir and the potential host are known, the likelihood of viral infection can be predicted if the virus does not mutate too abruptly.", [["viral infection", "DISEASE", 112, 127], ["primary reservoir", "TREATMENT", 42, 59], ["viral infection", "PROBLEM", 112, 127], ["the virus", "PROBLEM", 148, 157], ["viral", "OBSERVATION_MODIFIER", 112, 117], ["infection", "OBSERVATION", 118, 127]]], ["Our simplistic approach needs further refinement because the complex processes of host tropism of viruses are largely ignored in our current method.", [["further refinement", "TREATMENT", 30, 48], ["host tropism of viruses", "PROBLEM", 82, 105], ["host tropism", "OBSERVATION_MODIFIER", 82, 94], ["viruses", "OBSERVATION", 98, 105]]], ["For example, the process of host immune response could be included for better prediction of zoonosis.", [["zoonosis", "DISEASE", 92, 100], ["zoonosis", "PROBLEM", 92, 100], ["host immune", "OBSERVATION", 28, 39], ["zoonosis", "OBSERVATION", 92, 100]]], ["Although further refinements of our methods and analyses of larger databases are needed, this simple conceptual approach may be useful, even now, as a basic tool for the classification of zoonosis of new viral species.Data collectionViral infection requires the insertion of viral genes into host cells.", [["cells", "ANATOMY", 297, 302], ["zoonosis", "DISEASE", 188, 196], ["Viral infection", "DISEASE", 233, 248], ["host cells", "CELL", 292, 302], ["viral genes", "DNA", 275, 286], ["host cells", "CELL_TYPE", 292, 302], ["our methods", "TEST", 32, 43], ["larger databases", "TEST", 60, 76], ["zoonosis", "PROBLEM", 188, 196], ["new viral species", "PROBLEM", 200, 217], ["Data collection", "TEST", 218, 233], ["Viral infection", "PROBLEM", 233, 248], ["the insertion of viral genes into host cells", "TREATMENT", 258, 302], ["zoonosis", "OBSERVATION", 188, 196], ["new", "OBSERVATION_MODIFIER", 200, 203], ["viral species", "OBSERVATION", 204, 217], ["infection", "OBSERVATION", 239, 248], ["viral genes", "OBSERVATION", 275, 286], ["host cells", "OBSERVATION", 292, 302]]], ["Such a process begins with the binding of coat proteins to host receptors, and in some cases, coreceptors [24] .", [["coat proteins", "PROTEIN", 42, 55], ["host receptors", "PROTEIN", 59, 73], ["coreceptors", "PROTEIN", 94, 105]]], ["Ten RNA viruses (seven zoonotic viruses and three non-zoonotic viruses) were investigated.", [["zoonotic viruses", "DISEASE", 23, 39], ["Ten RNA viruses (seven zoonotic viruses", "PROBLEM", 0, 39], ["three non-zoonotic viruses", "PROBLEM", 44, 70], ["RNA viruses", "OBSERVATION", 4, 15]]], ["Viruses that use co-receptors were excluded from the study.", [["co-receptors", "PROTEIN", 17, 29], ["the study", "TEST", 49, 58]]], ["Receptor sequence data for each virus were collected from the National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/, and the research literature was examined to determine the specific species tropism of each virus [[25] , http://www.ictvonline.org/].", [["Receptor sequence data", "TEST", 0, 22], ["each virus", "PROBLEM", 27, 37], ["each virus", "PROBLEM", 224, 234]]], ["The viruses, host species, receptors, receptor sequences, and infection information for each host are shown in Table 1 .", [["infection", "DISEASE", 62, 71], ["The viruses", "PROBLEM", 0, 11], ["receptor sequences", "TEST", 38, 56], ["infection", "PROBLEM", 62, 71], ["viruses", "OBSERVATION", 4, 11], ["host species", "OBSERVATION", 13, 25], ["infection", "OBSERVATION", 62, 71]]], ["We selected viruses that are each a representative of a different family, with different primary reservoirs.", [["viruses", "OBSERVATION", 12, 19], ["primary reservoirs", "OBSERVATION", 89, 107]]], ["Viruses with unknown or poorly defined host receptors (particularly human receptors) were excluded from the study.", [["human", "ORGANISM", 68, 73], ["host receptors", "PROTEIN", 39, 53], ["human receptors", "PROTEIN", 68, 83], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["Viruses", "PROBLEM", 0, 7], ["the study", "TEST", 104, 113], ["poorly defined", "OBSERVATION_MODIFIER", 24, 38], ["host receptors", "OBSERVATION", 39, 53]]], ["Orthologues of the where N tot is the total number of amino acids in one sequence string; n tot is the total number of matched amino acids in the sequence; N phi and N pho are the numbers of hydrophilic and hydrophobic amino acids in the sequence, respectively; N others is the number of deleted amino acids (gaps/insertions in sequence) plus the number of amino acids with undetermined properties; n phi and n pho are the numbers of hydrophilic and hydrophobic amino acids matched, respectively; and g S i,1 is the similarity score for hydrophilic residues of the i th row of infection group g.", [["amino acids", "CHEMICAL", 54, 65], ["amino acids", "CHEMICAL", 127, 138], ["amino acids", "CHEMICAL", 219, 230], ["amino acids", "CHEMICAL", 296, 307], ["amino acids", "CHEMICAL", 357, 368], ["amino acids", "CHEMICAL", 462, 473], ["infection", "DISEASE", 577, 586], ["N", "CHEMICAL", 25, 26], ["amino acids", "CHEMICAL", 54, 65], ["amino acids", "CHEMICAL", 127, 138], ["N", "CHEMICAL", 166, 167], ["amino acids", "CHEMICAL", 219, 230], ["amino acids", "CHEMICAL", 296, 307], ["amino acids", "CHEMICAL", 357, 368], ["amino acids", "CHEMICAL", 462, 473], ["amino acids", "AMINO_ACID", 54, 65], ["amino acids", "AMINO_ACID", 127, 138], ["N pho", "GENE_OR_GENE_PRODUCT", 166, 171], ["amino acids", "AMINO_ACID", 219, 230], ["amino acids", "AMINO_ACID", 296, 307], ["amino acids", "AMINO_ACID", 357, 368], ["amino acids", "AMINO_ACID", 462, 473], ["N tot", "PROTEIN", 25, 30], ["N phi", "PROTEIN", 156, 161], ["N pho", "PROTEIN", 166, 171], ["amino acids", "TREATMENT", 54, 65], ["matched amino acids", "TREATMENT", 119, 138], ["phi and N pho", "TREATMENT", 158, 171], ["hydrophilic and hydrophobic amino acids", "TREATMENT", 191, 230], ["deleted amino acids", "TREATMENT", 288, 307], ["gaps/insertions in sequence", "TREATMENT", 309, 336], ["amino acids", "TREATMENT", 357, 368], ["phi and n pho", "TREATMENT", 401, 414], ["hydrophilic and hydrophobic amino acids", "TREATMENT", 434, 473], ["hydrophilic residues", "PROBLEM", 537, 557], ["infection group g.", "PROBLEM", 577, 595], ["infection", "OBSERVATION", 577, 586]]], ["Here, there are only three groups: g = 1, 2, or 3, which are the infection, non-infection, and near-infection groups, respectively.", [["infection", "DISEASE", 65, 74], ["non-infection", "DISEASE", 76, 89], ["infection", "DISEASE", 100, 109], ["the infection", "PROBLEM", 61, 74], ["non-infection", "PROBLEM", 76, 89], ["near-infection groups", "PROBLEM", 95, 116], ["infection", "OBSERVATION", 65, 74], ["infection", "OBSERVATION", 100, 109]]], ["The interspecies infection information was identified and classified among three infection states: group 1 (g = 1) represents infection; group 2 (g = 2) represents non-infection; and group 3 (g = 3) represents nearinfection.", [["infection", "DISEASE", 17, 26], ["infection", "DISEASE", 81, 90], ["infection", "DISEASE", 126, 135], ["non-infection", "DISEASE", 164, 177], ["The interspecies infection", "PROBLEM", 0, 26], ["infection", "PROBLEM", 126, 135], ["non-infection", "PROBLEM", 164, 177], ["nearinfection", "PROBLEM", 210, 223], ["infection", "OBSERVATION", 17, 26], ["infection", "OBSERVATION", 81, 90], ["infection", "OBSERVATION", 126, 135], ["nearinfection", "OBSERVATION", 210, 223]]], ["By definition, if a group 1 species pair includes humans, then the infection is zoonotic.", [["infection", "DISEASE", 67, 76], ["humans", "ORGANISM", 50, 56], ["humans", "SPECIES", 50, 56], ["humans", "SPECIES", 50, 56], ["a group 1 species pair", "PROBLEM", 18, 40], ["the infection", "PROBLEM", 63, 76], ["infection", "OBSERVATION", 67, 76]]], ["Decisions for grouping were made on the basis of experimental and epidemiological studies reported in the literature [4, [30] [31] [32] [33] .Data collectionThe variables (shown in Table 1 ) were arranged in matrices to allow for discriminant analysis, a method of multivariate analysis that can determine the group related to variables [34] .", [["[30] [31] [32] [33]", "SIMPLE_CHEMICAL", 121, 140], ["epidemiological studies", "TEST", 66, 89], ["Data collection", "TEST", 142, 157], ["discriminant analysis", "TEST", 230, 251], ["multivariate analysis", "TEST", 265, 286]]], ["Here, the matrix for group 1 is defined as:Data collectionSimilarly, 2 S and 3 S were defined as: All of the related variables were tabulated as shown in Table 1 .", [["matrix", "CELLULAR_COMPONENT", 10, 16], ["Data collection", "TEST", 43, 58]]], ["From the above matrices, three averages were found for each group:Data collectionThe averages 2 S m,1 , 2 S m,2 , and 2 S m,3 for group 2 and 3 S n,2 , 3 S n,2 , and 3 S n,3 for group 3 were calculated similarly.Data collectionThree covariant matrices were constructed as:Data collection1 C = \u23a1 \u23a3 1 C 1,1 1 C 1,2 1 C 1,3 1 C 2,1 1 C 2,2 1 C 2,3 1 C 3,1 1 C 3,2 1 C 3,3 \u23a4 \u23a6Data collectionwhere X 1,i = 1 S i,1 \u2212 1 S l,1 2 X 2,i = 1 S i,2 \u2212 1 S l,2 2 and X 3,i = 1 S i,3 \u2212 1 S l,3 2 Similar treatments yielded the 2 C and 3 C matrices, resulting in three covariance matrices ( 1 C, 2 C, and 3 C).", [["C 2,1 1 C 2,2 1 C 2,3 1 C 3,1 1 C 3,2 1 C", "CHEMICAL", 323, 364], ["C 1,3 1 C 2,1 1 C 2,2 1 C 2,3 1 C 3,1 1 C 3,2 1 C 3,3", "SIMPLE_CHEMICAL", 315, 368], ["X 1", "DNA", 393, 396], ["Data collection", "TEST", 66, 81], ["The averages", "TEST", 81, 93], ["group", "TEST", 130, 135], ["Data collection", "TEST", 212, 227], ["C", "TEST", 289, 290], ["\u23a1", "TEST", 293, 294], ["\u23a3", "TEST", 295, 296], ["C", "TEST", 299, 300], ["C", "TEST", 307, 308], ["C", "TEST", 315, 316], ["C", "TEST", 323, 324], ["C", "TEST", 331, 332], ["C", "TEST", 339, 340], ["C", "TEST", 347, 348], ["C", "TEST", 355, 356], ["C", "TEST", 363, 364], ["Data collectionwhere", "TEST", 372, 392], ["i", "TEST", 397, 398], ["S i", "TEST", 403, 406], ["\u2212", "TEST", 409, 410], ["S l", "TEST", 413, 416], ["i", "TEST", 425, 426], ["S i", "TEST", 431, 434], ["\u2212", "TEST", 437, 438], ["S l", "TEST", 441, 444], ["S i", "TEST", 463, 466], ["S l", "TEST", 473, 476], ["Similar treatments", "TEST", 481, 499], ["C matrices", "TEST", 522, 532], ["three covariance matrices", "TEST", 547, 572]]], ["We then created a pool-within-class covariance matrix P. If we define L = 3l-1, M = 3m-1, and N = 3n-1, then: P = \u23a1 \u23a3 P 1,1 P 1,2 P 1,3 P 2,1 P 2,2 P 2,3 P 3,1 P 3,2 P 3,3 \u23a4 \u23a6 where P 1,1 = ( 1 C 1,1 L + 2 C 1,1 M + 3 C 1,1 N)/(L + M + N) P 2,2 = ( 1 C 2,2 L + 2 C 2,2 M + 3 C 2,2 N)/(L + M + N) P 3,3 = ( 1 C 3,3 L + 2 C 3,3 M + 3 C 3,3 N)/(L + M + N) P 1,2 = ( 1 C 1,2 L + 2 C 1,2 M + 3 C 1,2 N)/(L + M + N) P 1,3 = ( 1 C 1,3 L + 2 C 1,3 M + 3 C 1,3 N)/(L + M + N) P 2,3 = ( 1 C 2,3 L + 2 C 2,3 M + 3 C 2,3 N)/(L + M + N) also P 2,1 = P 1,2 P 3,1 = P 1,3 P 3,2 = P 2,3Data collectionWe next found the inverse matrix I, where I = P -1 .", [["3 C 1,1 N)", "CHEMICAL", 216, 226], ["(L + M + N) P", "CHEMICAL", 227, 240], ["3 C 2,2 N)", "CHEMICAL", 273, 283], ["(L + M + N) P", "CHEMICAL", 284, 297], ["3 C 3,3 N)", "CHEMICAL", 330, 340], ["(L + M + N) P", "CHEMICAL", 341, 354], ["3 C 1,2 N)", "CHEMICAL", 387, 397], ["(L + M + N) P", "CHEMICAL", 398, 411], ["3 C 1,3 N)", "CHEMICAL", 444, 454], ["(L + M + N) P", "CHEMICAL", 455, 468], ["3 C 2,3 N)", "CHEMICAL", 501, 511], ["N", "CHEMICAL", 521, 522], ["P 2,1 = P 1,2 P 3,1 = P 1,3 P 3,2 = P", "CHEMICAL", 529, 566], ["1 C 1,1 L + 2 C 1,1 M + 3 C 1,1 N)", "SIMPLE_CHEMICAL", 192, 226], ["L + M + N) P 2,2 = ( 1 C 2,2 L + 2 C 2,2 M + 3 C 2,2 N)/(L + M + N) P 3,3 = ( 1 C 3,3 L + 2 C 3,3 M + 3 C 3,3 N)/(L + M + N) P 1,2 = ( 1 C 1,2 L + 2 C 1,2 M + 3 C 1,2 N)/(L + M + N) P 1,3 = ( 1 C 1,3 L + 2 C 1,3 M + 3 C 1,3 N)/(L + M + N) P 2,3 = ( 1 C 2,3 L + 2 C 2,3 M + 3 C 2,3 N)/(L + M + N)", "SIMPLE_CHEMICAL", 228, 523], ["P 2,1 = P 1,2 P 3,1 = P 1,3 P 3,2 = P 2,3Data", "SIMPLE_CHEMICAL", 529, 574], ["I = P -1", "PROTEIN", 627, 635], ["L", "TEST", 70, 71], ["N", "TEST", 94, 95], ["P", "TEST", 110, 111], ["\u23a1", "TEST", 114, 115], ["\u23a3", "TEST", 116, 117], ["P", "TEST", 118, 119], ["P", "TEST", 124, 125], ["P", "TEST", 130, 131], ["P", "TEST", 136, 137], ["P", "TEST", 142, 143], ["P", "TEST", 148, 149], ["P", "TEST", 154, 155], ["P", "TEST", 160, 161], ["P", "TEST", 166, 167], ["\u23a4", "TEST", 172, 173], ["\u23a6", "TEST", 174, 175], ["where", "TEST", 176, 181], ["P", "TEST", 182, 183], ["C", "TEST", 194, 195], ["L", "TEST", 200, 201], ["C", "TEST", 206, 207], ["M", "TEST", 212, 213], ["C", "TEST", 218, 219], ["N", "TEST", 224, 225], ["L", "TEST", 228, 229], ["M", "TEST", 232, 233], ["N", "TEST", 236, 237], ["P", "TEST", 239, 240], ["C", "TEST", 251, 252], ["L", "TEST", 257, 258], ["C", "TEST", 263, 264], ["M", "TEST", 269, 270], ["C", "TEST", 275, 276], ["N", "TEST", 281, 282], ["L", "TEST", 285, 286], ["M", "TEST", 289, 290], ["N", "TEST", 293, 294], ["P", "TEST", 296, 297], ["C", "TEST", 308, 309], ["L", "TEST", 314, 315], ["C", "TEST", 320, 321], ["M", "TEST", 326, 327], ["C", "TEST", 332, 333], ["N", "TEST", 338, 339], ["L", "TEST", 342, 343], ["M", "TEST", 346, 347], ["N", "TEST", 350, 351], ["P", "TEST", 353, 354], ["C", "TEST", 365, 366], ["L", "TEST", 371, 372], ["C", "TEST", 377, 378], ["M", "TEST", 383, 384], ["C", "TEST", 389, 390], ["N", "TEST", 395, 396], ["L", "TEST", 399, 400], ["M", "TEST", 403, 404], ["N", "TEST", 407, 408], ["P", "TEST", 410, 411], ["C", "TEST", 422, 423], ["L", "TEST", 428, 429], ["C", "TEST", 434, 435], ["M", "TEST", 440, 441], ["C", "TEST", 446, 447], ["N", "TEST", 452, 453], ["P", "TEST", 467, 468], ["C", "TEST", 479, 480], ["L", "TEST", 485, 486], ["C", "TEST", 491, 492], ["M", "TEST", 497, 498], ["C", "TEST", 503, 504], ["N", "TEST", 509, 510], ["L", "TEST", 513, 514], ["M", "TEST", 517, 518], ["P", "TEST", 529, 530], ["P", "TEST", 537, 538], ["P", "TEST", 543, 544], ["P", "TEST", 551, 552], ["P", "TEST", 557, 558], ["3,2", "TEST", 559, 562], ["P", "TEST", 565, 566], ["collectionWe", "TEST", 575, 587], ["next", "TEST", 588, 592], ["the inverse matrix I", "TEST", 599, 619], ["P", "TEST", 631, 632]]], ["Because there were three groups in our study, we predicted the likelihood of infection for a virus of unknown infection condition by calculating the Mahalanobis distance (generally D 2 = d 1 \u00d7 C -1 \u00d7 D i ).Data collectionHere, expansion of D 2 yielded three equations:Data collectionD 1 2 = \u03c3 1,l I 11 + \u03c3 2,l I 21 + \u03c3 3,l I 31 \u03c3 1,l + \u03c3 1,l I 12 + \u03c3 2,l I 22 + \u03c3 3,l I 32 \u03c3 2,l + \u03c3 1,l I 13 + \u03c3 2,l I 23 + \u03c3 3,l I 33 \u03c3 3,l D 2 2 = \u03c3 1,m I 11 + \u03c3 2,m I 21 + \u03c3 3,m I 31 \u03c3 1,m + \u03c3 1,m I 12 + \u03c3 2,m I 22 + \u03c3 3,m I 32 \u03c3 2,m + \u03c3 1,m I 13 + \u03c3 2,m I 23 + \u03c3 3,m I 33 \u03c3 3,m D 3 2 = \u03c3 1,n I 11 + \u03c3 2,n I 21 + \u03c3 3,n I 31 \u03c3 1,n + \u03c3 1,n I 12 + \u03c3 2,n I 22 + \u03c3 3,n I 32 \u03c3 2,n + \u03c3 1,n I 13 + \u03c3 2,n I 23 + \u03c3 3,n I 33 \u03c3 3,n where \u03c3 1,l = S 1 \u2212 1 S l,1 \u03c3 2,l = S 2 \u2212 1 S l,2 \u03c3 3,l = S 3 \u2212 1 S l,3 \u03c3 1,m = S 1 \u2212 1 S m,1 \u03c3 2,m = S 2 \u2212 1 S m,2 \u03c3 3,m = S 3 \u2212 1 S m,3 \u03c3 1,n = S 1 \u2212 1 S n,1 \u03c3 2,n = S 2 \u2212 1 S n,2 \u03c3 3,n = S 3 \u2212 1 S n,3Data collectionwhere S 1 , S 2 , and S 3 are the input variables; here, they were similarity variables of a virus of an unknown infection group.Data collectionGroup classification (G) was identified using the criterion:Data collectionFor example, if D 1 2 is the minimum among three values from the above set of three equations, then G = 1; i.e., \"group 1\" is the group classification.", [["infection", "DISEASE", 77, 86], ["infection", "DISEASE", 110, 119], ["infection", "DISEASE", 1037, 1046], ["S 3", "DNA", 946, 949], ["our study", "TEST", 35, 44], ["infection", "PROBLEM", 77, 86], ["a virus of unknown infection condition", "PROBLEM", 91, 129], ["Data collection", "TEST", 206, 221], ["l I", "TEST", 295, 298], ["l I", "TEST", 308, 311], ["\u03c3", "TEST", 317, 318], ["l I", "TEST", 321, 324], ["\u03c3", "TEST", 328, 329], ["l", "TEST", 332, 333], ["\u03c3", "TEST", 336, 337], ["\u03c3", "TEST", 349, 350], ["\u03c3", "TEST", 362, 363], ["\u03c3", "TEST", 373, 374], ["l", "TEST", 377, 378], ["\u03c3", "TEST", 381, 382], ["\u03c3", "TEST", 394, 395], ["\u03c3", "TEST", 407, 408], ["l I", "TEST", 411, 414], ["\u03c3", "TEST", 418, 419], ["D", "TEST", 424, 425], ["\u03c3", "TEST", 432, 433], ["m I", "TEST", 436, 439], ["\u03c3", "TEST", 445, 446], ["m I", "TEST", 449, 452], ["m I", "TEST", 462, 465], ["\u03c3", "TEST", 469, 470], ["m", "TEST", 473, 474], ["\u03c3", "TEST", 477, 478], ["m I", "TEST", 481, 484], ["\u03c3", "TEST", 490, 491], ["m I", "TEST", 494, 497], ["\u03c3", "TEST", 503, 504], ["m I", "TEST", 507, 510], ["\u03c3", "TEST", 514, 515], ["m", "TEST", 518, 519], ["\u03c3", "TEST", 522, 523], ["m I", "TEST", 526, 529], ["\u03c3", "TEST", 535, 536], ["m I", "TEST", 539, 542], ["\u03c3", "TEST", 548, 549], ["m I", "TEST", 552, 555], ["\u03c3", "TEST", 559, 560], ["D", "TEST", 565, 566], ["\u03c3", "TEST", 573, 574], ["I", "TEST", 579, 580], ["\u03c3", "TEST", 586, 587], ["I", "TEST", 592, 593], ["\u03c3", "TEST", 599, 600], ["I", "TEST", 605, 606], ["\u03c3", "TEST", 610, 611], ["n", "TEST", 614, 615], ["\u03c3", "TEST", 618, 619], ["I", "TEST", 624, 625], ["\u03c3", "TEST", 631, 632], ["I", "TEST", 637, 638], ["\u03c3", "TEST", 644, 645], ["I", "TEST", 650, 651], ["\u03c3", "TEST", 655, 656], ["\u03c3", "TEST", 663, 664], ["I", "TEST", 669, 670], ["\u03c3", "TEST", 676, 677], ["I", "TEST", 682, 683], ["\u03c3", "TEST", 689, 690], ["I", "TEST", 695, 696], ["\u03c3", "TEST", 712, 713], ["1,l", "TEST", 714, 717], ["S", "TEST", 720, 721], ["S l", "TEST", 728, 731], ["\u03c3", "TEST", 734, 735], [",l", "TEST", 737, 739], ["S", "TEST", 742, 743], ["\u2212", "TEST", 746, 747], ["S l", "TEST", 750, 753], ["\u03c3", "TEST", 756, 757], ["l", "TEST", 760, 761], ["S", "TEST", 764, 765], ["S l", "TEST", 772, 775], ["\u03c3", "TEST", 778, 779], ["m", "TEST", 782, 783], ["S", "TEST", 786, 787], ["S m", "TEST", 794, 797], ["\u03c3", "TEST", 800, 801], ["m", "TEST", 804, 805], ["S", "TEST", 808, 809], ["S m", "TEST", 816, 819], ["\u03c3", "TEST", 822, 823], ["m", "TEST", 826, 827], ["S", "TEST", 830, 831], ["S m", "TEST", 838, 841], ["\u03c3", "TEST", 844, 845], ["S", "TEST", 852, 853], ["S n", "TEST", 860, 863], ["\u03c3", "TEST", 866, 867], ["S", "TEST", 874, 875], ["S n", "TEST", 882, 885], ["\u03c3", "TEST", 888, 889], ["S", "TEST", 896, 897], ["S n", "TEST", 904, 907], ["3Data collectionwhere S", "TEST", 908, 931], ["S", "TEST", 936, 937], ["S", "TEST", 946, 947], ["the input variables", "TEST", 954, 973], ["a virus", "PROBLEM", 1015, 1022], ["an unknown infection group", "PROBLEM", 1026, 1052], ["Data collection", "TEST", 1053, 1068], ["Data collection", "TEST", 1128, 1143], ["infection", "OBSERVATION", 77, 86], ["infection", "OBSERVATION", 110, 119], ["l", "ANATOMY_MODIFIER", 340, 341], ["l", "ANATOMY_MODIFIER", 353, 354], ["virus", "OBSERVATION", 1017, 1022], ["infection", "OBSERVATION", 1037, 1046]]], ["To evaluate the accuracy of our method and software, we analysed a test data set (described in the Results & Discussion section).", [["a test data", "TEST", 65, 76]]]], "1a6bc37482c1bf714fe45b3a596281f764cc85d7": [["IntroductionGlobalization and climate changes continue to reshape the geographical distribution of humans, animals, vectors, and microbes, and allow their mixing to occur at an unprecedentedly high frequency (Chan et al., 2013b) .", [["humans", "ORGANISM", 99, 105], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 99, 105], ["IntroductionGlobalization", "TREATMENT", 0, 25], ["climate changes", "PROBLEM", 30, 45]]], ["These numerous emerging pathogens in the past few decades, such as avian influenza viruses, severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses, Ebola virus, and other viruses causing hemorrhagic fever MacNeil and Rollin, 2012; Marsh and Wang, 2012; To et al., 2013; To et al., 2015) .", [["avian influenza viruses", "DISEASE", 67, 90], ["acute respiratory syndrome", "DISEASE", 99, 125], ["Middle East respiratory syndrome coronaviruses", "DISEASE", 130, 176], ["Ebola virus", "DISEASE", 178, 189], ["hemorrhagic fever", "DISEASE", 217, 234], ["avian influenza viruses", "ORGANISM", 67, 90], ["Middle East respiratory syndrome coronaviruses", "ORGANISM", 130, 176], ["Ebola virus", "ORGANISM", 178, 189], ["avian influenza viruses", "SPECIES", 67, 90], ["Ebola virus", "SPECIES", 178, 189], ["Middle East respiratory syndrome coronaviruses", "SPECIES", 130, 176], ["Ebola virus", "SPECIES", 178, 189], ["avian influenza viruses", "PROBLEM", 67, 90], ["severe acute respiratory syndrome", "PROBLEM", 92, 125], ["Middle East respiratory syndrome coronaviruses", "PROBLEM", 130, 176], ["Ebola virus", "PROBLEM", 178, 189], ["other viruses", "PROBLEM", 195, 208], ["hemorrhagic fever", "PROBLEM", 217, 234], ["pathogens", "OBSERVATION", 24, 33], ["influenza viruses", "OBSERVATION", 73, 90], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["respiratory syndrome", "OBSERVATION", 105, 125], ["Middle", "ANATOMY_MODIFIER", 130, 136], ["respiratory syndrome", "OBSERVATION", 142, 162], ["hemorrhagic", "OBSERVATION_MODIFIER", 217, 228]]], ["The latest emerging viral epidemic that was declared as an international health emergency is the one caused by Zika virus (ZIKV) (Musso and Gubler, 2016) .", [["Zika virus", "ORGANISM", 111, 121], ["Zika virus", "SPECIES", 111, 121], ["Zika virus", "SPECIES", 111, 121], ["ZIKV", "SPECIES", 123, 127], ["Zika virus", "PROBLEM", 111, 121]]], ["ZIKV is a human-pathogenic flavivirus that has been neglected until recently, when it was found that ZIKV infection may be associated with severe clinical complications, including congenital microcephaly and other anomalies, neurological complications such as Guillain-Barre syndrome and meningoencephalitis, ophthalmological defects, auditory impairment, and rarely, multi-organ involvement and death (Chan et al., 2016b; Musso and Gubler, 2016) .IntroductionZIKV infection, similar to other emerging viral infections, may have non-specific clinical manifestations during the early phase of the disease (Chan et al., 2016b; Duffy et al., 2009) .", [["neurological", "ANATOMY", 225, 237], ["multi-organ", "ANATOMY", 368, 379], ["ZIKV", "CHEMICAL", 0, 4], ["human-pathogenic flavivirus", "DISEASE", 10, 37], ["ZIKV infection", "DISEASE", 101, 115], ["congenital microcephaly", "DISEASE", 180, 203], ["neurological complications", "DISEASE", 225, 251], ["Guillain-Barre syndrome", "DISEASE", 260, 283], ["meningoencephalitis", "DISEASE", 288, 307], ["ophthalmological defects", "DISEASE", 309, 333], ["auditory impairment", "DISEASE", 335, 354], ["death", "DISEASE", 396, 401], ["infection", "DISEASE", 465, 474], ["viral infections", "DISEASE", 502, 518], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 10, 15], ["flavivirus", "ORGANISM", 27, 37], ["human", "SPECIES", 10, 15], ["ZIKV", "SPECIES", 0, 4], ["human", "SPECIES", 10, 15], ["ZIKV", "SPECIES", 101, 105], ["a human-pathogenic flavivirus", "PROBLEM", 8, 37], ["ZIKV infection", "PROBLEM", 101, 115], ["severe clinical complications", "PROBLEM", 139, 168], ["congenital microcephaly", "PROBLEM", 180, 203], ["other anomalies", "PROBLEM", 208, 223], ["neurological complications", "PROBLEM", 225, 251], ["Guillain-Barre syndrome", "PROBLEM", 260, 283], ["meningoencephalitis", "PROBLEM", 288, 307], ["ophthalmological defects", "PROBLEM", 309, 333], ["auditory impairment", "PROBLEM", 335, 354], ["death", "PROBLEM", 396, 401], ["IntroductionZIKV infection", "PROBLEM", 448, 474], ["emerging viral infections", "PROBLEM", 493, 518], ["non-specific clinical manifestations", "PROBLEM", 529, 565], ["flavivirus", "OBSERVATION", 27, 37], ["ZIKV", "OBSERVATION", 101, 105], ["may be associated with", "UNCERTAINTY", 116, 138], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["congenital", "OBSERVATION_MODIFIER", 180, 190], ["microcephaly", "OBSERVATION", 191, 203], ["Barre syndrome", "OBSERVATION", 269, 283], ["meningoencephalitis", "OBSERVATION", 288, 307], ["auditory impairment", "OBSERVATION", 335, 354], ["multi-organ", "ANATOMY", 368, 379], ["infection", "OBSERVATION", 465, 474], ["viral", "OBSERVATION_MODIFIER", 502, 507], ["infections", "OBSERVATION", 508, 518], ["non-specific", "OBSERVATION_MODIFIER", 529, 541]]], ["For example, ZIKV infection may manifest as an acute febrile illness with rash and systemic upset which may be indistinguishable from dengue fever and other viral hemorrhagic fever syndromes (Chan et al., 2016b; Duffy et al., 2009 ).", [["infection", "DISEASE", 18, 27], ["febrile illness", "DISEASE", 53, 68], ["rash", "DISEASE", 74, 78], ["dengue fever", "DISEASE", 134, 146], ["viral hemorrhagic fever", "DISEASE", 157, 180], ["ZIKV", "SPECIES", 13, 17], ["ZIKV infection", "PROBLEM", 13, 27], ["an acute febrile illness", "PROBLEM", 44, 68], ["rash", "PROBLEM", 74, 78], ["systemic upset", "PROBLEM", 83, 97], ["dengue fever", "PROBLEM", 134, 146], ["other viral hemorrhagic fever syndromes", "PROBLEM", 151, 190], ["ZIKV", "OBSERVATION", 13, 17], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["febrile", "OBSERVATION_MODIFIER", 53, 60], ["illness", "OBSERVATION", 61, 68], ["viral", "OBSERVATION_MODIFIER", 157, 162], ["hemorrhagic", "OBSERVATION_MODIFIER", 163, 174]]], ["Moreover, ZIKV may co-circulate with other viruses in the same geographical regions and co-infect the same patient (Musso and Gubler, 2016) .", [["ZIKV", "GENE_OR_GENE_PRODUCT", 10, 14], ["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 107, 114], ["ZIKV", "SPECIES", 10, 14], ["ZIKV", "PROBLEM", 10, 14], ["other viruses", "PROBLEM", 37, 50], ["viruses", "OBSERVATION", 43, 50]]], ["As in the case of most other emerging viral infections, there are currently limited treatment options proven to be effective and safe for ZIKV infection.", [["viral infections", "DISEASE", 38, 54], ["infection", "DISEASE", 143, 152], ["ZIKV", "SPECIES", 138, 142], ["emerging viral infections", "PROBLEM", 29, 54], ["treatment options", "TREATMENT", 84, 101], ["ZIKV infection", "PROBLEM", 138, 152], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["infections", "OBSERVATION", 44, 54]]], ["Thus, broad-spectrum agents that can be used as empirical treatment for patients with an acute undifferentiated febrile illness before the diagnosis is confirmed by laboratory tests are urgently needed.IntroductionAn important group of drugs that have broad-spectrum antiviral activities are agents that target host pathways or enzymes that are involved in the replication cycles of different viruses (Zumla et al., 2016) .", [["febrile illness", "DISEASE", 112, 127], ["patients", "ORGANISM", 72, 80], ["enzymes", "PROTEIN", 328, 335], ["patients", "SPECIES", 72, 80], ["broad-spectrum agents", "TREATMENT", 6, 27], ["empirical treatment", "TREATMENT", 48, 67], ["an acute undifferentiated febrile illness", "PROBLEM", 86, 127], ["laboratory tests", "TEST", 165, 181], ["drugs", "TREATMENT", 236, 241], ["broad-spectrum antiviral activities", "TREATMENT", 252, 287], ["enzymes", "TEST", 328, 335], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["undifferentiated", "OBSERVATION_MODIFIER", 95, 111], ["febrile", "OBSERVATION", 112, 119]]], ["For example, host cellular kinases have been increasingly implicated in the pathogenesis of viral infections as they may be exploited by viruses to facilitate their own replication (Chu and Yang, 2007; Linero and Scolaro, 2009; Saeed et al., 2008; Urata et al., 2012) .", [["cellular", "ANATOMY", 18, 26], ["viral infections", "DISEASE", 92, 108], ["cellular", "CELL", 18, 26], ["host cellular kinases", "PROTEIN", 13, 34], ["host cellular kinases", "PROBLEM", 13, 34], ["viral infections", "PROBLEM", 92, 108], ["host", "OBSERVATION_MODIFIER", 13, 17], ["cellular kinases", "OBSERVATION", 18, 34], ["viral", "OBSERVATION_MODIFIER", 92, 97], ["infections", "OBSERVATION", 98, 108]]], ["For flaviviruses, the phosphatidylinositol 3 kinase/protein kinase B (PI3K/Akt) pathway has been shown to enhance viral replication through counteracting virus-induced cellular apoptosis (Lee et al., 2005; Tsai et al., 2014) .", [["cellular", "ANATOMY", 168, 176], ["phosphatidylinositol", "CHEMICAL", 22, 42], ["phosphatidylinositol 3 kinase", "GENE_OR_GENE_PRODUCT", 22, 51], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 52, 68], ["PI3K", "GENE_OR_GENE_PRODUCT", 70, 74], ["Akt", "GENE_OR_GENE_PRODUCT", 75, 78], ["cellular", "CELL", 168, 176], ["phosphatidylinositol 3 kinase", "PROTEIN", 22, 51], ["protein kinase B", "PROTEIN", 52, 68], ["PI3K", "PROTEIN", 70, 74], ["Akt", "PROTEIN", 75, 78], ["flaviviruses", "PROBLEM", 4, 16], ["the phosphatidylinositol", "TEST", 18, 42], ["protein kinase B (PI3K/Akt) pathway", "TEST", 52, 87], ["viral replication", "PROBLEM", 114, 131], ["counteracting virus", "PROBLEM", 140, 159], ["cellular apoptosis", "PROBLEM", 168, 186], ["cellular apoptosis", "OBSERVATION", 168, 186]]], ["AR-12 (OSU-03012), an FDA-approved investigational new drug (IND) compound, is a celecoxib derivative kinase inhibitor that does not inhibit cyclooxygenase activity, but instead downregulates the PI3K/Akt pathway which are involved in multiple cell signaling pathways (Chen et al., 2017; Mohr et al., 2015) .", [["cell", "ANATOMY", 244, 248], ["AR-12", "CHEMICAL", 0, 5], ["OSU-03012", "CHEMICAL", 7, 16], ["celecoxib", "CHEMICAL", 81, 90], ["AR-12", "CHEMICAL", 0, 5], ["OSU-03012", "CHEMICAL", 7, 16], ["celecoxib", "CHEMICAL", 81, 90], ["AR-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["OSU-03012", "SIMPLE_CHEMICAL", 7, 16], ["IND", "SIMPLE_CHEMICAL", 61, 64], ["celecoxib", "SIMPLE_CHEMICAL", 81, 90], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 141, 155], ["PI3K", "GENE_OR_GENE_PRODUCT", 196, 200], ["Akt", "GENE_OR_GENE_PRODUCT", 201, 204], ["cell", "CELL", 244, 248], ["cyclooxygenase", "PROTEIN", 141, 155], ["PI3K", "PROTEIN", 196, 200], ["Akt", "PROTEIN", 201, 204], ["AR", "TEST", 0, 2], ["an FDA", "TEST", 19, 25], ["a celecoxib derivative kinase inhibitor", "TREATMENT", 79, 118], ["cyclooxygenase activity", "PROBLEM", 141, 164]]], ["AR-12 has been evaluated in phase I clinical trials as an anticancer agent in adult patients with advanced or recurrent solid tumors or lymphoma (Clinical Trials registration no. NCT00978523).IntroductionIn addition to its anti-cancer effects, AR-12 has exhibited in vitro and/or in vivo antimicrobial activities against a wide range of pathogens.", [["anticancer", "ANATOMY", 58, 68], ["solid tumors", "ANATOMY", 120, 132], ["lymphoma", "ANATOMY", 136, 144], ["AR-12", "CHEMICAL", 0, 5], ["tumors", "DISEASE", 126, 132], ["lymphoma", "DISEASE", 136, 144], ["AR-12", "CHEMICAL", 244, 249], ["AR-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["anticancer", "CANCER", 58, 68], ["patients", "ORGANISM", 84, 92], ["solid tumors", "CANCER", 120, 132], ["lymphoma", "CANCER", 136, 144], ["AR-12", "GENE_OR_GENE_PRODUCT", 244, 249], ["AR", "PROTEIN", 0, 2], ["AR", "PROTEIN", 244, 246], ["patients", "SPECIES", 84, 92], ["an anticancer agent", "TREATMENT", 55, 74], ["advanced or recurrent solid tumors", "PROBLEM", 98, 132], ["lymphoma", "PROBLEM", 136, 144], ["IntroductionIn", "TREATMENT", 192, 206], ["its anti-cancer effects", "TREATMENT", 219, 242], ["AR", "TEST", 244, 246], ["pathogens", "PROBLEM", 337, 346], ["recurrent", "OBSERVATION_MODIFIER", 110, 119], ["solid", "OBSERVATION_MODIFIER", 120, 125], ["tumors", "OBSERVATION", 126, 132], ["lymphoma", "OBSERVATION", 136, 144], ["pathogens", "OBSERVATION", 337, 346]]], ["These microbes included intracellular bacteria (Salmonella enterica and Francisella tularensis), fungi (Candida albicans, non-albicans Candida sp., Cryptococcus neoformans, Fusarium sp., mucorales, Blastomyces dermatitidis, Histoplasma capsulatum, and Coccidioides immitis), parasite (Leishmania donovani), and viruses (Lassa, Marburg, and Ebola viruses) (Chiu et al., 2009a; Chiu et al., 2009b; Collier et al., 2016; Koselny et al., 2016; Mohr et al., 2015) .", [["intracellular", "ANATOMY", 24, 37], ["Candida albicans", "DISEASE", 104, 120], ["Cryptococcus neoformans", "DISEASE", 148, 171], ["Blastomyces dermatitidis", "DISEASE", 198, 222], ["Histoplasma capsulatum", "DISEASE", 224, 246], ["Coccidioides immitis", "DISEASE", 252, 272], ["Lassa, Marburg, and Ebola viruses", "DISEASE", 320, 353], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 37], ["Salmonella enterica", "ORGANISM", 48, 67], ["Francisella tularensis", "ORGANISM", 72, 94], ["fungi (", "ORGANISM", 97, 104], ["Candida albicans", "ORGANISM", 104, 120], ["non-albicans Candida sp.", "ORGANISM", 122, 146], ["Cryptococcus neoformans", "ORGANISM", 148, 171], ["Fusarium sp.", "ORGANISM", 173, 185], ["mucorales,", "ORGANISM", 187, 197], ["Blastomyces dermatitidis", "ORGANISM", 198, 222], ["Histoplasma capsulatum", "ORGANISM", 224, 246], ["Coccidioides immitis", "ORGANISM", 252, 272], ["Leishmania donovani", "ORGANISM", 285, 304], ["Lassa, Marburg", "ORGANISM", 320, 334], ["Ebola viruses", "ORGANISM", 340, 353], ["Salmonella enterica", "SPECIES", 48, 67], ["Francisella tularensis", "SPECIES", 72, 94], ["Candida albicans", "SPECIES", 104, 120], ["Candida sp.", "SPECIES", 135, 146], ["Cryptococcus neoformans", "SPECIES", 148, 171], ["Fusarium sp.", "SPECIES", 173, 185], ["Blastomyces dermatitidis", "SPECIES", 198, 222], ["Histoplasma capsulatum", "SPECIES", 224, 246], ["Coccidioides immitis", "SPECIES", 252, 272], ["Leishmania donovani", "SPECIES", 285, 304], ["Ebola", "SPECIES", 340, 345], ["Salmonella enterica", "SPECIES", 48, 67], ["Francisella tularensis", "SPECIES", 72, 94], ["Candida albicans", "SPECIES", 104, 120], ["Candida sp.", "SPECIES", 135, 146], ["Cryptococcus neoformans", "SPECIES", 148, 171], ["Fusarium sp.", "SPECIES", 173, 185], ["Blastomyces dermatitidis", "SPECIES", 198, 222], ["Histoplasma capsulatum", "SPECIES", 224, 246], ["Coccidioides immitis", "SPECIES", 252, 272], ["Leishmania donovani", "SPECIES", 285, 304], ["Ebola viruses", "SPECIES", 340, 353], ["intracellular bacteria", "PROBLEM", 24, 46], ["Salmonella enterica and Francisella tularensis", "PROBLEM", 48, 94], ["fungi (Candida albicans", "PROBLEM", 97, 120], ["non-albicans Candida sp.", "PROBLEM", 122, 146], ["Cryptococcus neoformans", "PROBLEM", 148, 171], ["Fusarium sp.", "PROBLEM", 173, 185], ["mucorales", "PROBLEM", 187, 196], ["Blastomyces dermatitidis", "PROBLEM", 198, 222], ["Histoplasma capsulatum", "PROBLEM", 224, 246], ["Coccidioides immitis", "PROBLEM", 252, 272], ["parasite (Leishmania donovani)", "PROBLEM", 275, 305], ["viruses", "PROBLEM", 311, 318], ["intracellular bacteria", "OBSERVATION", 24, 46], ["Salmonella enterica", "OBSERVATION", 48, 67], ["Francisella tularensis", "OBSERVATION", 72, 94], ["Cryptococcus neoformans", "OBSERVATION", 148, 171], ["Histoplasma capsulatum", "OBSERVATION", 224, 246], ["Coccidioides immitis", "OBSERVATION", 252, 272], ["Leishmania donovani", "OBSERVATION", 285, 304]]], ["Importantly, the European Commission has designated AR-12 as an orphan drug that could be used clinically in combination with other anti-infective agents for treatment of cryptococcosis (with fluconazole) and tularemia (with gentamicin) (Booth et al., 2016) .", [["cryptococcosis", "DISEASE", 171, 185], ["fluconazole", "CHEMICAL", 192, 203], ["tularemia", "DISEASE", 209, 218], ["gentamicin", "CHEMICAL", 225, 235], ["fluconazole", "CHEMICAL", 192, 203], ["gentamicin", "CHEMICAL", 225, 235], ["AR-12", "GENE_OR_GENE_PRODUCT", 52, 57], ["fluconazole", "SIMPLE_CHEMICAL", 192, 203], ["gentamicin", "SIMPLE_CHEMICAL", 225, 235], ["AR", "PROTEIN", 52, 54], ["an orphan drug", "TREATMENT", 61, 75], ["other anti-infective agents", "TREATMENT", 126, 153], ["cryptococcosis", "PROBLEM", 171, 185], ["fluconazole", "TREATMENT", 192, 203], ["tularemia", "PROBLEM", 209, 218], ["gentamicin", "TREATMENT", 225, 235], ["cryptococcosis", "OBSERVATION", 171, 185]]], ["These clinical experiences make AR-12 a clinically readily available drug for emerging infectious diseases lacking effective treatment options.", [["infectious diseases", "DISEASE", 87, 106], ["AR-12", "GENE_OR_GENE_PRODUCT", 32, 37], ["AR", "PROTEIN", 32, 34], ["emerging infectious diseases", "PROBLEM", 78, 106], ["effective treatment options", "TREATMENT", 115, 142]]], ["Recently, AR-12 was reported to have in vitro and in vivo antiviral activity against dengue virus (DENV), another flavivirus that is closely related to the emerging ZIKV (Chen et al., 2017; Hassandarvish et al., 2017) .", [["AR-12", "CHEMICAL", 10, 15], ["dengue virus (DENV)", "DISEASE", 85, 104], ["flavivirus", "DISEASE", 114, 124], ["AR-12", "GENE_OR_GENE_PRODUCT", 10, 15], ["dengue virus", "ORGANISM", 85, 97], ["DENV", "ORGANISM", 99, 103], ["AR", "PROTEIN", 10, 12], ["dengue virus", "SPECIES", 85, 97], ["dengue virus", "SPECIES", 85, 97], ["DENV", "SPECIES", 99, 103], ["ZIKV", "SPECIES", 165, 169], ["dengue virus (DENV", "PROBLEM", 85, 103], ["another flavivirus", "PROBLEM", 106, 124]]], ["We therefore hypothesized that this broad-spectrum host-targeting antiviral drug may also exhibit inhibitory activity against ZIKV.", [["ZIKV", "ORGANISM", 126, 130], ["ZIKV", "SPECIES", 126, 130], ["this broad-spectrum host", "TREATMENT", 31, 55], ["targeting antiviral drug", "TREATMENT", 56, 80], ["ZIKV", "PROBLEM", 126, 130]]], ["In this study, we evaluated the in vitro and in vivo antiviral activity of AR-12 against ZIKV and investigated the mechanism of AR-12's anti-ZIKV activity.Ethics and biosafetyThe animal experiments were approved by the Committee on the Use of Live Animals in Teaching and Research of The University of Hong Kong and performed according to established safety protocols in the biosafety level-2 laboratory at Department of Microbiology, The University of Hong Kong.Ethics and biosafety2.2.", [["AR-12", "CHEMICAL", 75, 80], ["AR-12", "GENE_OR_GENE_PRODUCT", 75, 80], ["ZIKV", "ORGANISM", 89, 93], ["AR", "GENE_OR_GENE_PRODUCT", 128, 130], ["AR", "PROTEIN", 75, 77], ["AR", "PROTEIN", 128, 130], ["ZIKV", "SPECIES", 89, 93], ["this study", "TEST", 3, 13], ["vivo antiviral activity of AR", "TREATMENT", 48, 77], ["ZIKV", "PROBLEM", 89, 93], ["AR", "PROBLEM", 128, 130]]], ["Virus strains, cell lines, and drug compounds ZIKV-PR (Puerto Rico strain PRVABC59) was isolated from a patient in the recent South American epidemic (kindly provided by Brandy Russell and Barbara Johnson, Centers for Disease Control and Prevention, USA).", [["strains", "ANATOMY", 6, 13], ["cell lines", "ANATOMY", 15, 25], ["Virus", "ORGANISM", 0, 5], ["cell lines", "CELL", 15, 25], ["ZIKV-PR", "ORGANISM", 46, 53], ["PRVABC59", "ORGANISM", 74, 82], ["patient", "ORGANISM", 104, 111], ["cell lines", "CELL_LINE", 15, 25], ["PR", "PROTEIN", 51, 53], ["patient", "SPECIES", 104, 111], ["Puerto Rico strain PRVABC59", "SPECIES", 55, 82], ["Virus strains", "PROBLEM", 0, 13], ["cell lines", "PROBLEM", 15, 25], ["drug compounds ZIKV", "PROBLEM", 31, 50], ["Puerto Rico strain PRVABC59", "TREATMENT", 55, 82], ["Disease Control", "TREATMENT", 218, 233], ["cell lines", "OBSERVATION", 15, 25]]], ["ZIKV-GD was isolated from a Chinese patient who returned to Guangdong after being infected by ZIKV while traveling to the Americas (kindly provided by George F. Gao, Chinese Academy of Sciences, China).", [["ZIKV-GD", "ORGANISM", 0, 7], ["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["ZIKV", "SPECIES", 0, 4], ["ZIKV", "SPECIES", 94, 98]]], ["ZIKV-U (976 Uganda strain) was isolated from a nonhuman primate in Uganda in 1947 (kindly provided by Tatjana Av\u0161i\u010d \u017dupanc, University of Ljubljana, Slovenia, the European Virus Archive).", [["ZIKV-U", "CHEMICAL", 0, 6], ["ZIKV-U (976 Uganda strain", "ORGANISM", 0, 25]]], ["The virus strains were cultured and titrated as we previously described (Chan et al., 2016c; Yuan et al., 2017) .", [["The virus strains", "PROBLEM", 0, 17], ["virus strains", "OBSERVATION", 4, 17]]], ["The U251 and SF268 cell lines were obtained from American Type Culture Collection, and the Huh-7 cell line was obtained from JCRB cell bank of Okayama University, Japan (Chan et al., 2016c) .", [["U251", "ANATOMY", 4, 8], ["SF268 cell lines", "ANATOMY", 13, 29], ["Huh-7 cell line", "ANATOMY", 91, 106], ["JCRB cell bank", "ANATOMY", 125, 139], ["U251", "CELL", 4, 8], ["SF268 cell lines", "CELL", 13, 29], ["Huh-7 cell line", "CELL", 91, 106], ["JCRB cell", "CELL", 125, 134], ["U251", "CELL_LINE", 4, 8], ["SF268 cell lines", "CELL_LINE", 13, 29], ["Huh-7 cell line", "CELL_LINE", 91, 106], ["The U251 and SF268 cell lines", "TREATMENT", 0, 29], ["American Type Culture Collection", "TEST", 49, 81], ["the Huh", "TEST", 87, 94], ["cell line", "OBSERVATION", 97, 106], ["JCRB cell bank", "OBSERVATION", 125, 139]]], ["AR-12 and the Akt inhibitor (Akt Inhibitor VIII) were purchased from InvivoGen (SanDiego, CA, USA) and Millipore (Burlington, MA, USA), respectively.", [["AR-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["Akt", "GENE_OR_GENE_PRODUCT", 14, 17], ["Akt Inhibitor VIII", "GENE_OR_GENE_PRODUCT", 29, 47], ["AR", "PROTEIN", 0, 2], ["Akt inhibitor", "PROTEIN", 14, 27], ["Akt Inhibitor VIII", "PROTEIN", 29, 47], ["AR", "TEST", 0, 2], ["the Akt inhibitor", "TREATMENT", 10, 27], ["Akt Inhibitor VIII", "TREATMENT", 29, 47]]], ["ON-TARGETplus human Akt siRNA and ON-TARGETplus non-targeting siRNA were purchased from Dharmacon (Lafayette, CO, USA).CellTiter-Glo \u00ae luminescent cell viability assayThe 50% effective cytotoxic concentration (CC 50 ) of AR-12 in Huh-7, U251, and SF268 cells and the cell protection effects of AR-12 against ZIKV infection in these cell lines were determined by the CellTiter-Glo \u00ae luminescent cell viability assay (PromegaCorporation, Madison, WI, USA) according to the manufacturer's instructions and as previously described (Mohr et al., 2015) .", [["cell", "ANATOMY", 147, 151], ["Huh-7", "ANATOMY", 230, 235], ["U251", "ANATOMY", 237, 241], ["SF268 cells", "ANATOMY", 247, 258], ["cell", "ANATOMY", 267, 271], ["cell lines", "ANATOMY", 332, 342], ["cell", "ANATOMY", 394, 398], ["CC", "CHEMICAL", 210, 212], ["AR-12", "CHEMICAL", 294, 299], ["infection", "DISEASE", 313, 322], ["human", "ORGANISM", 14, 19], ["Akt", "GENE_OR_GENE_PRODUCT", 20, 23], ["cell", "CELL", 147, 151], ["AR-12", "GENE_OR_GENE_PRODUCT", 221, 226], ["Huh-7", "CELL", 230, 235], ["U251", "CELL", 237, 241], ["SF268 cells", "CELL", 247, 258], ["cell", "CELL", 267, 271], ["AR-12", "GENE_OR_GENE_PRODUCT", 294, 299], ["ZIKV", "ORGANISM", 308, 312], ["cell lines", "CELL", 332, 342], ["cell", "CELL", 394, 398], ["TARGETplus human Akt siRNA", "DNA", 3, 29], ["AR", "PROTEIN", 221, 223], ["Huh-7", "CELL_LINE", 230, 235], ["U251", "CELL_LINE", 237, 241], ["SF268 cells", "CELL_LINE", 247, 258], ["AR", "PROTEIN", 294, 296], ["cell lines", "CELL_LINE", 332, 342], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["ZIKV", "SPECIES", 308, 312], ["TARGETplus human Akt siRNA", "TREATMENT", 3, 29], ["TARGETplus non-targeting siRNA", "TREATMENT", 37, 67], ["CellTiter", "TEST", 119, 128], ["Glo \u00ae luminescent cell viability assay", "TEST", 129, 167], ["cytotoxic concentration", "TEST", 185, 208], ["CC", "TEST", 210, 212], ["AR", "TEST", 221, 223], ["Huh", "TEST", 230, 233], ["U251", "TEST", 237, 241], ["SF268 cells", "PROBLEM", 247, 258], ["the cell protection effects", "TREATMENT", 263, 290], ["AR", "TEST", 294, 296], ["ZIKV infection in these cell lines", "PROBLEM", 308, 342], ["the CellTiter", "TEST", 362, 375], ["Akt siRNA", "OBSERVATION", 20, 29], ["luminescent cell viability", "OBSERVATION", 135, 161], ["cell protection", "OBSERVATION", 267, 282], ["cell lines", "OBSERVATION", 332, 342], ["luminescent cell viability", "OBSERVATION", 382, 408]]], ["For determination of CC 50 of AR-12 treatment without ZIKV infection, the cells were treated with different concentrations of AR-12 (0-20 \u03bcM) for 48 h.", [["cells", "ANATOMY", 74, 79], ["CC 50 of AR-12", "CHEMICAL", 21, 35], ["infection", "DISEASE", 59, 68], ["AR-12", "CHEMICAL", 126, 131], ["AR-12", "CHEMICAL", 126, 131], ["AR-12", "GENE_OR_GENE_PRODUCT", 30, 35], ["ZIKV", "SIMPLE_CHEMICAL", 54, 58], ["cells", "CELL", 74, 79], ["AR-12", "GENE_OR_GENE_PRODUCT", 126, 131], ["AR", "PROTEIN", 30, 32], ["AR", "PROTEIN", 126, 128], ["ZIKV", "SPECIES", 54, 58], ["AR-12 treatment", "TREATMENT", 30, 45], ["ZIKV infection", "PROBLEM", 54, 68], ["the cells", "PROBLEM", 70, 79], ["different concentrations of AR", "TREATMENT", 98, 128]]], ["For cell protection effects, the cells were infected by ZIKV-PR at 0.50 multiplicity of infection (MOI) for 1 h and then treated with dimethyl sulfoxide (DMSO) (ie: 0 \u03bcM AR-12) or up to 3 \u03bcM AR-12 for 48 h.", [["cell", "ANATOMY", 4, 8], ["cells", "ANATOMY", 33, 38], ["infection", "DISEASE", 88, 97], ["dimethyl sulfoxide", "CHEMICAL", 134, 152], ["DMSO", "CHEMICAL", 154, 158], ["dimethyl sulfoxide", "CHEMICAL", 134, 152], ["DMSO", "CHEMICAL", 154, 158], ["cell", "CELL", 4, 8], ["cells", "CELL", 33, 38], ["ZIKV-PR", "ORGANISM", 56, 63], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 134, 152], ["DMSO", "SIMPLE_CHEMICAL", 154, 158], ["PR", "PROTEIN", 61, 63], ["AR", "PROTEIN", 191, 193], ["ZIKV", "SPECIES", 56, 60], ["cell protection effects", "TREATMENT", 4, 27], ["the cells", "PROBLEM", 29, 38], ["ZIKV", "TEST", 56, 60], ["infection", "PROBLEM", 88, 97], ["dimethyl sulfoxide (DMSO", "TREATMENT", 134, 158], ["cell protection", "OBSERVATION", 4, 19], ["infection", "OBSERVATION", 88, 97]]], ["After 48 h, the reconstituted CellTiter-Glo \u00ae reagent was added to the cells according to the manufacturer's instructions.", [["cells", "ANATOMY", 71, 76], ["CellTiter-Glo \u00ae", "CHEMICAL", 30, 45], ["CellTiter-Glo \u00ae", "SIMPLE_CHEMICAL", 30, 45], ["cells", "CELL", 71, 76], ["the reconstituted CellTiter", "TREATMENT", 12, 39], ["Glo \u00ae reagent", "TREATMENT", 40, 53], ["the cells", "TREATMENT", 67, 76]]], ["The luminescent signal was detected by the Victor X3 2030 Multilabel Reader (PerkinElmer) according to the manufacturer's instructions.Antiviral evaluation of AR-12 in cell cultureThe antiviral activity of AR-12 against ZIKV was evaluated in cell culture as previously described (Chan et al., 2017a; Yuan et al., 2017) .", [["cell culture", "ANATOMY", 168, 180], ["cell culture", "ANATOMY", 242, 254], ["AR-12", "CHEMICAL", 206, 211], ["AR-12", "GENE_OR_GENE_PRODUCT", 159, 164], ["cell", "CELL", 168, 172], ["AR-12", "GENE_OR_GENE_PRODUCT", 206, 211], ["ZIKV", "ORGANISM", 220, 224], ["cell culture", "CELL", 242, 254], ["AR", "PROTEIN", 159, 161], ["cell culture", "CELL_LINE", 168, 180], ["AR", "PROTEIN", 206, 208], ["ZIKV", "SPECIES", 220, 224], ["Antiviral evaluation", "TEST", 135, 155], ["AR", "TEST", 159, 161], ["cell culture", "TEST", 168, 180], ["The antiviral activity of AR", "TREATMENT", 180, 208], ["ZIKV", "PROBLEM", 220, 224], ["cell culture", "TEST", 242, 254], ["antiviral activity", "OBSERVATION", 184, 202]]], ["Briefly, ZIKV-infected Huh-7, U251, and SF268 cells (MOI = 0.05) were treated with different concentrations of AR-12 or DMSO.", [["Huh-7", "ANATOMY", 23, 28], ["U251", "ANATOMY", 30, 34], ["SF268 cells", "ANATOMY", 40, 51], ["AR-12", "CHEMICAL", 111, 116], ["DMSO", "CHEMICAL", 120, 124], ["DMSO", "CHEMICAL", 120, 124], ["ZIKV", "CELL", 9, 13], ["Huh-7", "CELL", 23, 28], ["U251", "CELL", 30, 34], ["SF268 cells", "CELL", 40, 51], ["AR-12", "GENE_OR_GENE_PRODUCT", 111, 116], ["DMSO", "SIMPLE_CHEMICAL", 120, 124], ["ZIKV-infected Huh-7", "CELL_LINE", 9, 28], ["U251", "CELL_LINE", 30, 34], ["SF268 cells", "CELL_LINE", 40, 51], ["ZIKV", "SPECIES", 9, 13], ["Huh-7", "SPECIES", 23, 28], ["ZIKV", "TEST", 9, 13], ["Huh", "TEST", 23, 26], ["U251", "TEST", 30, 34], ["SF268 cells", "PROBLEM", 40, 51], ["MOI", "TEST", 53, 56], ["AR", "TEST", 111, 113], ["DMSO", "TREATMENT", 120, 124]]], ["The cell culture supernatants were then collected at 24 h post-inoculation (hpi), followed by total nucleic acid extraction and quantitative reverse transcription-PCR (qRT-PCR) as previously described (Chan et al., 2016c; Chan et al., 2017b) .", [["cell", "ANATOMY", 4, 8], ["supernatants", "ANATOMY", 17, 29], ["nucleic acid", "CHEMICAL", 100, 112], ["cell", "CELL", 4, 8], ["The cell culture supernatants", "TEST", 0, 29], ["total nucleic acid extraction", "TREATMENT", 94, 123], ["quantitative reverse transcription", "TEST", 128, 162], ["PCR", "TEST", 163, 166]]], ["Additionally, U251 cells were inoculated with high MOI of ZIKV (MOI = 1) for 1 h.", [["U251 cells", "ANATOMY", 14, 24], ["U251 cells", "CELL", 14, 24], ["U251 cells", "CELL_LINE", 14, 24], ["ZIKV", "SPECIES", 58, 62], ["U251 cells", "PROBLEM", 14, 24], ["ZIKV", "PROBLEM", 58, 62], ["MOI", "TEST", 64, 67], ["U251 cells", "OBSERVATION", 14, 24], ["high MOI", "OBSERVATION_MODIFIER", 46, 54]]], ["After the virus inoculum was removed, the cells were washed and cultured in fresh medium containing different concentrations of AR-12 or DMSO.", [["cells", "ANATOMY", 42, 47], ["AR-12", "CHEMICAL", 128, 133], ["DMSO", "CHEMICAL", 137, 141], ["DMSO", "CHEMICAL", 137, 141], ["cells", "CELL", 42, 47], ["AR-12", "SIMPLE_CHEMICAL", 128, 133], ["DMSO", "SIMPLE_CHEMICAL", 137, 141], ["the virus inoculum", "TREATMENT", 6, 24], ["the cells", "TREATMENT", 38, 47], ["AR", "PROBLEM", 128, 130], ["DMSO", "PROBLEM", 137, 141], ["virus inoculum", "OBSERVATION", 10, 24]]], ["At 24 hpi, the supernatants were collected and subsequently applied for virus titration using both qRT-PCR and plaque assay.", [["supernatants", "ANATOMY", 15, 27], ["plaque", "ANATOMY", 111, 117], ["the supernatants", "TREATMENT", 11, 27], ["virus titration", "TREATMENT", 72, 87], ["both qRT-PCR", "TEST", 94, 106], ["plaque assay", "TEST", 111, 123], ["plaque", "OBSERVATION", 111, 117]]], ["The half maximal inhibitory concentration (IC 50 ) was calculated using Sigma plot in an Excel add-in ED50V10 as we previously described (Chan et al., 2013a; Chan et al., 2017a; Chan et al., 2017b) .Flow cytometryTo more thoroughly compare the differences between the percentage of cells infected by ZIKV in AR-12-treated versus untreated samples, flow cytometry and immunostaining was performed as we previously described with slight modifications (Chu et al., 2014; Chu et al., 2016) .", [["cells", "ANATOMY", 282, 287], ["samples", "ANATOMY", 339, 346], ["ZIKV", "CHEMICAL", 300, 304], ["AR-12", "CHEMICAL", 308, 313], ["cells", "CELL", 282, 287], ["ZIKV", "CELL", 300, 304], ["AR-12", "CELL", 308, 313], ["AR", "PROTEIN", 308, 310], ["ZIKV", "SPECIES", 300, 304], ["The half maximal inhibitory concentration (IC", "TREATMENT", 0, 45], ["Flow cytometry", "TEST", 199, 213], ["ZIKV in AR", "PROBLEM", 300, 310], ["untreated samples", "PROBLEM", 329, 346], ["flow cytometry", "TEST", 348, 362], ["immunostaining", "TEST", 367, 381], ["flow cytometry", "OBSERVATION", 348, 362]]], ["Briefly, U251 cells were infected with ZIKV-PR at 0.50 MOI or were mock-infected for 1 h at 37\u00b0C. After 1 h, the inoculum was removed and the cells were washed with phosphate-buffered saline (PBS).", [["U251 cells", "ANATOMY", 9, 19], ["cells", "ANATOMY", 142, 147], ["phosphate", "CHEMICAL", 165, 174], ["phosphate", "CHEMICAL", 165, 174], ["U251 cells", "CELL", 9, 19], ["ZIKV-PR", "ORGANISM", 39, 46], ["cells", "CELL", 142, 147], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 165, 190], ["U251 cells", "CELL_LINE", 9, 19], ["PR", "PROTEIN", 44, 46], ["U251 cells", "PROBLEM", 9, 19], ["ZIKV", "PROBLEM", 39, 43], ["the inoculum", "TREATMENT", 109, 121], ["the cells", "TREATMENT", 138, 147], ["phosphate-buffered saline (PBS", "TREATMENT", 165, 195]]], ["Dulbecco's Modified Eagle Medium (DMEM) with 3 \u03bcM AR-12 or 1% DMSO (Sigma-Aldrich, St.Louis, MO, USA) was then added to the cells.", [["cells", "ANATOMY", 124, 129], ["DMSO", "CHEMICAL", 62, 66], ["DMSO", "CHEMICAL", 62, 66], ["DMSO", "SIMPLE_CHEMICAL", 62, 66], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 68, 81], ["St.Louis", "ORGANISM", 83, 91], ["cells", "CELL", 124, 129], ["Dulbecco's Modified Eagle Medium (DMEM)", "TREATMENT", 0, 39], ["3 \u03bcM AR", "TREATMENT", 45, 52]]], ["At 24 hpi, the cells were detached by using 10 mM ethylenediaminetetraacetic acid (EDTA)/PBS and fixed in 4% paraformaldehyde.", [["cells", "ANATOMY", 15, 20], ["ethylenediaminetetraacetic acid", "CHEMICAL", 50, 81], ["EDTA", "CHEMICAL", 83, 87], ["ethylenediaminetetraacetic acid", "CHEMICAL", 50, 81], ["EDTA", "CHEMICAL", 83, 87], ["paraformaldehyde", "CHEMICAL", 109, 125], ["cells", "CELL", 15, 20], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 50, 81], ["EDTA", "SIMPLE_CHEMICAL", 83, 87], ["paraformaldehyde", "SIMPLE_CHEMICAL", 109, 125], ["10 mM ethylenediaminetetraacetic acid (EDTA)/PBS and fixed in 4% paraformaldehyde", "TREATMENT", 44, 125]]], ["For immunostaining, the cells were first permeabilized with 0.1% Triton X-100 in PBS and then blocked with 2% fetal bovine serum (FBS) in PBS.", [["cells", "ANATOMY", 24, 29], ["fetal bovine serum", "ANATOMY", 110, 128], ["FBS", "ANATOMY", 130, 133], ["Triton X-100", "CHEMICAL", 65, 77], ["cells", "CELL", 24, 29], ["Triton X-100", "SIMPLE_CHEMICAL", 65, 77], ["PBS", "SIMPLE_CHEMICAL", 81, 84], ["bovine", "ORGANISM", 116, 122], ["serum", "ORGANISM_SUBSTANCE", 123, 128], ["FBS", "ORGANISM_SUBSTANCE", 130, 133], ["bovine", "SPECIES", 116, 122], ["immunostaining", "TEST", 4, 18], ["2% fetal bovine serum (FBS", "TREATMENT", 107, 133]]], ["ZIKV was detected with a mouse anti-ZIKV-NS1 primary antibody (Abcam, Cambridge, United Kingdom) or the mouse anti-pan-flavivirus primary antibody 4G2 (Millipore) and Alexa Fluor 488 goat anti-mouse immunoglobulin (IgG) (Invitrogen, Carlsbad, CA, USA) as the secondary antibody.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["mouse", "ORGANISM", 25, 30], ["anti-ZIKV-NS1", "ORGANISM", 31, 44], ["Abcam", "GENE_OR_GENE_PRODUCT", 63, 68], ["mouse", "ORGANISM", 104, 109], ["Alexa Fluor", "SIMPLE_CHEMICAL", 167, 178], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 199, 213], ["ZIKV", "PROTEIN", 0, 4], ["mouse anti-ZIKV-NS1 primary antibody", "PROTEIN", 25, 61], ["Abcam", "PROTEIN", 63, 68], ["mouse anti-pan-flavivirus primary antibody 4G2", "PROTEIN", 104, 150], ["Millipore", "PROTEIN", 152, 161], ["Alexa Fluor 488 goat anti-mouse immunoglobulin", "PROTEIN", 167, 213], ["IgG", "PROTEIN", 215, 218], ["secondary antibody", "PROTEIN", 259, 277], ["mouse", "SPECIES", 25, 30], ["mouse", "SPECIES", 104, 109], ["goat", "SPECIES", 183, 187], ["anti-mouse", "SPECIES", 188, 198], ["ZIKV", "SPECIES", 0, 4], ["mouse", "SPECIES", 25, 30], ["mouse", "SPECIES", 104, 109], ["Alexa Fluor 488", "SPECIES", 167, 182], ["goat", "SPECIES", 183, 187], ["ZIKV", "PROBLEM", 0, 4], ["a mouse anti-ZIKV", "TREATMENT", 23, 40], ["the mouse anti-pan-flavivirus primary antibody", "TEST", 100, 146], ["Alexa Fluor", "TEST", 167, 178], ["goat anti-mouse immunoglobulin", "TEST", 183, 213], ["IgG", "TEST", 215, 218], ["Invitrogen", "TEST", 221, 231], ["Carlsbad", "TEST", 233, 241], ["CA", "TEST", 243, 245], ["secondary antibody", "OBSERVATION", 259, 277]]], ["Flow cytometry was performed using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA) and the data were analyzed using FlowJo vX (Tree Star).", [["Flow cytometry", "TEST", 0, 14], ["the data", "TEST", 108, 116]]], ["AR-12 inhibits the replication of ZIKV strains belonging to both the Asian/American and African lineages in Huh-7 cells.", [["Huh-7 cells", "ANATOMY", 108, 119], ["AR-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["ZIKV strains", "ORGANISM", 34, 46], ["Huh-7 cells", "CELL", 108, 119], ["AR", "PROTEIN", 0, 2], ["Huh-7 cells", "CELL_LINE", 108, 119], ["ZIKV", "SPECIES", 34, 38], ["Huh-7", "SPECIES", 108, 113], ["AR", "TEST", 0, 2], ["ZIKV strains", "PROBLEM", 34, 46]]], ["Dose-dependent reduction of ZIKV RNA load was observed at 24 h after ZIKV-PR, ZIKV-GD, or ZIKV-U inoculation (0.05 MOI) in Huh-7 cells with 0-3 \u03bcM AR-12.", [["Huh-7 cells", "ANATOMY", 123, 134], ["ZIKV-U", "CHEMICAL", 90, 96], ["ZIKV", "ORGANISM", 28, 32], ["ZIKV-U", "GENE_OR_GENE_PRODUCT", 90, 96], ["Huh-7 cells", "CELL", 123, 134], ["ZIKV RNA", "RNA", 28, 36], ["PR", "PROTEIN", 74, 76], ["Huh-7 cells", "CELL_LINE", 123, 134], ["AR", "PROTEIN", 147, 149], ["ZIKV", "SPECIES", 28, 32], ["ZIKV", "SPECIES", 69, 73], ["ZIKV RNA load", "PROBLEM", 28, 41], ["ZIKV", "TEST", 69, 73], ["ZIKV", "PROBLEM", 78, 82], ["ZIKV", "PROBLEM", 90, 94], ["Huh", "TEST", 123, 126], ["AR", "TEST", 147, 149], ["ZIKV RNA", "OBSERVATION", 28, 36]]], ["All experiments were performed in triplicates in three independent experiments for confirmation. * denotes P < 0.05, ** denotes P < 0.01, and *** denotes P < 0.001 (compared with the DMSO control group by Student's t-test).", [["DMSO", "CHEMICAL", 183, 187], ["confirmation", "TEST", 83, 95], ["Student's t-test", "TEST", 205, 221]]], ["Data are presented as mean values \u00b1 standard deviations (error bars).", [["mean values", "TEST", 22, 33]]], ["Abbreviations: ZIKV, Zika virus.Western blotHuh-7 cells were lysed with radioimmunoprecipitation assay (RIPA) lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA) with protease inhibitors cocktail (Sigma-Aldrich).", [["blotHuh-7 cells", "ANATOMY", 40, 55], ["Zika virus", "ORGANISM", 21, 31], ["blotHuh-7 cells", "CELL", 40, 55], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 203, 216], ["Western blotHuh-7 cells", "CELL_LINE", 32, 55], ["Zika virus", "SPECIES", 21, 31], ["ZIKV", "PROBLEM", 15, 19], ["Zika virus", "PROBLEM", 21, 31], ["radioimmunoprecipitation assay", "TEST", 72, 102], ["protease inhibitors cocktail", "TREATMENT", 173, 201]]], ["Western blotting was performed as we previously described with slight modifications (Chan et al., 2016a) .", [["Western blotting", "TEST", 0, 16]]], ["Briefly, proteins were separated with electrophoresis on 10% sodium dodecyl sulfate (SDS) gels and transferred onto polyvinylidene difluoride (PVDF) membranes.", [["sodium dodecyl sulfate", "CHEMICAL", 61, 83], ["sodium dodecyl sulfate", "CHEMICAL", 61, 83], ["SDS", "CHEMICAL", 85, 88], ["polyvinylidene difluoride", "CHEMICAL", 116, 141], ["PVDF", "CHEMICAL", 143, 147], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 61, 83], ["electrophoresis", "TEST", 38, 53], ["10% sodium dodecyl sulfate (SDS) gels", "TREATMENT", 57, 94], ["polyvinylidene difluoride (PVDF) membranes", "TREATMENT", 116, 158]]], ["The PVDF membranes were subsequently blocked with 3% bovine serum albumin (BSA) for 1 h at room temperature and incubated with the primary antibodies at 4\u00b0C overnight.", [["PVDF membranes", "ANATOMY", 4, 18], ["serum", "ANATOMY", 60, 65], ["PVDF", "CHEMICAL", 4, 8], ["membranes", "CELLULAR_COMPONENT", 9, 18], ["bovine", "ORGANISM", 53, 59], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["albumin", "SIMPLE_CHEMICAL", 66, 73], ["BSA", "SIMPLE_CHEMICAL", 75, 78], ["primary antibodies", "PROTEIN", 131, 149], ["bovine", "SPECIES", 53, 59], ["The PVDF membranes", "TREATMENT", 0, 18], ["3% bovine serum albumin (BSA", "TREATMENT", 50, 78]]], ["On the next day, the membranes were washed thrice with 0.1% PBS with Tween 20 buffer and incubated with peroxidase-conjugated secondary antibodies for 2 h at room temperature.", [["membranes", "ANATOMY", 21, 30], ["Tween 20", "CHEMICAL", 69, 77], ["membranes", "CELLULAR_COMPONENT", 21, 30], ["peroxidase", "SIMPLE_CHEMICAL", 104, 114], ["peroxidase", "PROTEIN", 104, 114], ["Tween 20 buffer", "TREATMENT", 69, 84], ["peroxidase-conjugated secondary antibodies", "TREATMENT", 104, 146]]], ["The protein bands on the membranes were visualized by using horseradish peroxidase (HRP) substrate (Bio-Rad, Hercules, CA, USA).", [["membranes", "ANATOMY", 25, 34], ["membranes", "CELLULAR_COMPONENT", 25, 34], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 60, 82], ["HRP", "SIMPLE_CHEMICAL", 84, 87], ["horseradish peroxidase (HRP) substrate", "PROTEIN", 60, 98], ["horseradish", "SPECIES", 60, 71], ["The protein bands", "TEST", 0, 17], ["horseradish peroxidase", "TEST", 60, 82], ["protein bands", "OBSERVATION", 4, 17]]], ["The antibodies used for Western blotting in this study were as follows: anti-Akt 1 antibody [M1843] (ab108202, Abcam), anti-pan-Akt (phosphor T308) antibody (ab38449, Abcam), goat anti-rabbit IgG (H + L) secondary antibody (HRP 65-6120, Thermo Fisher), and goat anti-mouse IgG (H + L) secondary antibody (HRP 62-6520, Thermo Fisher).Akt inhibitor and small interfering RNA (siRNA) knockdownIn the Akt inhibitor assay, Huh-7 cells were inoculated with ZIKV for 1 h at 37\u00b0C. At 1 hpi, the inoculum was removed and the cells were washed with PBS.", [["Huh-7 cells", "ANATOMY", 418, 429], ["cells", "ANATOMY", 516, 521], ["anti-Akt 1", "GENE_OR_GENE_PRODUCT", 72, 82], ["M1843", "SIMPLE_CHEMICAL", 93, 98], ["ab108202", "SIMPLE_CHEMICAL", 101, 109], ["Abcam", "GENE_OR_GENE_PRODUCT", 111, 116], ["anti-pan-Akt", "GENE_OR_GENE_PRODUCT", 119, 131], ["phosphor T308", "SIMPLE_CHEMICAL", 133, 146], ["ab38449", "SIMPLE_CHEMICAL", 158, 165], ["Abcam", "GENE_OR_GENE_PRODUCT", 167, 172], ["goat", "ORGANISM", 175, 179], ["H + L", "SIMPLE_CHEMICAL", 197, 202], ["HRP 65-6120", "SIMPLE_CHEMICAL", 224, 235], ["goat", "ORGANISM", 257, 261], ["H + L", "SIMPLE_CHEMICAL", 278, 283], ["HRP 62-6520", "SIMPLE_CHEMICAL", 305, 316], ["Akt", "GENE_OR_GENE_PRODUCT", 333, 336], ["Akt", "GENE_OR_GENE_PRODUCT", 397, 400], ["Huh-7 cells", "CELL", 418, 429], ["cells", "CELL", 516, 521], ["antibodies", "PROTEIN", 4, 14], ["anti", "PROTEIN", 72, 76], ["Akt 1 antibody", "PROTEIN", 77, 91], ["M1843", "PROTEIN", 93, 98], ["ab108202", "PROTEIN", 101, 109], ["Abcam", "PROTEIN", 111, 116], ["anti-pan", "PROTEIN", 119, 127], ["Akt", "PROTEIN", 128, 131], ["phosphor T308) antibody", "PROTEIN", 133, 156], ["ab38449", "PROTEIN", 158, 165], ["Abcam", "PROTEIN", 167, 172], ["goat anti-rabbit IgG (H + L) secondary antibody", "PROTEIN", 175, 222], ["HRP 65-6120", "PROTEIN", 224, 235], ["goat anti-mouse IgG (H + L) secondary antibody", "PROTEIN", 257, 303], ["Akt", "PROTEIN", 333, 336], ["small interfering RNA", "RNA", 351, 372], ["Akt", "PROTEIN", 397, 400], ["Huh-7 cells", "CELL_LINE", 418, 429], ["goat", "SPECIES", 175, 179], ["anti-rabbit", "SPECIES", 180, 191], ["goat", "SPECIES", 257, 261], ["anti-mouse", "SPECIES", 262, 272], ["goat", "SPECIES", 175, 179], ["goat", "SPECIES", 257, 261], ["ZIKV", "SPECIES", 451, 455], ["The antibodies", "TEST", 0, 14], ["Western blotting", "TEST", 24, 40], ["this study", "TEST", 44, 54], ["anti-Akt 1 antibody", "TEST", 72, 91], ["Abcam", "TEST", 111, 116], ["anti-pan", "TEST", 119, 127], ["Akt", "TEST", 128, 131], ["phosphor", "TEST", 133, 141], ["antibody", "TEST", 148, 156], ["Abcam", "TEST", 167, 172], ["goat anti-rabbit IgG", "TEST", 175, 195], ["secondary antibody", "TEST", 204, 222], ["HRP", "TEST", 224, 227], ["goat anti-mouse IgG", "TEST", 257, 276], ["secondary antibody", "TEST", 285, 303], ["HRP", "TEST", 305, 308], ["Akt inhibitor", "TREATMENT", 333, 346], ["small interfering RNA (siRNA) knockdown", "TREATMENT", 351, 390], ["the Akt inhibitor assay", "TEST", 393, 416], ["Huh", "TEST", 418, 421], ["the inoculum", "TREATMENT", 483, 495], ["the cells", "TREATMENT", 512, 521], ["PBS", "TREATMENT", 539, 542], ["small", "OBSERVATION_MODIFIER", 351, 356], ["interfering RNA", "OBSERVATION", 357, 372]]], ["DMEM containing 15 \u03bcM Akt inhibitor or 1% DMSO was added to the ZIKV-infected cells.", [["cells", "ANATOMY", 78, 83], ["DMSO", "CHEMICAL", 42, 46], ["DMSO", "CHEMICAL", 42, 46], ["Akt", "GENE_OR_GENE_PRODUCT", 22, 25], ["DMSO", "SIMPLE_CHEMICAL", 42, 46], ["ZIKV", "ORGANISM", 64, 68], ["cells", "CELL", 78, 83], ["Akt", "PROTEIN", 22, 25], ["ZIKV-infected cells", "CELL_LINE", 64, 83], ["ZIKV", "SPECIES", 64, 68], ["DMEM", "TREATMENT", 0, 4], ["15 \u03bcM Akt inhibitor", "TREATMENT", 16, 35], ["1% DMSO", "TREATMENT", 39, 46], ["infected cells", "PROBLEM", 69, 83], ["infected cells", "OBSERVATION", 69, 83]]], ["At 24 hpi, the supernatants were harvested in RLT buffer and RNA was extracted with the EZ1 RNA tissue mini kit (Qiagen, Hilden, Germany).", [["supernatants", "ANATOMY", 15, 27], ["tissue", "TISSUE", 96, 102], ["the supernatants", "TREATMENT", 11, 27]]], ["The viral load was then quantified with qRT-PCR as we previously described (Chan et al., 2016c; Chan et al., 2017b) .", [["The viral load", "TEST", 0, 14], ["viral load", "OBSERVATION", 4, 14]]], ["In the siRNA knockdown assay, transfection of siRNA on Huh-7 cells was performed using Lipofectamine \u00ae RNAiMAX (Thermo Fisher Scientific) as we previously described with slight modifications (Chan et al., 2016a) .", [["Huh-7 cells", "ANATOMY", 55, 66], ["Huh-7 cells", "CELL", 55, 66], ["Huh-7 cells", "CELL_LINE", 55, 66], ["the siRNA knockdown assay", "TEST", 3, 28], ["transfection of siRNA", "PROBLEM", 30, 51], ["Huh", "TEST", 55, 58], ["Lipofectamine", "TREATMENT", 87, 100], ["siRNA knockdown", "OBSERVATION", 7, 22], ["siRNA", "ANATOMY", 46, 51]]], ["Briefly, 70 nM Akt siRNA or scramble siRNA was mixed with RNAiMAX and Opti-MEM, which was then used to transfect Huh-7 cells.", [["Huh-7 cells", "ANATOMY", 113, 124], ["Akt", "GENE_OR_GENE_PRODUCT", 15, 18], ["RNAiMAX", "SIMPLE_CHEMICAL", 58, 65], ["Huh-7 cells", "CELL", 113, 124], ["Huh-7 cells", "CELL_LINE", 113, 124], ["scramble siRNA", "TREATMENT", 28, 42], ["RNAiMAX and Opti-MEM", "TREATMENT", 58, 78], ["Huh", "TEST", 113, 116]]], ["At 24 h post-transfection, the siRNA- Differential viral kinetics of ZIKV in Huh-7 cells with or without AR-12 from 0 to 72 hpi.", [["Huh-7 cells", "ANATOMY", 77, 88], ["Huh-7 cells", "CELL", 77, 88], ["AR-12", "GENE_OR_GENE_PRODUCT", 105, 110], ["ZIKV", "PROTEIN", 69, 73], ["Huh-7 cells", "CELL_LINE", 77, 88], ["AR", "PROTEIN", 105, 107], ["ZIKV", "SPECIES", 69, 73], ["the siRNA", "TEST", 27, 36], ["ZIKV", "PROBLEM", 69, 73], ["Huh", "TEST", 77, 80], ["AR", "TEST", 105, 107], ["siRNA", "ANATOMY", 31, 36], ["viral kinetics", "OBSERVATION_MODIFIER", 51, 65]]], ["The ZIKV-PR RNA load in both the culture supernatant (top) and cell lysate (bottom) of the AR-12-treated (3 \u03bcM) samples were consistently \u223c1.0-1.5 logs lower than those of the DMSO-treated controls at different time points (24, 48, and 72 hpi).", [["culture supernatant", "ANATOMY", 33, 52], ["cell lysate", "ANATOMY", 63, 74], ["samples", "ANATOMY", 112, 119], ["DMSO", "CHEMICAL", 176, 180], ["DMSO", "CHEMICAL", 176, 180], ["ZIKV-PR", "GENE_OR_GENE_PRODUCT", 4, 11], ["cell lysate", "CELL", 63, 74], ["AR-12", "GENE_OR_GENE_PRODUCT", 91, 96], ["DMSO", "SIMPLE_CHEMICAL", 176, 180], ["PR", "PROTEIN", 9, 11], ["AR", "PROTEIN", 91, 93], ["The ZIKV", "TEST", 0, 8], ["PR RNA load", "PROBLEM", 9, 20], ["the culture supernatant", "TEST", 29, 52], ["cell lysate", "TEST", 63, 74], ["the AR", "TEST", 87, 93], ["samples", "TEST", 112, 119], ["the DMSO", "TREATMENT", 172, 180], ["cell lysate", "OBSERVATION", 63, 74]]], ["All experiments were performed in triplicates in three independent experiments for confirmation. *** denotes P < 0.001 (compared with the DMSO control group at the corresponding time point by Student's t-test).", [["DMSO", "CHEMICAL", 138, 142], ["DMSO", "CHEMICAL", 138, 142], ["confirmation", "TEST", 83, 95], ["the DMSO control group", "TREATMENT", 134, 156], ["Student's t-test", "TEST", 192, 208]]], ["Data are presented as mean values \u00b1 standard deviations (error bars).", [["mean values", "TEST", 22, 33]]], ["Abbreviations: DMSO, dimethyl sulfoxide; hpi, hours post-inoculation; ZIKV, Zika virus.", [["DMSO", "CHEMICAL", 15, 19], ["dimethyl sulfoxide", "CHEMICAL", 21, 39], ["DMSO", "CHEMICAL", 15, 19], ["dimethyl sulfoxide", "CHEMICAL", 21, 39], ["DMSO", "SIMPLE_CHEMICAL", 15, 19], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 21, 39], ["hpi", "SIMPLE_CHEMICAL", 41, 44], ["Zika virus", "ORGANISM", 76, 86], ["ZIKV", "SPECIES", 70, 74], ["Zika virus", "SPECIES", 76, 86], ["dimethyl sulfoxide", "TREATMENT", 21, 39], ["ZIKV", "PROBLEM", 70, 74], ["Zika virus", "PROBLEM", 76, 86]]], ["All experiments were performed in triplicates in three independent experiments for confirmation. ** denotes P < 0.01 and *** denotes P < 0.001 (compared with the DMSO control group by Student's t-test).", [["DMSO", "CHEMICAL", 162, 166], ["confirmation", "TEST", 83, 95], ["Student's t-test", "TEST", 184, 200]]], ["Data are presented as mean values \u00b1 standard deviations (error bars).", [["mean values", "TEST", 22, 33]]], ["Abbreviations: DMSO, dimethyl sulfoxide; hpi, hours post-inoculation; ZIKV, Zika virus.Akt inhibitor and small interfering RNA (siRNA) knockdowntransfected cells were inoculated with ZIKV for 1 h at 37\u00b0C. At 1 hpi, the inoculum was removed and the cells were washed with PBS.", [["cells", "ANATOMY", 156, 161], ["cells", "ANATOMY", 248, 253], ["DMSO", "CHEMICAL", 15, 19], ["dimethyl sulfoxide", "CHEMICAL", 21, 39], ["DMSO", "CHEMICAL", 15, 19], ["dimethyl sulfoxide", "CHEMICAL", 21, 39], ["DMSO", "SIMPLE_CHEMICAL", 15, 19], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 21, 39], ["hpi", "SIMPLE_CHEMICAL", 41, 44], ["Zika virus", "ORGANISM", 76, 86], ["Akt", "GENE_OR_GENE_PRODUCT", 87, 90], ["cells", "CELL", 156, 161], ["cells", "CELL", 248, 253], ["Akt", "PROTEIN", 87, 90], ["knockdowntransfected cells", "CELL_LINE", 135, 161], ["ZIKV", "SPECIES", 70, 74], ["Zika virus", "SPECIES", 76, 86], ["ZIKV", "SPECIES", 183, 187], ["dimethyl sulfoxide", "TREATMENT", 21, 39], ["ZIKV", "PROBLEM", 70, 74], ["Zika virus", "PROBLEM", 76, 86], ["Akt inhibitor", "TREATMENT", 87, 100], ["small interfering RNA (siRNA) knockdowntransfected cells", "PROBLEM", 105, 161], ["the inoculum", "TREATMENT", 215, 227], ["the cells", "TREATMENT", 244, 253], ["PBS", "TREATMENT", 271, 274], ["small", "OBSERVATION_MODIFIER", 105, 110], ["interfering RNA", "OBSERVATION", 111, 126]]], ["DMEM was then added to the cells.", [["cells", "ANATOMY", 27, 32], ["DMEM", "ORGANISM_SUBSTANCE", 0, 4], ["cells", "CELL", 27, 32], ["DMEM", "TREATMENT", 0, 4]]], ["At 24 hpi, the supernatants were harvested in RLT buffer and RNA was extracted with the EZ1 RNA tissue mini kit (Qiagen).", [["supernatants", "ANATOMY", 15, 27], ["tissue", "TISSUE", 96, 102], ["the supernatants", "TREATMENT", 11, 27], ["harvested", "OBSERVATION", 33, 42]]], ["The viral RNA load was then quantified with qRT-PCR as we previously described (Chan et al., 2016c; Chan et al., 2017b) .A129 mouse model for ZIKV infection and in vivo evaluation of AR-12 treatmentThe type I interferon receptor-deficient lethal A129 mouse model for ZIKV infection was performed as previously described with slight modifications (Dowall et al., 2016; Guo et al., 2018) .", [["ZIKV infection", "DISEASE", 142, 156], ["ZIKV infection", "DISEASE", 267, 281], ["mouse", "ORGANISM", 126, 131], ["AR-12", "GENE_OR_GENE_PRODUCT", 183, 188], ["type I interferon receptor", "GENE_OR_GENE_PRODUCT", 202, 228], ["mouse", "ORGANISM", 251, 256], ["ZIKV", "ORGANISM", 267, 271], ["AR", "PROTEIN", 183, 185], ["type I interferon receptor", "PROTEIN", 202, 228], ["mouse", "SPECIES", 126, 131], ["mouse", "SPECIES", 251, 256], ["mouse", "SPECIES", 126, 131], ["ZIKV", "SPECIES", 142, 146], ["mouse", "SPECIES", 251, 256], ["ZIKV", "SPECIES", 267, 271], ["The viral RNA load", "TEST", 0, 18], ["ZIKV infection", "PROBLEM", 142, 156], ["vivo evaluation", "TEST", 164, 179], ["AR", "TEST", 183, 185], ["treatment", "TREATMENT", 189, 198], ["The type I interferon receptor-deficient lethal", "TREATMENT", 198, 245], ["ZIKV infection", "PROBLEM", 267, 281], ["viral RNA load", "OBSERVATION", 4, 18], ["ZIKV infection", "OBSERVATION", 142, 156]]], ["Briefly, 4-6-weekold A129 mice (Mutant Mouse Resource Research Centers, USA) were randomly divided into different groups to receive AR-12 treatment or sham treatment (n = 12-24/group).", [["AR-12", "CHEMICAL", 132, 137], ["A129", "ORGANISM", 21, 25], ["mice", "ORGANISM", 26, 30], ["AR-12", "GENE_OR_GENE_PRODUCT", 132, 137], ["AR", "PROTEIN", 132, 134], ["mice", "SPECIES", 26, 30], ["Mouse", "SPECIES", 39, 44], ["mice", "SPECIES", 26, 30], ["AR-12 treatment", "TREATMENT", 132, 147], ["sham treatment", "TREATMENT", 151, 165]]], ["Additional groups of uninfected mice receiving intraperitoneal or oral AR-12 treatment were also included as controls (Table S1 ).", [["intraperitoneal", "ANATOMY", 47, 62], ["oral", "ANATOMY", 66, 70], ["AR-12", "CHEMICAL", 71, 76], ["mice", "ORGANISM", 32, 36], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 62], ["AR", "PROTEIN", 71, 73], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["uninfected mice", "TREATMENT", 21, 36], ["intraperitoneal", "TREATMENT", 47, 62], ["oral AR-12 treatment", "TREATMENT", 66, 86]]], ["The mice were inoculated subcutaneously with 8 \u00d7 10 6 plaque-forming units (PFU) (in 80 \u03bcl PBS) of ZIKV-PR under anesthesia at 0 days post-infection (dpi).", [["subcutaneously", "ANATOMY", 25, 39], ["plaque", "ANATOMY", 54, 60], ["infection", "DISEASE", 139, 148], ["mice", "ORGANISM", 4, 8], ["PR", "PROTEIN", 104, 106], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["The mice", "TREATMENT", 0, 8], ["ZIKV", "PROBLEM", 99, 103], ["anesthesia", "TREATMENT", 113, 123], ["infection", "PROBLEM", 139, 148], ["infection", "OBSERVATION", 139, 148]]], ["Each mouse then received 1 dose of intraperitoneally administered AR-12 (25 mg/kg intraperitoneally or 200 mg/kg orally by oral gavage suspended in PBS with 0.5% methylcellulose-0.1% Tween 80) or sham treatment (PBS) at 1 hpi or 48 hpi as previously described (Table S1 ) (Chen et al., 2017; Lee et al., 2009) .", [["intraperitoneally", "ANATOMY", 35, 52], ["oral", "ANATOMY", 123, 127], ["AR-12", "CHEMICAL", 66, 71], ["methylcellulose", "CHEMICAL", 162, 177], ["Tween 80", "CHEMICAL", 183, 191], ["Tween 80", "CHEMICAL", 183, 191], ["mouse", "ORGANISM", 5, 10], ["oral", "ORGANISM_SUBDIVISION", 123, 127], ["methylcellulose", "SIMPLE_CHEMICAL", 162, 177], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["intraperitoneally administered AR", "TREATMENT", 35, 68], ["0.5% methylcellulose", "TREATMENT", 157, 177], ["sham treatment", "TREATMENT", 196, 210]]], ["The mice were monitored three times per day for body weight change and clinical signs of disease as previously described (Dowall et al., 2016) .", [["body", "ANATOMY", 48, 52], ["mice", "ORGANISM", 4, 8], ["body", "ORGANISM_SUBDIVISION", 48, 52], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["body weight change", "PROBLEM", 48, 66], ["clinical signs of disease", "PROBLEM", 71, 96], ["disease", "OBSERVATION", 89, 96]]], ["Six (12 for sham treatment control group) mice in each group were euthanized when there was \u226520% weight loss or \u226510% weight loss with \u22651 clinical sign or at 6 dpi (the expected day of death of all untreated control mice).", [["weight loss", "DISEASE", 97, 108], ["weight loss", "DISEASE", 117, 128], ["death", "DISEASE", 184, 189], ["mice", "ORGANISM", 42, 46], ["mice", "ORGANISM", 215, 219], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 215, 219], ["sham treatment control group)", "TREATMENT", 12, 41], ["20% weight loss", "PROBLEM", 93, 108], ["\u226510% weight loss", "PROBLEM", 112, 128]]], ["Their blood and organ tissues were collected for viral load studies as previously described (Chan et al., 2016d; Yuan et al., 2017) .", [["blood", "ANATOMY", 6, 11], ["organ tissues", "ANATOMY", 16, 29], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["organ tissues", "TISSUE", 16, 29], ["viral load studies", "TEST", 49, 67], ["organ tissues", "ANATOMY", 16, 29]]], ["The survival of the other mice was monitored until 14 dpi.Statistical analysisAll data were analyzed with GraphPad Prism software (GraphPad Software, Inc) as we previously described (Chan et al., 2016d) .", [["mice", "ORGANISM", 26, 30], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["Statistical analysis", "TEST", 58, 78], ["All data", "TEST", 78, 86]]], ["Kaplan-Meier survival curves were analyzed by the log rank test, and weight losses were compared using two-way ANOVA.", [["Meier survival curves", "TEST", 7, 28], ["the log rank test", "TEST", 46, 63], ["weight losses", "PROBLEM", 69, 82]]], ["Student's t-test was used to determine significant differences in viral loads, and Tukey-Kramer post hoc test was used to discern differences among the groups.", [["Student's t-test", "TEST", 0, 16], ["significant differences in viral loads", "PROBLEM", 39, 77], ["Kramer post hoc test", "TEST", 89, 109], ["viral loads", "OBSERVATION", 66, 77]]], ["P < 0.05 was considered statistically significant.AR-12 inhibited the replication of ZIKV strains belonging to both the Asian/American and African lineagesBoth the Asian/American and African lineages of ZIKV are considered to be pathogenic and medically important (Musso and Gubler, 2016; Simonin et al., 2016; Zhu et al., 2016) .", [["AR-12", "CHEMICAL", 50, 55], ["ZIKV", "CHEMICAL", 203, 207], ["AR-12", "GENE_OR_GENE_PRODUCT", 50, 55], ["ZIKV strains", "ORGANISM", 85, 97], ["ZIKV", "GENE_OR_GENE_PRODUCT", 203, 207], ["AR", "PROTEIN", 50, 52], ["ZIKV", "SPECIES", 85, 89], ["ZIKV", "SPECIES", 203, 207], ["ZIKV strains", "PROBLEM", 85, 97], ["ZIKV", "PROBLEM", 203, 207]]], ["We therefore evaluated the antiviral activity of AR-12 against ZIKV strains belonging to both lineages.", [["AR-12", "CHEMICAL", 49, 54], ["AR-12", "GENE_OR_GENE_PRODUCT", 49, 54], ["ZIKV strains", "ORGANISM", 63, 75], ["AR", "PROTEIN", 49, 51], ["ZIKV", "SPECIES", 63, 67], ["the antiviral activity of AR", "TREATMENT", 23, 51], ["ZIKV strains", "PROBLEM", 63, 75]]], ["In the viral load reduction assay, AR-12 inhibited the replication of all 3 ZIKV strains used in the study, including ZIKV-PR (Asian/American), ZIKV-GD (Asian/American), and ZIKV-U (African), in Huh-7 cells in a dose-dependent manner (Fig. 1) .", [["Huh-7 cells", "ANATOMY", 195, 206], ["AR-12", "CHEMICAL", 35, 40], ["AR-12", "GENE_OR_GENE_PRODUCT", 35, 40], ["ZIKV-PR", "ORGANISM", 118, 125], ["ZIKV-GD", "ORGANISM", 144, 151], ["ZIKV-U", "CELL", 174, 180], ["Huh-7 cells", "CELL", 195, 206], ["AR", "PROTEIN", 35, 37], ["Huh-7 cells", "CELL_LINE", 195, 206], ["ZIKV", "SPECIES", 76, 80], ["ZIKV-U", "SPECIES", 174, 180], ["Huh-7", "SPECIES", 195, 200], ["the viral load reduction assay", "TEST", 3, 33], ["AR", "TEST", 35, 37], ["all 3 ZIKV strains", "PROBLEM", 70, 88], ["the study", "TEST", 97, 106], ["ZIKV", "PROBLEM", 144, 148], ["viral load", "OBSERVATION", 7, 17]]], ["The reduction in viral RNA load of all 3 ZIKV strains was \u223c1.0-1.5 logs in culture supernatant and cell lysate of AR-12-treated samples.", [["supernatant", "ANATOMY", 83, 94], ["cell lysate", "ANATOMY", 99, 110], ["samples", "ANATOMY", 128, 135], ["AR-12", "CHEMICAL", 114, 119], ["cell", "CELL", 99, 103], ["AR-12", "CELL", 114, 119], ["samples", "CANCER", 128, 135], ["viral RNA", "RNA", 17, 26], ["AR", "PROTEIN", 114, 116], ["ZIKV", "SPECIES", 41, 45], ["The reduction", "TREATMENT", 0, 13], ["viral RNA load", "TEST", 17, 31], ["ZIKV strains", "TEST", 41, 53], ["culture supernatant", "TEST", 75, 94], ["cell lysate", "TEST", 99, 110], ["AR", "TEST", 114, 116], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["viral RNA load", "OBSERVATION", 17, 31]]], ["These findings demonstrated that AR-12 could inhibit both the Asian/American and African lineages of ZIKV.AR-12 effectively inhibited multi-cycle replication of ZIKV in vitroTo further characterize the inhibition of ZIKV by AR-12, we prolonged the incubation of Huh-7 cells infected with ZIKV-PR and either AR-12 or DMSO for up to 72 h to study their differential viral kinetics.", [["Huh-7 cells", "ANATOMY", 262, 273], ["AR-12", "CHEMICAL", 33, 38], ["AR-12", "CHEMICAL", 106, 111], ["DMSO", "CHEMICAL", 316, 320], ["DMSO", "CHEMICAL", 316, 320], ["AR-12", "GENE_OR_GENE_PRODUCT", 33, 38], ["ZIKV", "ORGANISM", 101, 105], ["AR-12", "GENE_OR_GENE_PRODUCT", 106, 111], ["ZIKV", "ORGANISM", 161, 165], ["ZIKV", "GENE_OR_GENE_PRODUCT", 216, 220], ["AR-12", "GENE_OR_GENE_PRODUCT", 224, 229], ["Huh-7 cells", "CELL", 262, 273], ["ZIKV-PR", "GENE_OR_GENE_PRODUCT", 288, 295], ["AR-12", "GENE_OR_GENE_PRODUCT", 307, 312], ["DMSO", "SIMPLE_CHEMICAL", 316, 320], ["AR", "PROTEIN", 33, 35], ["AR", "PROTEIN", 106, 108], ["ZIKV", "DNA", 161, 165], ["ZIKV", "PROTEIN", 216, 220], ["AR", "PROTEIN", 224, 226], ["Huh-7 cells", "CELL_LINE", 262, 273], ["ZIKV", "PROTEIN", 288, 292], ["PR", "PROTEIN", 293, 295], ["AR", "PROTEIN", 307, 309], ["ZIKV", "SPECIES", 101, 105], ["ZIKV", "SPECIES", 161, 165], ["ZIKV", "SPECIES", 216, 220], ["Huh-7", "SPECIES", 262, 267], ["AR", "TEST", 33, 35], ["ZIKV", "PROBLEM", 101, 105], ["AR", "TEST", 106, 108], ["ZIKV", "TREATMENT", 161, 165], ["ZIKV", "PROBLEM", 216, 220], ["Huh", "TEST", 262, 265], ["ZIKV", "PROBLEM", 288, 292], ["DMSO", "TREATMENT", 316, 320], ["ZIKV", "OBSERVATION", 101, 105], ["viral kinetics", "OBSERVATION", 364, 378]]], ["As shown in Fig. 2 , the ZIKV-PR RNA loads in both the culture supernatant and cell lysate of the AR-12-treated samples were consistently \u223c1.0-1.5 logs lower than those of the DMSO-treated controls at multiple time points (24, 48, and 72 hpi).", [["culture supernatant", "ANATOMY", 55, 74], ["cell lysate", "ANATOMY", 79, 90], ["samples", "ANATOMY", 112, 119], ["AR-12", "CHEMICAL", 98, 103], ["DMSO", "CHEMICAL", 176, 180], ["DMSO", "CHEMICAL", 176, 180], ["ZIKV-PR", "GENE_OR_GENE_PRODUCT", 25, 32], ["cell lysate", "CELL", 79, 90], ["AR-12", "GENE_OR_GENE_PRODUCT", 98, 103], ["DMSO", "SIMPLE_CHEMICAL", 176, 180], ["PR", "PROTEIN", 30, 32], ["AR", "PROTEIN", 98, 100], ["the ZIKV", "TEST", 21, 29], ["the culture supernatant", "TEST", 51, 74], ["cell lysate", "TEST", 79, 90], ["the AR", "TEST", 94, 100], ["the DMSO", "TREATMENT", 172, 180]]], ["The CC 50 , IC 50 , and selectivity index of AR-12 in Huh-7 cells were 7.01 \u03bcM, 0.82-0.88 \u03bcM (culture supernatant and cell lysate), and 7.97-8.55, respectively.AR-12 provided cell protection effects against ZIKV infectionIn addition to inhibition of viral replication, it was important to determine if cell protection effects against ZIKV infection were present in AR-12-treated cells.", [["Huh-7 cells", "ANATOMY", 54, 65], ["supernatant", "ANATOMY", 102, 113], ["cell lysate", "ANATOMY", 118, 129], ["cell", "ANATOMY", 175, 179], ["cell", "ANATOMY", 302, 306], ["cells", "ANATOMY", 379, 384], ["CC", "CHEMICAL", 4, 6], ["ZIKV infection", "DISEASE", 207, 221], ["ZIKV", "CHEMICAL", 334, 338], ["infection", "DISEASE", 339, 348], ["AR-12", "CHEMICAL", 365, 370], ["AR-12", "GENE_OR_GENE_PRODUCT", 45, 50], ["Huh-7 cells", "CELL", 54, 65], ["cell", "CELL", 118, 122], ["AR-12", "GENE_OR_GENE_PRODUCT", 160, 165], ["cell", "CELL", 175, 179], ["ZIKV", "ORGANISM", 207, 211], ["cell", "CELL", 302, 306], ["ZIKV", "ORGANISM", 334, 338], ["AR-12", "GENE_OR_GENE_PRODUCT", 365, 370], ["cells", "CELL", 379, 384], ["AR", "PROTEIN", 45, 47], ["Huh-7 cells", "CELL_LINE", 54, 65], ["AR", "PROTEIN", 160, 162], ["AR-12-treated cells", "CELL_LINE", 365, 384], ["ZIKV", "SPECIES", 207, 211], ["ZIKV", "SPECIES", 334, 338], ["The CC", "TEST", 0, 6], ["IC", "TEST", 12, 14], ["selectivity index", "TEST", 24, 41], ["AR", "TEST", 45, 47], ["Huh", "TEST", 54, 57], ["\u03bcM", "TEST", 76, 78], ["culture supernatant", "TEST", 94, 113], ["cell lysate", "TEST", 118, 129], ["AR", "TEST", 160, 162], ["cell protection effects", "TREATMENT", 175, 198], ["ZIKV infection", "PROBLEM", 207, 221], ["viral replication", "TREATMENT", 250, 267], ["cell protection effects", "TREATMENT", 302, 325], ["ZIKV infection", "PROBLEM", 334, 348], ["AR", "TEST", 365, 367], ["viral replication", "OBSERVATION", 250, 267]]], ["In the cell viability assay, a dose-dependent increase in the percentage of viable cells was observed in AR-12-treated Huh-7 cells (Fig. 3) .", [["cell", "ANATOMY", 7, 11], ["cells", "ANATOMY", 83, 88], ["Huh-7 cells", "ANATOMY", 119, 130], ["AR-12", "CHEMICAL", 105, 110], ["cell", "CELL", 7, 11], ["cells", "CELL", 83, 88], ["AR-12", "GENE_OR_GENE_PRODUCT", 105, 110], ["Huh-7 cells", "CELL", 119, 130], ["AR-12-treated Huh-7 cells", "CELL_LINE", 105, 130], ["the cell viability assay", "TEST", 3, 27], ["dependent increase", "PROBLEM", 36, 54], ["viable cells", "PROBLEM", 76, 88], ["AR", "TEST", 105, 107], ["Huh", "TEST", 119, 122], ["cell viability assay", "OBSERVATION", 7, 27], ["dependent", "OBSERVATION_MODIFIER", 36, 45], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["percentage", "OBSERVATION_MODIFIER", 62, 72], ["viable cells", "OBSERVATION", 76, 88]]], ["The mean cell viability increased from 55.6% in untreated Huh-7 cells to approximately 100% in cells treated with 3 \u03bcM AR-12, suggesting that AR-12 provided cell protection effects against ZIKV infection.", [["cell", "ANATOMY", 9, 13], ["Huh-7 cells", "ANATOMY", 58, 69], ["cells", "ANATOMY", 95, 100], ["cell", "ANATOMY", 157, 161], ["ZIKV infection", "DISEASE", 189, 203], ["cell", "CELL", 9, 13], ["Huh-7 cells", "CELL", 58, 69], ["cells", "CELL", 95, 100], ["AR-12", "GENE_OR_GENE_PRODUCT", 119, 124], ["AR-12", "GENE_OR_GENE_PRODUCT", 142, 147], ["cell", "CELL", 157, 161], ["ZIKV", "ORGANISM", 189, 193], ["Huh-7 cells", "CELL_LINE", 58, 69], ["AR", "PROTEIN", 119, 121], ["AR", "PROTEIN", 142, 144], ["Huh-7", "SPECIES", 58, 63], ["ZIKV", "SPECIES", 189, 193], ["The mean cell viability", "TEST", 0, 23], ["Huh", "TEST", 58, 61], ["3 \u03bcM AR", "TREATMENT", 114, 121], ["AR", "TEST", 142, 144], ["cell protection effects", "TREATMENT", 157, 180], ["ZIKV infection", "PROBLEM", 189, 203], ["mean cell", "OBSERVATION", 4, 13], ["viability", "OBSERVATION_MODIFIER", 14, 23], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["All experiments were performed in triplicates in three independent experiments for confirmation. * denotes P < 0.05 and ** denotes P < 0.01 (compared to the DMSO control group by Student's t-test).", [["DMSO", "CHEMICAL", 157, 161], ["confirmation", "TEST", 83, 95], ["Student's t-test", "TEST", 179, 195]]], ["Data are presented as mean values \u00b1 standard deviations (error bars).", [["mean values", "TEST", 22, 33]]], ["Abbreviations: ZIKV, Zika virus.AR-12 inhibited ZIKV replication in multiple cell typesThe major clinical manifestations of ZIKV infection, such as congenital microcephaly and meningoencephalitis, mainly involve neuronal cells.", [["ZIKV", "ANATOMY", 48, 52], ["cell", "ANATOMY", 77, 81], ["neuronal cells", "ANATOMY", 212, 226], ["AR-12", "CHEMICAL", 32, 37], ["infection", "DISEASE", 129, 138], ["congenital microcephaly", "DISEASE", 148, 171], ["meningoencephalitis", "DISEASE", 176, 195], ["Zika virus", "ORGANISM", 21, 31], ["AR-12", "GENE_OR_GENE_PRODUCT", 32, 37], ["ZIKV", "GENE_OR_GENE_PRODUCT", 48, 52], ["cell", "CELL", 77, 81], ["ZIKV", "ORGANISM", 124, 128], ["neuronal cells", "CELL", 212, 226], ["AR", "PROTEIN", 32, 34], ["neuronal cells", "CELL_TYPE", 212, 226], ["Zika virus", "SPECIES", 21, 31], ["ZIKV", "SPECIES", 48, 52], ["ZIKV", "SPECIES", 124, 128], ["ZIKV", "PROBLEM", 15, 19], ["Zika virus", "PROBLEM", 21, 31], ["AR", "PROBLEM", 32, 34], ["ZIKV replication", "PROBLEM", 48, 64], ["ZIKV infection", "PROBLEM", 124, 138], ["congenital microcephaly", "PROBLEM", 148, 171], ["meningoencephalitis", "PROBLEM", 176, 195], ["neuronal cells", "PROBLEM", 212, 226], ["12 inhibited", "OBSERVATION_MODIFIER", 35, 47], ["ZIKV replication", "OBSERVATION", 48, 64], ["multiple cell types", "OBSERVATION", 68, 87], ["ZIKV infection", "OBSERVATION", 124, 138], ["congenital", "OBSERVATION_MODIFIER", 148, 158], ["microcephaly", "OBSERVATION", 159, 171], ["meningoencephalitis", "OBSERVATION", 176, 195], ["neuronal cells", "OBSERVATION", 212, 226]]], ["To confirm the observation in the viral load reduction assay using Huh-7 cells, we further evaluated the antiviral activity of AR-12 against the epidemic ZIKV-PR strain in two neuronal (glioblastoma) cell lines, namely, U251 and SF268.", [["Huh-7 cells", "ANATOMY", 67, 78], ["neuronal", "ANATOMY", 176, 184], ["glioblastoma) cell lines", "ANATOMY", 186, 210], ["U251", "ANATOMY", 220, 224], ["SF268", "ANATOMY", 229, 234], ["AR-12", "CHEMICAL", 127, 132], ["glioblastoma", "DISEASE", 186, 198], ["Huh-7 cells", "CELL", 67, 78], ["AR-12", "GENE_OR_GENE_PRODUCT", 127, 132], ["ZIKV-PR strain", "ORGANISM", 154, 168], ["neuronal", "CELL", 176, 184], ["glioblastoma) cell lines", "CELL", 186, 210], ["U251", "CELL", 220, 224], ["SF268", "CELL", 229, 234], ["Huh-7 cells", "CELL_LINE", 67, 78], ["AR", "PROTEIN", 127, 129], ["neuronal (glioblastoma) cell lines", "CELL_LINE", 176, 210], ["U251", "CELL_LINE", 220, 224], ["SF268", "CELL_LINE", 229, 234], ["the observation", "TEST", 11, 26], ["the viral load reduction", "TREATMENT", 30, 54], ["Huh-7 cells", "TREATMENT", 67, 78], ["AR", "TEST", 127, 129], ["the epidemic ZIKV", "PROBLEM", 141, 158], ["PR strain", "PROBLEM", 159, 168], ["U251", "TEST", 220, 224], ["cell lines", "OBSERVATION", 200, 210]]], ["As shown in Fig. 4 , the ZIKV-PR RNA load was significantly reduced by AR-12 in both U251 (P < 0.01) and SF268 cells (P < 0.001).", [["U251", "ANATOMY", 85, 89], ["SF268 cells", "ANATOMY", 105, 116], ["ZIKV-PR", "GENE_OR_GENE_PRODUCT", 25, 32], ["AR-12", "GENE_OR_GENE_PRODUCT", 71, 76], ["U251", "CELL", 85, 89], ["SF268 cells", "CELL", 105, 116], ["PR", "PROTEIN", 30, 32], ["AR", "PROTEIN", 71, 73], ["U251", "CELL_LINE", 85, 89], ["SF268 cells", "CELL_LINE", 105, 116], ["the ZIKV", "TEST", 21, 29], ["PR RNA load", "TEST", 30, 41], ["AR", "TEST", 71, 73], ["P", "TEST", 91, 92], ["P", "TEST", 118, 119]]], ["The CC 50 , IC 50 , and selectivity index of AR-12 in U251 cells were 6.99 \u03bcM, 0.84 \u03bcM, and 8.32, respectively, and those in SF268 cells were 11.00 \u03bcM, 1.18 \u03bcM, and 9.32, respectively.", [["U251 cells", "ANATOMY", 54, 64], ["SF268 cells", "ANATOMY", 125, 136], ["CC", "CHEMICAL", 4, 6], ["AR-12", "GENE_OR_GENE_PRODUCT", 45, 50], ["U251 cells", "CELL", 54, 64], ["SF268 cells", "CELL", 125, 136], ["AR", "PROTEIN", 45, 47], ["U251 cells", "CELL_LINE", 54, 64], ["SF268 cells", "CELL_LINE", 125, 136], ["The CC", "TEST", 0, 6], ["IC", "TEST", 12, 14], ["selectivity index", "TEST", 24, 41], ["AR", "TEST", 45, 47], ["U251 cells", "TEST", 54, 64], ["\u03bcM", "TEST", 75, 77], ["\u03bcM", "TEST", 148, 150], ["\u03bcM", "TEST", 157, 159]]], ["The antiviral activity of AR-12 against ZIKV was confirmed even at high MOI by both qRT-PCR and plaque assays (Fig. 5) .", [["plaque", "ANATOMY", 96, 102], ["AR-12", "CHEMICAL", 26, 31], ["AR-12", "GENE_OR_GENE_PRODUCT", 26, 31], ["ZIKV", "ORGANISM", 40, 44], ["AR", "PROTEIN", 26, 28], ["ZIKV", "SPECIES", 40, 44], ["The antiviral activity of AR", "TREATMENT", 0, 28], ["ZIKV", "PROBLEM", 40, 44], ["PCR", "TEST", 88, 91], ["plaque assays", "TEST", 96, 109], ["antiviral activity", "OBSERVATION", 4, 22], ["plaque", "OBSERVATION", 96, 102]]], ["We next further evaluated the impact of AR-12 on the antigen expression of ZIKV-PR in neuronal cells with flow cytometry (Fig. 6) .", [["neuronal cells", "ANATOMY", 86, 100], ["AR-12", "GENE_OR_GENE_PRODUCT", 40, 45], ["ZIKV-PR", "GENE_OR_GENE_PRODUCT", 75, 82], ["neuronal cells", "CELL", 86, 100], ["AR", "PROTEIN", 40, 42], ["ZIKV", "PROTEIN", 75, 79], ["PR", "PROTEIN", 80, 82], ["neuronal cells", "CELL_TYPE", 86, 100], ["AR", "TEST", 40, 42], ["ZIKV", "PROBLEM", 75, 79], ["flow cytometry", "TEST", 106, 120], ["neuronal cells", "OBSERVATION", 86, 100], ["flow cytometry", "OBSERVATION", 106, 120]]], ["Remarkably, our result demonstrated that AR-12 significantly inhibited the expression of both the envelope protein (Fig. 6A ) and non-structural protein 1 (Fig. 6B ) of ZIKV-PR in the infected cells.", [["cells", "ANATOMY", 193, 198], ["AR-12", "GENE_OR_GENE_PRODUCT", 41, 46], ["Fig. 6A", "GENE_OR_GENE_PRODUCT", 116, 123], ["non-structural protein 1", "GENE_OR_GENE_PRODUCT", 130, 154], ["Fig. 6B", "GENE_OR_GENE_PRODUCT", 156, 163], ["ZIKV-PR", "GENE_OR_GENE_PRODUCT", 169, 176], ["cells", "CELL", 193, 198], ["AR", "PROTEIN", 41, 43], ["envelope protein", "PROTEIN", 98, 114], ["Fig. 6A", "PROTEIN", 116, 123], ["non-structural protein 1", "PROTEIN", 130, 154], ["Fig. 6B", "PROTEIN", 156, 163], ["ZIKV", "PROTEIN", 169, 173], ["PR", "PROTEIN", 174, 176], ["infected cells", "CELL_TYPE", 184, 198], ["AR", "TEST", 41, 43], ["the envelope protein", "TEST", 94, 114], ["non-structural protein", "TEST", 130, 152], ["ZIKV", "PROBLEM", 169, 173], ["the infected cells", "PROBLEM", 180, 198], ["infected cells", "OBSERVATION", 184, 198]]], ["The inhibition was evidenced by the reduction in the percentage of positive cells (Fig. 6C) as well as the reduction in the mean fluorescent intensity (Fig. 6D) .AR-12 treatment improved clinical and virological outcome of ZIKVinfected A129 miceTo assess the in vivo anti-ZIKV activity of AR-12, we infected type I interferon-receptor-deficient A129 mice with ZIKV-PR and treated them with either AR-12 or sham treatment.", [["cells", "ANATOMY", 76, 81], ["AR-12", "CHEMICAL", 162, 167], ["AR-12", "CHEMICAL", 397, 402], ["cells", "CELL", 76, 81], ["AR-12", "GENE_OR_GENE_PRODUCT", 162, 167], ["ZIKVinfected A129 miceTo", "CELL", 223, 247], ["anti-ZIKV", "CANCER", 267, 276], ["AR-12", "GENE_OR_GENE_PRODUCT", 289, 294], ["type I interferon-receptor", "GENE_OR_GENE_PRODUCT", 308, 334], ["mice", "ORGANISM", 350, 354], ["ZIKV-PR", "GENE_OR_GENE_PRODUCT", 360, 367], ["AR-12", "GENE_OR_GENE_PRODUCT", 397, 402], ["positive cells", "CELL_TYPE", 67, 81], ["AR", "PROTEIN", 162, 164], ["AR", "PROTEIN", 289, 291], ["type I interferon-receptor", "PROTEIN", 308, 334], ["ZIKV", "PROTEIN", 360, 364], ["PR", "PROTEIN", 365, 367], ["AR", "PROTEIN", 397, 399], ["mice", "SPECIES", 350, 354], ["A129", "SPECIES", 236, 240], ["anti-ZIKV", "SPECIES", 267, 276], ["mice", "SPECIES", 350, 354], ["ZIKV", "SPECIES", 360, 364], ["positive cells", "PROBLEM", 67, 81], ["the reduction", "TREATMENT", 103, 116], ["AR", "TEST", 162, 164], ["treatment", "TREATMENT", 168, 177], ["type I interferon", "TREATMENT", 308, 325], ["ZIKV-PR", "TREATMENT", 360, 367], ["either AR", "TREATMENT", 390, 399], ["sham treatment", "TREATMENT", 406, 420], ["reduction", "OBSERVATION_MODIFIER", 36, 45], ["positive cells", "OBSERVATION", 67, 81], ["reduction", "OBSERVATION_MODIFIER", 107, 116]]], ["The ZIKV-infected mice treated with AR-12 early after infection (1 hpi) had less mean body weight loss (< 10%) (Fig. 7A ) and significantly higher survival rate (83.3% vs 0%, P < 0.001) (Fig. 7B ) than the untreated ZIKV-infected controls.", [["body", "ANATOMY", 86, 90], ["infection", "DISEASE", 54, 63], ["weight loss", "DISEASE", 91, 102], ["ZIKV-infected", "DISEASE", 216, 229], ["ZIKV", "GENE_OR_GENE_PRODUCT", 4, 8], ["mice", "ORGANISM", 18, 22], ["AR-12", "GENE_OR_GENE_PRODUCT", 36, 41], ["body", "ORGANISM_SUBDIVISION", 86, 90], ["ZIKV", "ORGANISM", 216, 220], ["controls", "ORGANISM", 230, 238], ["AR", "PROTEIN", 36, 38], ["mice", "SPECIES", 18, 22], ["ZIKV", "SPECIES", 4, 8], ["mice", "SPECIES", 18, 22], ["ZIKV", "SPECIES", 216, 220], ["The ZIKV", "PROBLEM", 0, 8], ["AR", "TREATMENT", 36, 38], ["infection", "PROBLEM", 54, 63], ["mean body weight loss", "PROBLEM", 81, 102], ["survival rate", "TEST", 147, 160], ["P", "TEST", 175, 176], ["the untreated ZIKV", "PROBLEM", 202, 220], ["infected", "OBSERVATION_MODIFIER", 9, 17], ["infection", "OBSERVATION", 54, 63], ["infected", "OBSERVATION", 221, 229]]], ["Moreover, the mean ZIKV RNA loads in the blood and necropsied tissues of these AR-12-treated mice at necropsy were generally 0.8-1.5 logs lower than those of the untreated mice (Fig. 7C) .", [["blood", "ANATOMY", 41, 46], ["tissues", "ANATOMY", 62, 69], ["AR-12", "CHEMICAL", 79, 84], ["ZIKV", "GENE_OR_GENE_PRODUCT", 19, 23], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["tissues", "TISSUE", 62, 69], ["AR-12", "GENE_OR_GENE_PRODUCT", 79, 84], ["mice", "ORGANISM", 93, 97], ["mice", "ORGANISM", 172, 176], ["ZIKV RNA", "RNA", 19, 27], ["AR", "PROTEIN", 79, 81], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 172, 176], ["ZIKV", "SPECIES", 19, 23], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 172, 176], ["the mean ZIKV RNA loads", "PROBLEM", 10, 33], ["the blood", "TEST", 37, 46], ["these AR", "TEST", 73, 81], ["necropsy", "TEST", 101, 109], ["ZIKV RNA loads", "OBSERVATION", 19, 33], ["blood", "ANATOMY", 41, 46]]], ["We also evaluated regimens of delayed administration of AR-12 either intraperitoneally or by oral gavage to ZIKV-infected mice at 48 hpi to more closely mimic clinical situations in which viremic patients do not receive treatment immediately after infection.", [["oral", "ANATOMY", 93, 97], ["AR-12", "CHEMICAL", 56, 61], ["infection", "DISEASE", 248, 257], ["AR-12", "GENE_OR_GENE_PRODUCT", 56, 61], ["oral", "ORGANISM_SUBDIVISION", 93, 97], ["ZIKV", "SIMPLE_CHEMICAL", 108, 112], ["mice", "ORGANISM", 122, 126], ["patients", "ORGANISM", 196, 204], ["AR", "PROTEIN", 56, 58], ["mice", "SPECIES", 122, 126], ["patients", "SPECIES", 196, 204], ["ZIKV", "SPECIES", 108, 112], ["mice", "SPECIES", 122, 126], ["delayed administration of AR", "TREATMENT", 30, 58], ["ZIKV", "PROBLEM", 108, 112], ["treatment", "TREATMENT", 220, 229], ["infection", "PROBLEM", 248, 257]]], ["The improved clinical and virological parameters were more obvious in the mice treated with the oral regimen, which consisted of a much higher dose (200 mg/kg) of AR-12 than the intraperitoneal regimen (25 mg/kg) (Fig. 7) .", [["oral", "ANATOMY", 96, 100], ["intraperitoneal", "ANATOMY", 178, 193], ["AR-12", "CHEMICAL", 163, 168], ["mice", "ORGANISM", 74, 78], ["oral", "ORGANISM_SUBDIVISION", 96, 100], ["AR-12", "GENE_OR_GENE_PRODUCT", 163, 168], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 178, 193], ["AR", "PROTEIN", 163, 165], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 74, 78], ["virological parameters", "TEST", 26, 48], ["the oral regimen", "TREATMENT", 92, 108], ["AR", "TREATMENT", 163, 165], ["the intraperitoneal regimen", "TREATMENT", 174, 201], ["improved", "OBSERVATION_MODIFIER", 4, 12]]], ["These findings illustrated that AR-12 not only inhibited ZIKV in vitro, but also in vivo, especially if given early or at a high dose.AR-12 inhibited ZIKV replication via down-regulation of AktDownregulation of 78 kDa glucose-regulated protein (GRP-78) and/ or Akt has been previously proposed to be the anti-DENV mechanism of AR-12 (Chen et al., 2017) .", [["ZIKV", "ANATOMY", 150, 154], ["glucose", "CHEMICAL", 218, 225], ["glucose", "CHEMICAL", 218, 225], ["AR-12", "GENE_OR_GENE_PRODUCT", 32, 37], ["ZIKV", "GENE_OR_GENE_PRODUCT", 57, 61], ["AR-12", "GENE_OR_GENE_PRODUCT", 134, 139], ["ZIKV", "GENE_OR_GENE_PRODUCT", 150, 154], ["glucose-regulated protein", "GENE_OR_GENE_PRODUCT", 218, 243], ["GRP-78", "GENE_OR_GENE_PRODUCT", 245, 251], ["Akt", "GENE_OR_GENE_PRODUCT", 261, 264], ["AR-12", "GENE_OR_GENE_PRODUCT", 327, 332], ["AR", "PROTEIN", 32, 34], ["AR", "PROTEIN", 134, 136], ["78 kDa glucose-regulated protein", "PROTEIN", 211, 243], ["GRP", "PROTEIN", 245, 248], ["Akt", "PROTEIN", 261, 264], ["AR", "PROTEIN", 327, 329], ["ZIKV", "SPECIES", 57, 61], ["ZIKV", "SPECIES", 150, 154], ["AR", "TEST", 32, 34], ["AR", "TEST", 134, 136], ["ZIKV replication", "TREATMENT", 150, 166], ["AktDownregulation", "TEST", 190, 207], ["kDa glucose", "TEST", 214, 225], ["protein", "TEST", 236, 243], ["GRP", "TEST", 245, 248]]], ["Surprisingly, in contrast to this previous report, we did not find AR-12 to be downregulating GRP-78 (Fig. 8A) .", [["AR-12", "GENE_OR_GENE_PRODUCT", 67, 72], ["GRP-78", "GENE_OR_GENE_PRODUCT", 94, 100], ["AR", "PROTEIN", 67, 69], ["GRP", "PROTEIN", 94, 97], ["AR", "TEST", 67, 69], ["GRP", "TEST", 94, 97]]], ["Instead, we found that AR-12 substantially downregulated the phosphorylation of the Akt protein (Fig. 8B) .", [["AR-12", "GENE_OR_GENE_PRODUCT", 23, 28], ["Akt", "GENE_OR_GENE_PRODUCT", 84, 87], ["Fig. 8B", "GENE_OR_GENE_PRODUCT", 97, 104], ["AR", "PROTEIN", 23, 25], ["Akt protein", "PROTEIN", 84, 95], ["Fig. 8B", "PROTEIN", 97, 104], ["AR", "TEST", 23, 25], ["the Akt protein", "TEST", 80, 95]]], ["In this regard, our data suggested that AR-12 potentially inhibited ZIKV replication by negatively regulating the Akt signaling pathway.", [["AR-12", "GENE_OR_GENE_PRODUCT", 40, 45], ["ZIKV", "GENE_OR_GENE_PRODUCT", 68, 72], ["Akt", "GENE_OR_GENE_PRODUCT", 114, 117], ["AR", "PROTEIN", 40, 42], ["Akt", "PROTEIN", 114, 117], ["ZIKV", "SPECIES", 68, 72], ["our data", "TEST", 16, 24], ["AR", "TEST", 40, 42], ["ZIKV replication", "TREATMENT", 68, 84]]], ["To further investigate if the Akt signaling pathway modulated ZIKV replication, we treated ZIKV-infected Huh-7 cells with an Akt inhibitor, Akt inhibitor VIII, which has been previously shown to inhibit Akt activation (Lindsley et al., 2005) .", [["Huh-7 cells", "ANATOMY", 105, 116], ["Akt", "GENE_OR_GENE_PRODUCT", 30, 33], ["ZIKV", "GENE_OR_GENE_PRODUCT", 62, 66], ["ZIKV", "CELL", 91, 95], ["Huh-7 cells", "CELL", 105, 116], ["Akt", "GENE_OR_GENE_PRODUCT", 125, 128], ["Akt", "GENE_OR_GENE_PRODUCT", 140, 143], ["VIII", "GENE_OR_GENE_PRODUCT", 154, 158], ["Akt", "GENE_OR_GENE_PRODUCT", 203, 206], ["Akt", "PROTEIN", 30, 33], ["ZIKV-infected Huh-7 cells", "CELL_LINE", 91, 116], ["Akt", "PROTEIN", 125, 128], ["Akt inhibitor VIII", "PROTEIN", 140, 158], ["Akt", "PROTEIN", 203, 206], ["ZIKV", "SPECIES", 62, 66], ["ZIKV", "SPECIES", 91, 95], ["Huh-7", "SPECIES", 105, 110], ["the Akt signaling pathway", "PROBLEM", 26, 51], ["ZIKV replication", "TREATMENT", 62, 78], ["ZIKV", "TEST", 91, 95], ["an Akt inhibitor", "TREATMENT", 122, 138], ["Akt inhibitor VIII", "TREATMENT", 140, 158]]], ["Interestingly, our result demonstrated that ZIKV replication was significantly (P < 0.05) inhibited in the presence of Akt inhibitor VIII (Fig. 8C) .", [["Akt", "GENE_OR_GENE_PRODUCT", 119, 122], ["VIII", "GENE_OR_GENE_PRODUCT", 133, 137], ["Akt", "PROTEIN", 119, 122], ["VIII", "PROTEIN", 133, 137], ["ZIKV", "SPECIES", 44, 48], ["ZIKV replication", "PROBLEM", 44, 60], ["Akt inhibitor VIII", "TREATMENT", 119, 137]]], ["The involvement of the Akt signaling pathway in ZIKV replication was further validated with siRNA knockdown (Fig. 8D) .", [["Akt", "GENE_OR_GENE_PRODUCT", 23, 26], ["ZIKV", "CANCER", 48, 52], ["Akt", "PROTEIN", 23, 26], ["ZIKV", "SPECIES", 48, 52], ["the Akt signaling pathway", "TREATMENT", 19, 44], ["ZIKV replication", "TREATMENT", 48, 64], ["siRNA knockdown", "TREATMENT", 92, 107]]], ["Akt knockdown resulted in a significant (P < 0.01) decrease in ZIKV replication, which was in agreement with the result of the Akt inhibitor VIII experiment (Fig. 8E) .", [["Akt", "GENE_OR_GENE_PRODUCT", 0, 3], ["ZIKV", "GENE_OR_GENE_PRODUCT", 63, 67], ["Akt", "GENE_OR_GENE_PRODUCT", 127, 130], ["VIII", "GENE_OR_GENE_PRODUCT", 141, 145], ["Akt", "PROTEIN", 0, 3], ["Akt", "PROTEIN", 127, 130], ["ZIKV", "SPECIES", 63, 67], ["Akt knockdown", "TEST", 0, 13], ["ZIKV replication", "TREATMENT", 63, 79], ["the Akt inhibitor", "TREATMENT", 123, 140], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["ZIKV replication", "OBSERVATION", 63, 79]]], ["Taken together, these findings suggested that AR-12 inhibits ZIKV replication through downregulation of the Akt signaling pathway.DiscussionDrug compounds that target common host pathways involved in the replication cycles of different viruses have the potential advantage of being broad-spectrum antivirals (Zumla et al., 2016) .", [["AR-12", "GENE_OR_GENE_PRODUCT", 46, 51], ["ZIKV", "GENE_OR_GENE_PRODUCT", 61, 65], ["Akt", "GENE_OR_GENE_PRODUCT", 108, 111], ["AR", "PROTEIN", 46, 48], ["Akt", "PROTEIN", 108, 111], ["ZIKV", "SPECIES", 61, 65], ["AR", "TEST", 46, 48], ["ZIKV replication", "TREATMENT", 61, 77], ["different viruses", "PROBLEM", 226, 243], ["broad-spectrum antivirals", "TREATMENT", 282, 307]]], ["AR-12 inhibits the antigen expression of ZIKV-PR in U251 cells.", [["U251 cells", "ANATOMY", 52, 62], ["AR-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["ZIKV-PR", "GENE_OR_GENE_PRODUCT", 41, 48], ["U251 cells", "CELL", 52, 62], ["AR", "PROTEIN", 0, 2], ["ZIKV", "PROTEIN", 41, 45], ["PR", "PROTEIN", 46, 48], ["U251 cells", "CELL_LINE", 52, 62], ["AR", "TEST", 0, 2], ["ZIKV", "PROBLEM", 41, 45]]], ["U251 cells were infected with ZIKV-PR at 0.5 MOI or were mock-infected for 1 h at 37\u00b0C. The infected cells were subsequently treated with 3 \u03bcM AR-12 or DMSO for 24 h.", [["U251 cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 101, 106], ["AR-12", "CHEMICAL", 143, 148], ["DMSO", "CHEMICAL", 152, 156], ["DMSO", "CHEMICAL", 152, 156], ["U251 cells", "CELL", 0, 10], ["ZIKV-PR", "GENE_OR_GENE_PRODUCT", 30, 37], ["cells", "CELL", 101, 106], ["DMSO", "SIMPLE_CHEMICAL", 152, 156], ["U251 cells", "CELL_LINE", 0, 10], ["PR", "PROTEIN", 35, 37], ["infected cells", "CELL_TYPE", 92, 106], ["U251 cells", "PROBLEM", 0, 10], ["ZIKV", "TREATMENT", 30, 34], ["The infected cells", "PROBLEM", 88, 106], ["3 \u03bcM AR", "TREATMENT", 138, 145], ["DMSO", "TREATMENT", 152, 156], ["infected cells", "OBSERVATION", 92, 106]]], ["At 24 hpi, the cells were harvested and immunolabeled for flow cytometry analysis.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["flow cytometry analysis", "TEST", 58, 81]]], ["The expression level of ZIKV envelope protein (A) and non-structural 1 protein (B) were labeled with mouse anti-4G2 and mouse anti-NS1, respectively.", [["ZIKV envelope protein (A)", "GENE_OR_GENE_PRODUCT", 24, 49], ["non-structural 1 protein (B)", "GENE_OR_GENE_PRODUCT", 54, 82], ["mouse", "ORGANISM", 101, 106], ["anti-4G2", "GENE_OR_GENE_PRODUCT", 107, 115], ["mouse", "ORGANISM", 120, 125], ["NS1", "GENE_OR_GENE_PRODUCT", 131, 134], ["ZIKV envelope protein", "PROTEIN", 24, 45], ["A", "PROTEIN", 47, 48], ["non-structural 1 protein", "PROTEIN", 54, 78], ["B", "PROTEIN", 80, 81], ["mouse anti-4G2", "PROTEIN", 101, 115], ["NS1", "PROTEIN", 131, 134], ["mouse", "SPECIES", 101, 106], ["mouse", "SPECIES", 120, 125], ["mouse", "SPECIES", 101, 106], ["mouse", "SPECIES", 120, 125], ["ZIKV envelope protein", "TEST", 24, 45], ["mouse anti-4G2 and mouse anti-NS1", "TREATMENT", 101, 134]]], ["The percentage of 4G2 or NS1 positive cells (C) and the mean fluorescent intensity (D) were quantified.", [["cells", "ANATOMY", 38, 43], ["NS1", "GENE_OR_GENE_PRODUCT", 25, 28], ["4G2", "PROTEIN", 18, 21], ["NS1 positive cells", "CELL_LINE", 25, 43], ["The percentage", "TEST", 0, 14], ["NS1 positive cells", "PROBLEM", 25, 43], ["positive cells", "OBSERVATION", 29, 43]]], ["All experiments were performed in triplicates in three independent experiments for confirmation. * denotes P < 0.05 and ** denotes P < 0.01 (compared with the DMSO control group by Student's t-test).", [["DMSO", "CHEMICAL", 159, 163], ["confirmation", "TEST", 83, 95], ["Student's t-test", "TEST", 181, 197]]], ["Data are presented as mean values \u00b1 standard deviations (error bars).", [["mean values", "TEST", 22, 33]]], ["Abbreviations: DMSO, dimethyl sulfoxide; hpi, hours post-inoculation; MFI, mean fluorescence intensity; NS1, non-structural protein 1; ZIKV, Zika virus.Discussionimportant for arboviruses such as ZIKV, DENV, and Chikungunya virus, which co-circulate in the same geographical regions and/or have similar clinical features.", [["DMSO", "CHEMICAL", 15, 19], ["dimethyl sulfoxide", "CHEMICAL", 21, 39], ["Chikungunya virus", "DISEASE", 212, 229], ["DMSO", "CHEMICAL", 15, 19], ["dimethyl sulfoxide", "CHEMICAL", 21, 39], ["DMSO", "SIMPLE_CHEMICAL", 15, 19], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 21, 39], ["non-structural protein 1", "GENE_OR_GENE_PRODUCT", 109, 133], ["ZIKV", "GENE_OR_GENE_PRODUCT", 135, 139], ["Zika virus", "ORGANISM", 141, 151], ["ZIKV", "GENE_OR_GENE_PRODUCT", 196, 200], ["DENV", "ORGANISM", 202, 206], ["Chikungunya virus", "ORGANISM", 212, 229], ["NS1", "PROTEIN", 104, 107], ["non-structural protein 1", "PROTEIN", 109, 133], ["ZIKV", "PROTEIN", 135, 139], ["Chikungunya virus", "SPECIES", 212, 229], ["Zika virus", "SPECIES", 141, 151], ["ZIKV", "SPECIES", 196, 200], ["DENV", "SPECIES", 202, 206], ["Chikungunya virus", "SPECIES", 212, 229], ["dimethyl sulfoxide", "TREATMENT", 21, 39], ["MFI", "TEST", 70, 73], ["mean fluorescence intensity", "TEST", 75, 102], ["NS1", "PROBLEM", 104, 107], ["non-structural protein 1", "PROBLEM", 109, 133], ["ZIKV", "PROBLEM", 135, 139], ["Zika virus", "PROBLEM", 141, 151], ["arboviruses", "PROBLEM", 176, 187], ["ZIKV", "PROBLEM", 196, 200], ["DENV", "PROBLEM", 202, 206], ["Chikungunya virus", "PROBLEM", 212, 229], ["Zika virus", "OBSERVATION", 141, 151], ["Chikungunya virus", "OBSERVATION", 212, 229]]], ["We and others have previously identified a number of clinically approved drugs, such as novobiocin, lopinavir-ritonavir, ribavirin, and sofosbuvir, to have anti-ZIKV activity in vitro and/or in vivo (Bullard-Feibelman et al., 2016; Kamiyama et al., 2017; Yuan et al., 2017) .", [["novobiocin", "CHEMICAL", 88, 98], ["lopinavir-ritonavir", "CHEMICAL", 100, 119], ["ribavirin", "CHEMICAL", 121, 130], ["sofosbuvir", "CHEMICAL", 136, 146], ["novobiocin", "CHEMICAL", 88, 98], ["lopinavir", "CHEMICAL", 100, 109], ["ritonavir", "CHEMICAL", 110, 119], ["ribavirin", "CHEMICAL", 121, 130], ["sofosbuvir", "CHEMICAL", 136, 146], ["novobiocin", "SIMPLE_CHEMICAL", 88, 98], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 100, 119], ["ribavirin", "SIMPLE_CHEMICAL", 121, 130], ["sofosbuvir", "SIMPLE_CHEMICAL", 136, 146], ["anti-ZIKV", "CANCER", 156, 165], ["drugs", "TREATMENT", 73, 78], ["novobiocin", "TREATMENT", 88, 98], ["lopinavir", "TREATMENT", 100, 109], ["ritonavir", "TREATMENT", 110, 119], ["ribavirin", "TREATMENT", 121, 130], ["sofosbuvir", "TREATMENT", 136, 146], ["anti-ZIKV activity", "TREATMENT", 156, 174]]], ["These repurposed drugs directly target the virus by inhibition of key viral enzymes, such as the viral protease and polymerase, and may not have antiviral activity against other co-circulating arboviruses with structurally different viral enzymes.DiscussionHost-targeting treatment options for ZIKV remain scarce.", [["ZIKV", "DISEASE", 294, 298], ["viral enzymes", "PROTEIN", 70, 83], ["viral protease", "PROTEIN", 97, 111], ["polymerase", "PROTEIN", 116, 126], ["viral enzymes", "PROTEIN", 233, 246], ["ZIKV", "SPECIES", 294, 298], ["These repurposed drugs", "TREATMENT", 0, 22], ["the virus", "PROBLEM", 39, 48], ["key viral enzymes", "TEST", 66, 83], ["the viral protease and polymerase", "TREATMENT", 93, 126], ["antiviral activity", "TREATMENT", 145, 163], ["other co-circulating arboviruses", "PROBLEM", 172, 204], ["structurally different viral enzymes", "PROBLEM", 210, 246], ["treatment options", "TREATMENT", 272, 289], ["ZIKV", "PROBLEM", 294, 298]]], ["We have previously shown the in vitro and in vivo anti-ZIKV activity of recombinant interferons, but their side effect profiles may limit their clinical use, especially in pregnant women (Chan et al., 2017a; Chan et al., 2016d) .", [["anti-ZIKV", "CANCER", 50, 59], ["women", "ORGANISM", 181, 186], ["recombinant interferons", "PROTEIN", 72, 95], ["women", "SPECIES", 181, 186], ["anti-ZIKV", "SPECIES", 50, 59], ["recombinant interferons", "TREATMENT", 72, 95]]], ["A recent study reported the in vitro anti-ZIKV activity of a protein kinase A inhibitor in endothelial cells and astrocytes.", [["endothelial cells", "ANATOMY", 91, 108], ["astrocytes", "ANATOMY", 113, 123], ["anti-ZIKV", "CANCER", 37, 46], ["protein kinase A", "GENE_OR_GENE_PRODUCT", 61, 77], ["endothelial cells", "CELL", 91, 108], ["astrocytes", "CELL", 113, 123], ["protein kinase A", "PROTEIN", 61, 77], ["endothelial cells", "CELL_TYPE", 91, 108], ["astrocytes", "CELL_TYPE", 113, 123], ["A recent study", "TEST", 0, 14], ["a protein kinase A inhibitor", "TREATMENT", 59, 87], ["endothelial cells", "OBSERVATION", 91, 108]]], ["Another recent study reported that the activation of adenosine monophosphate-activated protein kinase by a small molecule activator (PF-06409577) inhibited ZIKV replication through modulation of host cell lipid metabolism (Jim\u00e9nez de Oya et al., 2018) .", [["ZIKV", "ANATOMY", 156, 160], ["cell", "ANATOMY", 200, 204], ["adenosine", "CHEMICAL", 53, 62], ["PF-06409577", "CHEMICAL", 133, 144], ["adenosine monophosphate", "CHEMICAL", 53, 76], ["PF-06409577", "CHEMICAL", 133, 144], ["adenosine monophosphate-activated protein kinase", "GENE_OR_GENE_PRODUCT", 53, 101], ["PF-06409577", "SIMPLE_CHEMICAL", 133, 144], ["ZIKV", "GENE_OR_GENE_PRODUCT", 156, 160], ["host cell", "CELL", 195, 204], ["adenosine monophosphate-activated protein kinase", "PROTEIN", 53, 101], ["ZIKV", "SPECIES", 156, 160], ["Another recent study", "TEST", 0, 20], ["adenosine monophosphate", "TREATMENT", 53, 76], ["activated protein kinase", "PROBLEM", 77, 101], ["a small molecule activator", "TREATMENT", 105, 131], ["PF", "TEST", 133, 135], ["ZIKV replication", "TREATMENT", 156, 172], ["host cell", "OBSERVATION", 195, 204], ["lipid metabolism", "OBSERVATION", 205, 221]]], ["These findings supported our hypothesis that drugs which target host signaling pathways may be useful for treating ZIKV infection (Cheng et al., 2018) .DiscussionDuring the preparation of this work, AR-12 and a few other kinase inhibitors were recently identified to exhibit in vitro anti-ZIKV activity in human osteosarcoma (U2OS) cells in a drug screening programme (Rausch et al., 2017) .", [["osteosarcoma (U2OS) cells", "ANATOMY", 312, 337], ["ZIKV infection", "DISEASE", 115, 129], ["osteosarcoma", "DISEASE", 312, 324], ["ZIKV", "ORGANISM", 115, 119], ["AR-12", "GENE_OR_GENE_PRODUCT", 199, 204], ["anti-ZIKV", "CANCER", 284, 293], ["human", "ORGANISM", 306, 311], ["osteosarcoma (U2OS) cells", "CELL", 312, 337], ["AR", "PROTEIN", 199, 201], ["human osteosarcoma (U2OS) cells", "CELL_LINE", 306, 337], ["human", "SPECIES", 306, 311], ["ZIKV", "SPECIES", 115, 119], ["human", "SPECIES", 306, 311], ["drugs", "TREATMENT", 45, 50], ["ZIKV infection", "PROBLEM", 115, 129], ["AR", "TEST", 199, 201], ["a few other kinase inhibitors", "TREATMENT", 209, 238], ["human osteosarcoma", "PROBLEM", 306, 324], ["a drug screening", "TEST", 341, 357], ["osteosarcoma", "OBSERVATION", 312, 324]]], ["However, no further validation of this preliminary finding in other clinically relevant cell lines or suitable animal model was reported, and the anti-ZIKV mechanism of AR-12 was not investigated.", [["cell lines", "ANATOMY", 88, 98], ["cell lines", "CELL", 88, 98], ["AR-12", "GENE_OR_GENE_PRODUCT", 169, 174], ["cell lines", "CELL_LINE", 88, 98], ["AR", "PROTEIN", 169, 171], ["the anti-ZIKV mechanism", "TEST", 142, 165], ["no", "UNCERTAINTY", 9, 11], ["cell lines", "OBSERVATION", 88, 98]]], ["In this study, we demonstrated the anti-ZIKV activity of AR-12 in vitro and in vivo, and provided novel insights into the drug's anti-ZIKV mechanism.DiscussionWe first showed that AR-12 inhibited the replication of ZIKV belonging to both the American/Asian and African lineages.", [["AR-12", "CHEMICAL", 57, 62], ["AR-12", "CHEMICAL", 180, 185], ["AR-12", "GENE_OR_GENE_PRODUCT", 57, 62], ["anti-ZIKV", "CANCER", 129, 138], ["AR-12", "GENE_OR_GENE_PRODUCT", 180, 185], ["ZIKV", "GENE_OR_GENE_PRODUCT", 215, 219], ["AR", "PROTEIN", 57, 59], ["AR", "PROTEIN", 180, 182], ["ZIKV", "SPECIES", 215, 219], ["this study", "TEST", 3, 13], ["AR", "TEST", 57, 59], ["AR", "TEST", 180, 182], ["ZIKV", "PROBLEM", 215, 219]]], ["This was important as both lineages of ZIKV are considered to be pathogenic to human.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 39, 43], ["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["ZIKV", "SPECIES", 39, 43], ["human", "SPECIES", 79, 84], ["ZIKV", "PROBLEM", 39, 43]]], ["Moreover, treatment with AR-12 provided cell protection effects against ZIKV-induced damage.", [["cell", "ANATOMY", 40, 44], ["AR-12", "CHEMICAL", 25, 30], ["ZIKV", "CHEMICAL", 72, 76], ["AR-12", "GENE_OR_GENE_PRODUCT", 25, 30], ["cell", "CELL", 40, 44], ["ZIKV", "SIMPLE_CHEMICAL", 72, 76], ["AR", "PROTEIN", 25, 27], ["ZIKV", "SPECIES", 72, 76], ["AR", "TREATMENT", 25, 27], ["cell protection effects", "TREATMENT", 40, 63], ["ZIKV", "PROBLEM", 72, 76], ["induced damage", "PROBLEM", 77, 91]]], ["The anti-ZIKV activity of AR-12 was then validated in multiple cell types, including neuronal cells which are clinically relevant for the neurotropic ZIKV.", [["cell", "ANATOMY", 63, 67], ["neuronal cells", "ANATOMY", 85, 99], ["anti-ZIKV", "CANCER", 4, 13], ["AR-12", "GENE_OR_GENE_PRODUCT", 26, 31], ["cell", "CELL", 63, 67], ["neuronal cells", "CELL", 85, 99], ["ZIKV", "ORGANISM", 150, 154], ["AR", "PROTEIN", 26, 28], ["neuronal cells", "CELL_TYPE", 85, 99], ["ZIKV", "SPECIES", 150, 154], ["The anti-ZIKV activity of AR", "TEST", 0, 28], ["neuronal cells", "PROBLEM", 85, 99], ["the neurotropic ZIKV", "PROBLEM", 134, 154], ["multiple cell types", "OBSERVATION", 54, 73], ["neuronal cells", "OBSERVATION", 85, 99]]], ["Importantly, type I interferon receptor-deficient A129 mice treated with AR-12 (either early or delayed regimen) had significantly higher survival rates and lower viral loads than untreated mice, suggesting that the anti-ZIKV effect of AR-12 was not only present in vitro, but also in a lethal animal model.", [["AR-12", "CHEMICAL", 73, 78], ["AR-12", "CHEMICAL", 236, 241], ["type I interferon receptor", "GENE_OR_GENE_PRODUCT", 13, 39], ["AR-12", "GENE_OR_GENE_PRODUCT", 73, 78], ["mice", "ORGANISM", 190, 194], ["AR-12", "GENE_OR_GENE_PRODUCT", 236, 241], ["type I interferon receptor", "PROTEIN", 13, 39], ["AR", "PROTEIN", 73, 75], ["AR", "PROTEIN", 236, 238], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 190, 194], ["type I interferon receptor-deficient", "TREATMENT", 13, 49], ["AR", "TREATMENT", 73, 75], ["delayed regimen", "TREATMENT", 96, 111], ["significantly higher survival rates", "PROBLEM", 117, 152], ["lower viral loads", "PROBLEM", 157, 174], ["the anti-ZIKV effect of AR", "PROBLEM", 212, 238], ["viral loads", "OBSERVATION", 163, 174]]], ["We further demonstrated that AR-12 inhibited the phosphorylation of Akt, which is a downstream component of the PI3K/ (Table S1 ).", [["AR-12", "GENE_OR_GENE_PRODUCT", 29, 34], ["Akt", "GENE_OR_GENE_PRODUCT", 68, 71], ["PI3K", "GENE_OR_GENE_PRODUCT", 112, 116], ["Table S1", "GENE_OR_GENE_PRODUCT", 119, 127], ["AR", "PROTEIN", 29, 31], ["Akt", "PROTEIN", 68, 71], ["PI3K", "PROTEIN", 112, 116], ["S1", "PROTEIN", 125, 127], ["AR", "TEST", 29, 31]]], ["Six (12 for sham treatment controls) mice in each group were euthanized when there was \u226520% weight loss or \u226510% weight loss with \u22651 clinical sign or at 6 dpi for blood and organ tissue collection.", [["blood", "ANATOMY", 162, 167], ["organ tissue", "ANATOMY", 172, 184], ["weight loss", "DISEASE", 92, 103], ["weight loss", "DISEASE", 112, 123], ["mice", "ORGANISM", 37, 41], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["organ tissue", "TISSUE", 172, 184], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["sham treatment controls", "TREATMENT", 12, 35], ["20% weight loss", "PROBLEM", 88, 103], ["\u226510% weight loss", "PROBLEM", 107, 123], ["blood and organ tissue collection", "PROBLEM", 162, 195], ["organ tissue", "ANATOMY", 172, 184], ["collection", "OBSERVATION", 185, 195]]], ["ZIKV RNA loads in the blood (copies/ml) and tissues (copies/10 6 \u03b2-actin) (C) of the mice were determined by qRT-PCR.", [["blood", "ANATOMY", 22, 27], ["tissues", "ANATOMY", 44, 51], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["tissues", "TISSUE", 44, 51], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 65, 72], ["mice", "ORGANISM", 85, 89], ["ZIKV RNA", "RNA", 0, 8], ["mice", "SPECIES", 85, 89], ["ZIKV", "SPECIES", 0, 4], ["mice", "SPECIES", 85, 89], ["ZIKV RNA loads", "PROBLEM", 0, 14], ["tissues", "ANATOMY", 44, 51]]], ["The body weight and the survival rate of the other mice were monitored from 0 to 14 dpi or until death/euthanasia.", [["body", "ANATOMY", 4, 8], ["death", "DISEASE", 97, 102], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["mice", "ORGANISM", 51, 55], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["The body weight", "TEST", 0, 15], ["death", "PROBLEM", 97, 102], ["euthanasia", "PROBLEM", 103, 113], ["euthanasia", "OBSERVATION", 103, 113]]], ["The body weight trends represented those of the survived mice.", [["body", "ANATOMY", 4, 8], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["mice", "ORGANISM", 57, 61], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61]]], ["Statistical significance in (C) represented the difference between the individual treatment groups with the sham treatment control group. * denotes P-values of < 0.05, ** denotes P-values of < 0.01, and *** denotes P-values of < 0.001.", [["the individual treatment groups", "TREATMENT", 67, 98], ["the sham treatment control group", "TREATMENT", 104, 136], ["P-values", "TEST", 148, 156], ["P-values", "TEST", 179, 187], ["P-values", "TEST", 215, 223]]], ["Data are presented as mean values \u00b1 standard deviations (error bars).", [["mean values", "TEST", 22, 33]]], ["Abbreviations: ip, intraperitoneal; PBS, phosphate-buffered saline; po, per os; ZIKV, Zika virus.DiscussionAkt signaling pathway that promotes flavivirus replication by counteracting virus-induced cellular apoptosis.", [["intraperitoneal", "ANATOMY", 19, 34], ["cellular", "ANATOMY", 197, 205], ["phosphate", "CHEMICAL", 41, 50], ["phosphate", "CHEMICAL", 41, 50], ["ip", "SIMPLE_CHEMICAL", 15, 17], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 34], ["PBS", "SIMPLE_CHEMICAL", 36, 39], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 41, 66], ["po", "SIMPLE_CHEMICAL", 68, 70], ["Zika virus", "ORGANISM", 86, 96], ["Akt", "GENE_OR_GENE_PRODUCT", 107, 110], ["flavivirus", "ORGANISM", 143, 153], ["cellular", "CELL", 197, 205], ["Akt", "PROTEIN", 107, 110], ["Zika virus", "SPECIES", 86, 96], ["flavivirus", "SPECIES", 143, 153], ["phosphate", "TREATMENT", 41, 50], ["buffered saline", "TREATMENT", 51, 66], ["ZIKV", "PROBLEM", 80, 84], ["Zika virus", "PROBLEM", 86, 96], ["flavivirus replication", "TREATMENT", 143, 165], ["counteracting virus", "PROBLEM", 169, 188], ["cellular apoptosis", "PROBLEM", 197, 215], ["intraperitoneal", "ANATOMY", 19, 34], ["cellular apoptosis", "OBSERVATION", 197, 215]]], ["The ZIKV RNA load reduction (\u223c1.0-1.5 logs) observed in our cell culture systems and animal model with AR-12 treatment is comparable with previous findings on AR-12's antiviral effects against other RNA viruses.", [["cell culture systems", "ANATOMY", 60, 80], ["AR-12", "CHEMICAL", 103, 108], ["cell", "CELL", 60, 64], ["AR-12", "GENE_OR_GENE_PRODUCT", 103, 108], ["AR-12's", "SIMPLE_CHEMICAL", 159, 166], ["AR", "PROTEIN", 103, 105], ["AR", "PROTEIN", 159, 161], ["ZIKV", "SPECIES", 4, 8], ["The ZIKV RNA load reduction", "TREATMENT", 0, 27], ["\u223c", "TEST", 29, 30], ["our cell culture systems", "TEST", 56, 80], ["animal model", "TEST", 85, 97], ["AR-12 treatment", "TREATMENT", 103, 118], ["AR", "TEST", 159, 161], ["antiviral effects", "TREATMENT", 167, 184], ["other RNA viruses", "PROBLEM", 193, 210], ["ZIKV", "OBSERVATION", 4, 8], ["RNA load", "OBSERVATION", 9, 17]]], ["For example, the CC 50 , IC 50 , and selectivity index values of AR-12 against other hemorrhagic fever viruses were comparable with our findings for ZIKV (Mohr et al., 2015) .", [["CC", "CHEMICAL", 17, 19], ["hemorrhagic fever", "DISEASE", 85, 102], ["AR-12", "GENE_OR_GENE_PRODUCT", 65, 70], ["AR", "PROTEIN", 65, 67], ["ZIKV", "SPECIES", 149, 153], ["the CC", "TEST", 13, 19], ["IC", "TEST", 25, 27], ["selectivity index values", "TEST", 37, 61], ["AR", "TEST", 65, 67], ["other hemorrhagic fever viruses", "PROBLEM", 79, 110], ["ZIKV", "PROBLEM", 149, 153], ["hemorrhagic", "OBSERVATION_MODIFIER", 85, 96], ["fever", "OBSERVATION", 97, 102]]], ["For flaviviruses, there was about 1 log reduction of DENV RNA load with 2-4 \u03bcM AR-12 and the IC 50 values of AR-12 against DENV serotypes 1-4 were between 0.60 \u03bcM and 0.80 \u03bcM in Vero cells (Hassandarvish et al., 2017) .", [["Vero cells", "ANATOMY", 178, 188], ["DENV", "ORGANISM", 53, 57], ["AR-12", "GENE_OR_GENE_PRODUCT", 109, 114], ["DENV serotypes 1-4", "ORGANISM", 123, 141], ["Vero cells", "CELL", 178, 188], ["DENV RNA", "RNA", 53, 61], ["AR", "PROTEIN", 79, 81], ["AR", "PROTEIN", 109, 111], ["Vero cells", "CELL_LINE", 178, 188], ["DENV", "SPECIES", 53, 57], ["DENV", "SPECIES", 123, 127], ["flaviviruses", "PROBLEM", 4, 16], ["DENV RNA load", "PROBLEM", 53, 66], ["the IC", "TEST", 89, 95], ["AR", "TEST", 109, 111], ["DENV serotypes", "TEST", 123, 137], ["flaviviruses", "OBSERVATION", 4, 16], ["DENV RNA load", "OBSERVATION", 53, 66]]], ["The CC 50 of AR-12 was higher in Vero cells (65.90 \u03bcM) than in our Huh-7 and neuronal cells, suggesting that the selectivity index of AR-12 against flaviviruses may be even higher in other cell types (up to > 100) (Hassandarvish et al., 2017) .", [["Vero cells", "ANATOMY", 33, 43], ["Huh-7", "ANATOMY", 67, 72], ["neuronal cells", "ANATOMY", 77, 91], ["cell", "ANATOMY", 189, 193], ["CC", "CHEMICAL", 4, 6], ["AR-12", "GENE_OR_GENE_PRODUCT", 13, 18], ["Vero cells", "CELL", 33, 43], ["Huh-7", "CELL", 67, 72], ["neuronal cells", "CELL", 77, 91], ["AR-12", "GENE_OR_GENE_PRODUCT", 134, 139], ["flaviviruses", "ORGANISM", 148, 160], ["cell", "CELL", 189, 193], ["AR", "PROTEIN", 13, 15], ["Vero cells", "CELL_LINE", 33, 43], ["Huh-7", "CELL_LINE", 67, 72], ["neuronal cells", "CELL_TYPE", 77, 91], ["AR", "PROTEIN", 134, 136], ["Huh-7", "SPECIES", 67, 72], ["The CC", "TEST", 0, 6], ["AR", "TEST", 13, 15], ["Vero cells", "TEST", 33, 43], ["our Huh", "TEST", 63, 70], ["the selectivity index", "TEST", 109, 130], ["AR", "TEST", 134, 136], ["flaviviruses", "PROBLEM", 148, 160], ["Vero cells", "OBSERVATION", 33, 43], ["neuronal cells", "OBSERVATION", 77, 91], ["higher", "OBSERVATION_MODIFIER", 173, 179]]], ["In DENV-infected suckling mice treated with AR-12 intracranially and intraperitoneally, there was about 0.5-0.7 log reduction in infectious virus particles (plaque forming units) in their brain tissues (Chen et al., 2017) .", [["plaque", "ANATOMY", 157, 163], ["brain tissues", "ANATOMY", 188, 201], ["DENV-infected", "DISEASE", 3, 16], ["DENV", "ORGANISM", 3, 7], ["mice", "ORGANISM", 26, 30], ["AR-12", "GENE_OR_GENE_PRODUCT", 44, 49], ["brain tissues", "TISSUE", 188, 201], ["AR", "PROTEIN", 44, 46], ["mice", "SPECIES", 26, 30], ["DENV", "SPECIES", 3, 7], ["mice", "SPECIES", 26, 30], ["DENV", "PROBLEM", 3, 7], ["infected suckling mice", "TREATMENT", 8, 30], ["AR", "TREATMENT", 44, 46], ["infectious virus particles", "PROBLEM", 129, 155], ["DENV", "OBSERVATION", 3, 7], ["infected", "OBSERVATION_MODIFIER", 8, 16], ["infectious virus", "OBSERVATION", 129, 145], ["brain tissues", "ANATOMY", 188, 201]]], ["In comparison, virus-targeting drugs often achieve a higher degree of viral load reduction (> 2 logs) in vitro and in vivo.", [["virus-targeting drugs", "TREATMENT", 15, 36], ["viral load reduction", "TREATMENT", 70, 90], ["higher degree", "OBSERVATION_MODIFIER", 53, 66], ["viral load", "OBSERVATION", 70, 80]]], ["For example, the ZIKV NS2B-NS3 protease inhibitor novobiocin reduces ZIKV RNA load by \u2265 2 logs both in vitro (Vero and Huh-7 cells) and in the blood and tissues of ZIKV-infected mice (Yuan et al., 2017) .", [["Vero", "ANATOMY", 110, 114], ["Huh-7 cells", "ANATOMY", 119, 130], ["blood", "ANATOMY", 143, 148], ["tissues", "ANATOMY", 153, 160], ["novobiocin", "CHEMICAL", 50, 60], ["novobiocin", "CHEMICAL", 50, 60], ["NS2B", "GENE_OR_GENE_PRODUCT", 22, 26], ["novobiocin", "SIMPLE_CHEMICAL", 50, 60], ["Vero", "CELL", 110, 114], ["Huh-7 cells", "CELL", 119, 130], ["blood", "ORGANISM_SUBSTANCE", 143, 148], ["tissues", "TISSUE", 153, 160], ["ZIKV", "GENE_OR_GENE_PRODUCT", 164, 168], ["mice", "ORGANISM", 178, 182], ["ZIKV NS2B-NS3 protease", "PROTEIN", 17, 39], ["ZIKV RNA", "RNA", 69, 77], ["Huh-7 cells", "CELL_LINE", 119, 130], ["mice", "SPECIES", 178, 182], ["ZIKV", "SPECIES", 17, 21], ["ZIKV", "SPECIES", 69, 73], ["ZIKV", "SPECIES", 164, 168], ["mice", "SPECIES", 178, 182], ["the ZIKV NS2B", "TREATMENT", 13, 26], ["NS3 protease inhibitor novobiocin", "TREATMENT", 27, 60], ["ZIKV RNA load", "PROBLEM", 69, 82], ["vitro", "TEST", 103, 108], ["Vero", "TEST", 110, 114], ["Huh", "TEST", 119, 122], ["ZIKV", "PROBLEM", 164, 168], ["blood", "ANATOMY", 143, 148], ["tissues", "ANATOMY", 153, 160]]], ["Our recently described antiviral peptide (Z2 peptide) targeting the stem region of the ZIKV envelope protein to inhibit virus entry into host cells significantly reduced viral RNA load in ZIKV-infected interferon receptor-deficient mice and inhibited vertical transmission of ZIKV in pregnant C57BL/6 mice (Yu et al., 2017) .", [["stem region", "ANATOMY", 68, 79], ["cells", "ANATOMY", 142, 147], ["ZIKV", "GENE_OR_GENE_PRODUCT", 87, 91], ["host cells", "CELL", 137, 147], ["ZIKV-infected", "ORGANISM", 188, 201], ["interferon receptor", "GENE_OR_GENE_PRODUCT", 202, 221], ["mice", "ORGANISM", 232, 236], ["ZIKV", "ORGANISM", 276, 280], ["C57BL/6 mice", "ORGANISM", 293, 305], ["ZIKV envelope protein", "PROTEIN", 87, 108], ["host cells", "CELL_TYPE", 137, 147], ["interferon receptor", "PROTEIN", 202, 221], ["mice", "SPECIES", 232, 236], ["mice", "SPECIES", 301, 305], ["ZIKV", "SPECIES", 188, 192], ["mice", "SPECIES", 232, 236], ["ZIKV", "SPECIES", 276, 280], ["mice", "SPECIES", 301, 305], ["antiviral peptide (Z2 peptide", "TREATMENT", 23, 52], ["the ZIKV envelope protein", "PROBLEM", 83, 108], ["host cells", "PROBLEM", 137, 147], ["viral RNA load", "PROBLEM", 170, 184], ["ZIKV", "PROBLEM", 188, 192], ["infected interferon receptor-deficient mice", "TREATMENT", 193, 236], ["ZIKV", "PROBLEM", 276, 280], ["stem", "ANATOMY_MODIFIER", 68, 72], ["viral RNA load", "OBSERVATION", 170, 184]]], ["These findings are not unexpected as our mice only received one dose of AR-12 treatment post- Fig. 8 .", [["AR-12", "CHEMICAL", 72, 77], ["mice", "ORGANISM", 41, 45], ["AR-12", "GENE_OR_GENE_PRODUCT", 72, 77], ["AR", "PROTEIN", 72, 74], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["AR-12 treatment", "TREATMENT", 72, 87], ["not unexpected", "UNCERTAINTY", 19, 33]]], ["AR-12 inhibits ZIKV replication via down-regulation of Akt.", [["AR-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["ZIKV", "GENE_OR_GENE_PRODUCT", 15, 19], ["Akt", "GENE_OR_GENE_PRODUCT", 55, 58], ["AR", "PROTEIN", 0, 2], ["Akt", "PROTEIN", 55, 58], ["ZIKV", "SPECIES", 15, 19], ["AR", "TEST", 0, 2], ["ZIKV replication", "TREATMENT", 15, 31]]], ["AR-12 did not downregulate the expression of GRP-78 (A), but reduced Akt phosphorylation (B).", [["AR-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["GRP-78", "GENE_OR_GENE_PRODUCT", 45, 51], ["A", "GENE_OR_GENE_PRODUCT", 53, 54], ["Akt", "GENE_OR_GENE_PRODUCT", 69, 72], ["B", "GENE_OR_GENE_PRODUCT", 90, 91], ["AR", "PROTEIN", 0, 2], ["GRP", "PROTEIN", 45, 48], ["Akt", "PROTEIN", 69, 72], ["AR", "TEST", 0, 2], ["GRP", "TEST", 45, 48]]], ["Addition of Akt Inhibitor VIII (C) significantly reduced ZIKV RNA load.", [["Akt Inhibitor VIII (C)", "GENE_OR_GENE_PRODUCT", 12, 34], ["Akt", "PROTEIN", 12, 15], ["VIII (C)", "PROTEIN", 26, 34], ["ZIKV RNA", "RNA", 57, 65], ["ZIKV", "SPECIES", 57, 61], ["Akt Inhibitor VIII (C)", "TREATMENT", 12, 34], ["significantly reduced ZIKV RNA load", "PROBLEM", 35, 70], ["ZIKV RNA load", "OBSERVATION", 57, 70]]], ["Similarly, Akt siRNA used in this study downregulated the expression levels of Akt and pAkt (D) and significantly reduced ZIKV RNA load (E).", [["Akt", "GENE_OR_GENE_PRODUCT", 11, 14], ["Akt", "GENE_OR_GENE_PRODUCT", 79, 82], ["pAkt", "GENE_OR_GENE_PRODUCT", 87, 91], ["D", "GENE_OR_GENE_PRODUCT", 93, 94], ["Akt", "PROTEIN", 11, 14], ["Akt", "PROTEIN", 79, 82], ["pAkt (D)", "PROTEIN", 87, 95], ["ZIKV RNA", "RNA", 122, 130], ["ZIKV", "SPECIES", 122, 126], ["Akt siRNA", "TREATMENT", 11, 20], ["this study", "TEST", 29, 39], ["the expression levels", "TEST", 54, 75], ["Akt", "TEST", 79, 82], ["pAkt (D)", "TEST", 87, 95], ["significantly reduced ZIKV RNA load", "PROBLEM", 100, 135], ["Akt siRNA", "OBSERVATION", 11, 20], ["ZIKV RNA", "OBSERVATION", 122, 130]]], ["All experiments were performed in triplicates in three independent experiments for confirmation. * denotes P < 0.05 and ** denotes P < 0.01 (compared with the DMSO or scramble siRNA control groups by Student's t-test).", [["DMSO", "CHEMICAL", 159, 163], ["DMSO", "CHEMICAL", 159, 163], ["confirmation", "TEST", 83, 95], ["the DMSO", "TREATMENT", 155, 163], ["scramble siRNA control groups", "TREATMENT", 167, 196], ["Student's t-test", "TEST", 200, 216]]], ["Data in Fig. 8C and E are presented as mean values \u00b1 standard deviations (error bars).", [["Data in Fig", "TEST", 0, 11], ["mean values", "TEST", 39, 50]]], ["Abbreviations: Akt, protein kinase B; DMSO, dimethyl sulfoxide; GRP-78, 78 kDA glucose-regulated protein; NS1, nonstructural protein 1; pAkt, phosphorylated protein kinase B; ZIKV, Zika virus. infection and because AR-12's antiviral mechanism via downregulation of the PI3K/Akt signaling pathway is not as direct as those of virustargeting drugs.DiscussionAR-12 has the advantages of being broad-spectrum and orally available, and may be clinically useful as an empirical therapy before laboratory diagnosis is established in patients living in or returning from endemic areas of arboviral and hemorrhagic fever viral diseases who develop an acute febrile illness.", [["DMSO", "CHEMICAL", 38, 42], ["dimethyl sulfoxide", "CHEMICAL", 44, 62], ["glucose", "CHEMICAL", 79, 86], ["infection", "DISEASE", 193, 202], ["hemorrhagic fever", "DISEASE", 594, 611], ["viral diseases", "DISEASE", 612, 626], ["febrile illness", "DISEASE", 648, 663], ["DMSO", "CHEMICAL", 38, 42], ["dimethyl sulfoxide", "CHEMICAL", 44, 62], ["GRP-78", "CHEMICAL", 64, 70], ["glucose", "CHEMICAL", 79, 86], ["Akt", "GENE_OR_GENE_PRODUCT", 15, 18], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 20, 36], ["DMSO", "SIMPLE_CHEMICAL", 38, 42], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 44, 62], ["GRP-78", "SIMPLE_CHEMICAL", 64, 70], ["glucose", "SIMPLE_CHEMICAL", 79, 86], ["NS1", "GENE_OR_GENE_PRODUCT", 106, 109], ["nonstructural protein 1", "GENE_OR_GENE_PRODUCT", 111, 134], ["pAkt", "GENE_OR_GENE_PRODUCT", 136, 140], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 157, 173], ["ZIKV", "GENE_OR_GENE_PRODUCT", 175, 179], ["Zika virus", "ORGANISM", 181, 191], ["AR-12's", "GENE_OR_GENE_PRODUCT", 215, 222], ["PI3K", "GENE_OR_GENE_PRODUCT", 269, 273], ["Akt", "GENE_OR_GENE_PRODUCT", 274, 277], ["patients", "ORGANISM", 526, 534], ["Akt", "PROTEIN", 15, 18], ["protein kinase B", "PROTEIN", 20, 36], ["78 kDA glucose-regulated protein", "PROTEIN", 72, 104], ["NS1", "PROTEIN", 106, 109], ["nonstructural protein 1", "PROTEIN", 111, 134], ["pAkt", "PROTEIN", 136, 140], ["phosphorylated protein kinase B", "PROTEIN", 142, 173], ["ZIKV", "PROTEIN", 175, 179], ["AR", "PROTEIN", 215, 217], ["PI3K", "PROTEIN", 269, 273], ["Akt", "PROTEIN", 274, 277], ["patients", "SPECIES", 526, 534], ["Zika virus", "SPECIES", 181, 191], ["Akt", "TEST", 15, 18], ["protein kinase B", "TEST", 20, 36], ["DMSO", "TEST", 38, 42], ["dimethyl sulfoxide", "TREATMENT", 44, 62], ["GRP", "TEST", 64, 67], ["kDA glucose", "TEST", 75, 86], ["protein", "TEST", 97, 104], ["NS1", "TEST", 106, 109], ["nonstructural protein", "TEST", 111, 132], ["pAkt", "TEST", 136, 140], ["phosphorylated protein kinase B", "TEST", 142, 173], ["ZIKV", "PROBLEM", 175, 179], ["Zika virus", "PROBLEM", 181, 191], ["infection", "PROBLEM", 193, 202], ["AR", "TEST", 215, 217], ["antiviral mechanism", "TREATMENT", 223, 242], ["Akt signaling pathway", "PROBLEM", 274, 295], ["virustargeting drugs", "TREATMENT", 325, 345], ["an empirical therapy", "TREATMENT", 459, 479], ["laboratory diagnosis", "TEST", 487, 507], ["arboviral", "PROBLEM", 580, 589], ["hemorrhagic fever viral diseases", "PROBLEM", 594, 626], ["an acute febrile illness", "PROBLEM", 639, 663], ["arboviral", "OBSERVATION", 580, 589], ["hemorrhagic", "OBSERVATION_MODIFIER", 594, 605], ["acute", "OBSERVATION_MODIFIER", 642, 647], ["febrile", "OBSERVATION_MODIFIER", 648, 655], ["illness", "OBSERVATION", 656, 663]]], ["The effect of AR-12 as part of combination treatment regimens consisting of both virus-targeting and host-targeting drugs should be evaluated in future studies, as this treatment strategy may be associated with improved clinical outcomes for ZIKV and other RNA viral infections (Hung et al., 2017; Pires de Mello et al., 2017; Zumla et al., 2016) .", [["AR-12", "CHEMICAL", 14, 19], ["viral infections", "DISEASE", 261, 277], ["AR-12", "GENE_OR_GENE_PRODUCT", 14, 19], ["AR", "PROTEIN", 14, 16], ["ZIKV", "SPECIES", 242, 246], ["AR", "TEST", 14, 16], ["combination treatment regimens", "TREATMENT", 31, 61], ["both virus", "TREATMENT", 76, 86], ["host-targeting drugs", "TREATMENT", 101, 121], ["future studies", "TEST", 145, 159], ["this treatment strategy", "TREATMENT", 164, 187], ["ZIKV", "PROBLEM", 242, 246], ["other RNA viral infections", "PROBLEM", 251, 277]]], ["Further optimization of the delivery of AR-12, such as encapsulation of the drug into biodegradable polymeric nanoparticles to reduce cytotoxicity and increase drug concentration per cell may facilitate its use in these clinical settings Hoang et al., 2016) .Conflicts of interestJ.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited, and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation.", [["cell", "ANATOMY", 183, 187], ["AR-12", "CHEMICAL", 40, 45], ["AR-12", "GENE_OR_GENE_PRODUCT", 40, 45], ["cell", "CELL", 183, 187], ["AR", "PROTEIN", 40, 42], ["the delivery of AR", "TREATMENT", 24, 42], ["encapsulation", "TREATMENT", 55, 68], ["the drug into biodegradable polymeric nanoparticles", "TREATMENT", 72, 123], ["cytotoxicity", "PROBLEM", 134, 146], ["increase drug concentration", "TREATMENT", 151, 178]]], ["The funding sources had no role in study design, data collection, analysis or interpretation or writing of the report.", [["data collection", "TEST", 49, 64], ["analysis", "TEST", 66, 74]]], ["The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.", [["the study", "TEST", 61, 70]]]], "2d2b8279913163157a789c8e73481ac69e293fa1": [["I n late 2019, the Wuhan Province of mainland China experienced an outbreak of a novel coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19).", [["coronavirus strain", "DISEASE", 87, 105], ["acute respiratory syndrome coronavirus", "DISEASE", 114, 152], ["coronavirus disease", "DISEASE", 183, 202], ["coronavirus", "ORGANISM", 87, 98], ["SARS-CoV-2", "ORGANISM", 156, 166], ["coronavirus", "SPECIES", 87, 98], ["severe acute respiratory syndrome coronavirus", "SPECIES", 107, 152], ["SARS-CoV-2", "SPECIES", 156, 166], ["a novel coronavirus strain", "PROBLEM", 79, 105], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 107, 152], ["SARS-CoV", "TEST", 156, 164], ["coronavirus disease", "PROBLEM", 183, 202], ["COVID", "TEST", 209, 214], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["respiratory syndrome", "OBSERVATION", 120, 140], ["coronavirus disease", "OBSERVATION", 183, 202]]], ["1 Similar to outbreaks of 2 other coronavirus pathogens, SARS-CoV and Middle East respiratory syndrome (MERS-CoV), SARS-CoV-2 is capable of causing severe and occasionally fatal (<10%) respiratory tract infection as it grows better in human airway epithelial cells than in standard tissue culture cells.", [["respiratory tract", "ANATOMY", 185, 202], ["airway epithelial cells", "ANATOMY", 241, 264], ["tissue culture cells", "ANATOMY", 282, 302], ["coronavirus pathogens", "DISEASE", 34, 55], ["SARS-CoV", "DISEASE", 57, 65], ["Middle East respiratory syndrome", "DISEASE", 70, 102], ["SARS", "DISEASE", 115, 119], ["respiratory tract infection", "DISEASE", 185, 212], ["coronavirus", "ORGANISM", 34, 45], ["SARS-CoV", "ORGANISM", 57, 65], ["Middle East respiratory", "ORGANISM", 70, 93], ["MERS-CoV", "ORGANISM", 104, 112], ["SARS-CoV-2", "ORGANISM", 115, 125], ["tract", "ORGANISM_SUBDIVISION", 197, 202], ["human", "ORGANISM", 235, 240], ["airway epithelial cells", "CELL", 241, 264], ["tissue culture cells", "CELL", 282, 302], ["human airway epithelial cells", "CELL_TYPE", 235, 264], ["standard tissue culture cells", "CELL_LINE", 273, 302], ["coronavirus", "SPECIES", 34, 45], ["human", "SPECIES", 235, 240], ["SARS-CoV", "SPECIES", 57, 65], ["Middle East respiratory syndrome (MERS-CoV", "SPECIES", 70, 112], ["SARS-CoV", "SPECIES", 115, 123], ["human", "SPECIES", 235, 240], ["2 other coronavirus pathogens", "PROBLEM", 26, 55], ["SARS", "PROBLEM", 57, 61], ["Middle East respiratory syndrome", "PROBLEM", 70, 102], ["SARS", "PROBLEM", 115, 119], ["occasionally fatal (<10%) respiratory tract infection", "PROBLEM", 159, 212], ["standard tissue culture cells", "TEST", 273, 302], ["coronavirus", "OBSERVATION_MODIFIER", 34, 45], ["pathogens", "OBSERVATION", 46, 55], ["Middle", "ANATOMY_MODIFIER", 70, 76], ["respiratory syndrome", "OBSERVATION", 82, 102], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["occasionally", "OBSERVATION_MODIFIER", 159, 171], ["fatal", "OBSERVATION_MODIFIER", 172, 177], ["respiratory tract", "ANATOMY", 185, 202], ["infection", "OBSERVATION", 203, 212], ["airway", "ANATOMY", 241, 247], ["epithelial cells", "OBSERVATION", 248, 264]]], ["2, 3 In the subsequent months, the global spread of this viral pathogen has created a healthcare crisis not experienced since the Spanish Flu pandemic of 1918.", [["this viral pathogen", "PROBLEM", 52, 71], ["global", "OBSERVATION_MODIFIER", 35, 41], ["spread", "OBSERVATION_MODIFIER", 42, 48]]], ["As concerns for this disease progress, efforts to curb its progression in both the general population and in the healthcare professionals who treat these patients have been scrutinized.", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["this disease progress", "PROBLEM", 16, 37]]], ["Healthcare providers who treat orofacial pathology such as craniofacial surgeons, otolaryngologists, dentists, oral surgeons, and ophthalmologists have an innately high risk of contracting SARS-CoV-2 compared with other providers.", [["oral", "ANATOMY", 111, 115], ["orofacial pathology", "DISEASE", 31, 50], ["SARS", "DISEASE", 189, 193], ["oral", "ORGANISM_SUBDIVISION", 111, 115], ["orofacial pathology", "PROBLEM", 31, 50], ["contracting SARS", "PROBLEM", 177, 193]]], ["4 This is a direct result of an infected person's viral load being highest in the pharynx and upper aerodigestive tract.", [["pharynx", "ANATOMY", 82, 89], ["upper aerodigestive tract", "ANATOMY", 94, 119], ["pharynx", "ORGAN", 82, 89], ["upper aerodigestive", "ORGANISM_SUBDIVISION", 94, 113], ["tract", "ORGANISM_SUBDIVISION", 114, 119], ["person", "SPECIES", 41, 47], ["an infected person's viral load", "PROBLEM", 29, 60], ["infected", "OBSERVATION", 32, 40], ["viral load", "OBSERVATION", 50, 60], ["pharynx", "ANATOMY", 82, 89], ["upper", "ANATOMY_MODIFIER", 94, 99], ["aerodigestive tract", "ANATOMY", 100, 119]]], ["5 Zou et al further reported that asymptomatic carriers of SARS-CoV-2 can have positive viral cultures from the oro/nasopharynx for 7 to 11 days with no clinical signs of fever, cough, or shortness of breath.", [["oro", "ANATOMY", 112, 115], ["nasopharynx", "ANATOMY", 116, 127], ["SARS", "DISEASE", 59, 63], ["fever", "DISEASE", 171, 176], ["cough", "DISEASE", 178, 183], ["shortness of breath", "DISEASE", 188, 207], ["SARS-CoV-2", "ORGANISM", 59, 69], ["nasopharynx", "ORGAN", 116, 127], ["SARS-CoV", "SPECIES", 59, 67], ["SARS", "PROBLEM", 59, 63], ["positive viral cultures", "PROBLEM", 79, 102], ["fever", "PROBLEM", 171, 176], ["cough", "PROBLEM", 178, 183], ["shortness of breath", "PROBLEM", 188, 207], ["nasopharynx", "ANATOMY", 116, 127], ["fever", "OBSERVATION", 171, 176]]], ["In a recent New England Journal of Medicine publication, van Doremalen et al demonstrated that aerosolized droplets of SARS-CoV-2 were viable and capable of disease transmission for a minimum of 3 hours.", [["SARS", "DISEASE", 119, 123], ["SARS-CoV", "SPECIES", 119, 127], ["disease transmission", "PROBLEM", 157, 177], ["New", "OBSERVATION_MODIFIER", 12, 15], ["aerosolized droplets", "OBSERVATION", 95, 115], ["disease", "OBSERVATION", 157, 164]]], ["Furthermore, the virus can remain stable and viable on a host of innate (cardboard, metal, and plastic) surfaces for at least 72 hours.", [["the virus", "PROBLEM", 13, 22], ["innate (cardboard, metal, and plastic) surfaces", "TREATMENT", 65, 112], ["stable", "OBSERVATION_MODIFIER", 34, 40]]], ["6 Following the recent Diamond Princess cruise ship outbreak, the Center for Disease Control found SARS-CoV-2 RNA on cabin surfaces 17 days after last occupancy; however, the clinical significance of this finding as related to its viability and transmission is unclear.", [["Disease Control", "TREATMENT", 77, 92], ["SARS", "PROBLEM", 99, 103], ["CoV", "TEST", 104, 107]]], ["7 Li et al reported a mean interval time of 9.1 to 12.5 days between the onset of symptoms and hospitalization in their early experience in the Wuhan province.", [["Li", "CHEMICAL", 2, 4], ["symptoms", "PROBLEM", 82, 90]]], ["8 This prolonged interval is why 14 days is most commonly used at the initial means of quarantine when a suspected or confirmed infection presents.", [["infection", "DISEASE", 128, 137], ["infection", "PROBLEM", 128, 137], ["infection", "OBSERVATION", 128, 137]]]], "be5855c69303ee1cbd49ce1ed23e9680f16c8f6a": [["IntroductionThe COVID-19 pandemic with at more than 6.5 million cases worldwide and more than 397,000 fatalities (date 07 June 2020) is an unprecedent situation for society and health care [1] .", [["fatalities", "DISEASE", 102, 112], ["The COVID", "TREATMENT", 12, 21]]], ["Although, most infections are not severe [2] [3] [4] [5] , about 5% develop a critical disease with respiratory failure, shock, or multiorgan dysfunction [5] .", [["respiratory", "ANATOMY", 100, 111], ["multiorgan", "ANATOMY", 131, 141], ["infections", "DISEASE", 15, 25], ["respiratory failure", "DISEASE", 100, 119], ["shock", "DISEASE", 121, 126], ["multiorgan dysfunction", "DISEASE", 131, 153], ["[2] [3] [4", "SIMPLE_CHEMICAL", 41, 51], ["most infections", "PROBLEM", 10, 25], ["a critical disease", "PROBLEM", 76, 94], ["respiratory failure", "PROBLEM", 100, 119], ["shock", "PROBLEM", 121, 126], ["multiorgan dysfunction", "PROBLEM", 131, 153], ["infections", "OBSERVATION", 15, 25], ["disease", "OBSERVATION", 87, 94], ["respiratory failure", "OBSERVATION", 100, 119], ["shock", "OBSERVATION", 121, 126], ["multiorgan dysfunction", "OBSERVATION", 131, 153]]], ["The overall case fatality rate is estimated at around 0.7 to 2.3% [5, 6] .", [["fatality rate", "TEST", 17, 30]]], ["Pneumonia appears to be the most frequent severe manifestation of infection [2, 6] .", [["Pneumonia", "DISEASE", 0, 9], ["infection", "DISEASE", 66, 75], ["Pneumonia", "PROBLEM", 0, 9], ["infection", "PROBLEM", 66, 75], ["most frequent", "OBSERVATION_MODIFIER", 28, 41], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["infection", "OBSERVATION", 66, 75]]], ["Additional COVID-19-induced coagulopathy might play an important role in COVID-19-related death [7] .IntroductionWhereas the majority of patients presents with mild symptoms [2] [3] [4] [5] and can be treated as outpatients, severely ill COVID-19 patients and patients with similar symptoms cross their way in the emergency department (ED).", [["COVID-19", "CHEMICAL", 11, 19], ["coagulopathy", "DISEASE", 28, 40], ["death", "DISEASE", 90, 95], ["COVID-19", "CHEMICAL", 11, 19], ["COVID-19", "SIMPLE_CHEMICAL", 11, 19], ["patients", "ORGANISM", 137, 145], ["patients", "ORGANISM", 247, 255], ["patients", "ORGANISM", 260, 268], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 247, 255], ["patients", "SPECIES", 260, 268], ["COVID", "TEST", 11, 16], ["induced coagulopathy", "PROBLEM", 20, 40], ["mild symptoms", "PROBLEM", 160, 173], ["similar symptoms", "PROBLEM", 274, 290], ["coagulopathy", "OBSERVATION", 28, 40]]], ["Due to the high infectiousness of SARS-Cov-2, it is crucial to separate patients with suspicion of COVID- 19 and other patients as soon as possible to avoid further spread of the infection.", [["SARS", "DISEASE", 34, 38], ["infection", "DISEASE", 179, 188], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 119, 127], ["the high infectiousness of SARS", "PROBLEM", 7, 38], ["COVID", "TEST", 99, 104], ["the infection", "PROBLEM", 175, 188], ["infection", "OBSERVATION", 179, 188]]], ["Especially, the variety of symptoms in COVID-19 patients is challenging for the primary triage in the ED: fever, fatigue, dry cough, anorexia, myalgias, dyspnea, sputum production, and olfactory and taste disorders are the most frequent symptoms [2, 8] .IntroductionParticular laboratory features like lymphopenia, elevated liver enzymes, elevated lactate dehydrogenase, Creactive protein, elevated D-dimer, elevated prothrombin time, elevated troponin, and acute kidney injury have been associated with worse outcomes [9, 10] .", [["sputum", "ANATOMY", 162, 168], ["olfactory", "ANATOMY", 185, 194], ["liver", "ANATOMY", 324, 329], ["kidney", "ANATOMY", 464, 470], ["COVID", "DISEASE", 39, 44], ["fever", "DISEASE", 106, 111], ["fatigue", "DISEASE", 113, 120], ["dry cough", "DISEASE", 122, 131], ["anorexia", "DISEASE", 133, 141], ["myalgias", "DISEASE", 143, 151], ["dyspnea", "DISEASE", 153, 160], ["olfactory and taste disorders", "DISEASE", 185, 214], ["lymphopenia", "DISEASE", 302, 313], ["lactate", "CHEMICAL", 348, 355], ["acute kidney injury", "DISEASE", 458, 477], ["lactate", "CHEMICAL", 348, 355], ["patients", "ORGANISM", 48, 56], ["olfactory", "ORGAN", 185, 194], ["liver", "ORGAN", 324, 329], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 348, 369], ["D-dimer", "GENE_OR_GENE_PRODUCT", 399, 406], ["prothrombin", "GENE_OR_GENE_PRODUCT", 417, 428], ["troponin", "GENE_OR_GENE_PRODUCT", 444, 452], ["kidney", "ORGAN", 464, 470], ["liver enzymes", "PROTEIN", 324, 337], ["lactate dehydrogenase", "PROTEIN", 348, 369], ["Creactive protein", "PROTEIN", 371, 388], ["D-dimer", "PROTEIN", 399, 406], ["prothrombin", "PROTEIN", 417, 428], ["troponin", "PROTEIN", 444, 452], ["patients", "SPECIES", 48, 56], ["symptoms", "PROBLEM", 27, 35], ["fever", "PROBLEM", 106, 111], ["fatigue", "PROBLEM", 113, 120], ["dry cough", "PROBLEM", 122, 131], ["anorexia", "PROBLEM", 133, 141], ["myalgias", "PROBLEM", 143, 151], ["dyspnea", "PROBLEM", 153, 160], ["sputum production", "PROBLEM", 162, 179], ["olfactory and taste disorders", "PROBLEM", 185, 214], ["the most frequent symptoms", "PROBLEM", 219, 245], ["lymphopenia", "PROBLEM", 302, 313], ["elevated liver enzymes", "PROBLEM", 315, 337], ["elevated lactate dehydrogenase", "PROBLEM", 339, 369], ["Creactive protein", "PROBLEM", 371, 388], ["elevated D-dimer", "PROBLEM", 390, 406], ["elevated prothrombin time", "PROBLEM", 408, 433], ["elevated troponin", "PROBLEM", 435, 452], ["acute kidney injury", "PROBLEM", 458, 477], ["variety", "OBSERVATION_MODIFIER", 16, 23], ["fever", "OBSERVATION", 106, 111], ["anorexia", "OBSERVATION", 133, 141], ["lymphopenia", "OBSERVATION", 302, 313], ["liver", "ANATOMY", 324, 329], ["elevated", "OBSERVATION_MODIFIER", 339, 347], ["lactate dehydrogenase", "OBSERVATION", 348, 369], ["acute", "OBSERVATION_MODIFIER", 458, 463], ["kidney", "ANATOMY", 464, 470], ["injury", "OBSERVATION", 471, 477]]], ["However, data about possible parameters to distinguish between COVID-19 and other patients are sparse.IntroductionTherefore, we conducted a retrospective analysis to identify clinical parameters and laboratory features which could improve early triage between patients with and without COVID-19.PatientsWe performed a retrospective, single-center case-control study that included all inpatient patients with possible symptoms of COVID-19 who were admitted to the emergency department between March and April 2020 and were tested by nasopharyngeal swab for SARS-Cov-2.", [["nasopharyngeal swab", "ANATOMY", 532, 551], ["COVID", "DISEASE", 429, 434], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 260, 268], ["Patients", "ORGANISM", 295, 303], ["patients", "ORGANISM", 394, 402], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 260, 268], ["Patients", "SPECIES", 295, 303], ["patients", "SPECIES", 394, 402], ["COVID", "TEST", 63, 68], ["a retrospective analysis", "TEST", 138, 162], ["clinical parameters", "TEST", 175, 194], ["laboratory features", "TEST", 199, 218], ["COVID", "TEST", 286, 291], ["control study", "TEST", 352, 365], ["symptoms", "PROBLEM", 417, 425], ["SARS", "PROBLEM", 556, 560], ["Cov", "TEST", 561, 564]]], ["At least one symptom upon arrival to the ED out of the following was required for inclusion: dyspnea, sore throat, cough, fever, headache, fatigue, myalgia, chest pain, nausea, diarrhea, and/ or dysgeusia.", [["chest", "ANATOMY", 157, 162], ["dyspnea", "DISEASE", 93, 100], ["sore throat", "DISEASE", 102, 113], ["cough", "DISEASE", 115, 120], ["fever", "DISEASE", 122, 127], ["headache", "DISEASE", 129, 137], ["fatigue", "DISEASE", 139, 146], ["myalgia", "DISEASE", 148, 155], ["chest pain", "DISEASE", 157, 167], ["nausea", "DISEASE", 169, 175], ["diarrhea", "DISEASE", 177, 185], ["dysgeusia", "DISEASE", 195, 204], ["chest", "ORGANISM_SUBDIVISION", 157, 162], ["dyspnea", "PROBLEM", 93, 100], ["sore throat", "PROBLEM", 102, 113], ["cough", "PROBLEM", 115, 120], ["fever", "PROBLEM", 122, 127], ["headache", "PROBLEM", 129, 137], ["fatigue", "PROBLEM", 139, 146], ["myalgia", "PROBLEM", 148, 155], ["chest pain", "PROBLEM", 157, 167], ["nausea", "PROBLEM", 169, 175], ["diarrhea", "PROBLEM", 177, 185], ["dysgeusia", "PROBLEM", 195, 204], ["sore throat", "ANATOMY", 102, 113], ["cough", "OBSERVATION", 115, 120], ["chest", "ANATOMY", 157, 162], ["diarrhea", "OBSERVATION", 177, 185], ["dysgeusia", "OBSERVATION", 195, 204]]], ["Patients without any of the mentioned symptoms were excluded as well as those without valid nasopharyngeal swab results.", [["nasopharyngeal swab", "ANATOMY", 92, 111], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the mentioned symptoms", "PROBLEM", 24, 46], ["valid nasopharyngeal swab", "TEST", 86, 111]]], ["Our study was approved by the institutional ethics committee and informed consent was waived (file number: 20-9310-BO, date: 6 May 2020).", [["Our study", "TEST", 0, 9]]], ["The study was registered at the German Clinical Trials registry (trial number: DRKS00021675, date 8 May 2020).PatientsPatients and the public were not involved in this study.COVID-19 ED workflow model EssenTo establish a central COVID-19 pandemia care center within the city of Essen (560,000 inhabitants), the university hospital was required to develop a safe and efficient workflow in the emergency department.COVID-19 ED workflow model EssenA separate outpatient COVID-19 ED was established next to the non-trauma ED for all walking patients with quick workflow filtering out those who need inpatient care.", [["Patients", "ORGANISM", 110, 118], ["Patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 537, 545], ["Patients", "SPECIES", 110, 118], ["Patients", "SPECIES", 118, 126], ["patients", "SPECIES", 537, 545], ["The study", "TEST", 0, 9], ["this study", "TEST", 163, 173], ["a central COVID-19 pandemia care", "TREATMENT", 219, 251], ["inpatient care", "TREATMENT", 595, 609]]], ["To streamline patient workup, the existing ED isolation capacities were extended by a fourteen bed holding area for patients under evaluation for COVID-19; three more isolation units were established for those with proven COVID-19 disease, as well as a separate intermediate care unit and ICU with ECMO available (Fig. 1 ).COVID-19 ED workflow model EssenOur workflow (Fig. 2 ) combines a definite diagnosis/ rule out strategy for COVID-19 with a high level of isolation measures.", [["patient", "ORGANISM", 14, 21], ["patients", "ORGANISM", 116, 124], ["patient", "SPECIES", 14, 21], ["patients", "SPECIES", 116, 124], ["streamline patient workup", "TEST", 3, 28], ["the existing ED isolation capacities", "TEST", 30, 66], ["a fourteen bed holding area", "TREATMENT", 84, 111], ["patients under evaluation", "TEST", 116, 141], ["COVID", "TEST", 146, 151], ["three more isolation units", "TREATMENT", 156, 182], ["ECMO", "TREATMENT", 298, 302], ["COVID", "TEST", 323, 328], ["COVID", "TEST", 431, 436], ["isolation measures", "TREATMENT", 461, 479]]], ["All patients with symptoms suggestive of COVID-19 were isolated upon arrival to the ED.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["symptoms", "PROBLEM", 18, 26], ["COVID", "TEST", 41, 46]]], ["After initial triage and vital parameters, unstable patients were transferred to a shock room/ COVID-19 ICU.COVID-19 ED workflow model EssenAll patients were tested for COVID-19 by a SARS-Cov-2 nasopharyngeal swab (ViroCult\u00ae, Medical Wire & Equipment Co. Ltd., Corsham, Wiltshire, UK).", [["shock", "DISEASE", 83, 88], ["SARS", "DISEASE", 183, 187], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 144, 152], ["initial triage", "TEST", 6, 20], ["vital parameters", "TEST", 25, 41], ["COVID", "TEST", 108, 113], ["COVID", "TEST", 169, 174], ["a SARS", "TEST", 181, 187], ["Cov", "TEST", 188, 191], ["nasopharyngeal swab", "TEST", 194, 213], ["nasopharyngeal", "ANATOMY", 194, 208]]], ["To detect SARS-CoV-2, a RT-PCR (SARS-CoV-2 RT-PCR Kit 1.0, Altona Diagnostics GmbH, Hamburg, Germany) was performed [11] .", [["SARS-CoV-2", "DNA", 10, 20], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "TEST", 10, 14], ["CoV", "TEST", 15, 18], ["a RT-PCR", "TEST", 22, 30], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["PCR Kit", "TEST", 46, 53]]], ["Additional laboratory testing and CT pulmonary angiography were performed when symptoms of lower respiratory tract involvement occurred.", [["pulmonary", "ANATOMY", 37, 46], ["lower respiratory tract", "ANATOMY", 91, 114], ["lower respiratory tract involvement", "DISEASE", 91, 126], ["pulmonary", "ORGAN", 37, 46], ["lower", "ORGANISM_SUBDIVISION", 91, 96], ["respiratory tract", "ORGANISM_SUBDIVISION", 97, 114], ["Additional laboratory testing", "TEST", 0, 29], ["CT pulmonary angiography", "TEST", 34, 58], ["symptoms", "PROBLEM", 79, 87], ["lower respiratory tract involvement", "PROBLEM", 91, 126], ["pulmonary", "ANATOMY", 37, 46], ["lower", "ANATOMY_MODIFIER", 91, 96], ["respiratory tract", "ANATOMY", 97, 114]]], ["Retesting or additional bronchoscopy/ CT scan could be added in case of ongoing suspicion and negative swab testing.", [["additional bronchoscopy/ CT scan", "TEST", 13, 45], ["swab testing", "TEST", 103, 115]]], ["Strict isolation measures were kept until COVID-19 was definitely ruled out.", [["Strict isolation measures", "TREATMENT", 0, 25], ["COVID", "TEST", 42, 47]]], ["From the onset of pandemia, all ED employees had to wear faceshields and FFP3 masks whenever in contact with any patient irrespective of symptoms suggestive for COVID-19 and keeping distance to each other while wearing a regular mask inside the ED.ParametersWe compared and analyzed clinical parameters, Manchester Triage System (MTS) categories, and laboratory parameters between patients with negative and patients with positive swab results for SARS-CoV-2.ParametersClinical parameters were symptoms upon arrival comprising dyspnea, sore throat, cough, fever, headache, fatigue, myalgia, chest pain, nausea, diarrhea, and dysgeusia.ParametersLaboratory results were white blood cell count, lymphocytes, C-reactive protein, procalcitonine, glomerular filtration rate, creatinine, troponine, and D-dimers.", [["chest", "ANATOMY", 591, 596], ["white blood cell", "ANATOMY", 669, 685], ["lymphocytes", "ANATOMY", 693, 704], ["glomerular", "ANATOMY", 742, 752], ["pandemia", "DISEASE", 18, 26], ["SARS", "DISEASE", 448, 452], ["dyspnea", "DISEASE", 527, 534], ["sore throat", "DISEASE", 536, 547], ["cough", "DISEASE", 549, 554], ["fever", "DISEASE", 556, 561], ["headache", "DISEASE", 563, 571], ["fatigue", "DISEASE", 573, 580], ["myalgia", "DISEASE", 582, 589], ["chest pain", "DISEASE", 591, 601], ["nausea", "DISEASE", 603, 609], ["diarrhea", "DISEASE", 611, 619], ["dysgeusia", "DISEASE", 625, 634], ["creatinine", "CHEMICAL", 770, 780], ["troponine", "CHEMICAL", 782, 791], ["procalcitonine", "CHEMICAL", 726, 740], ["creatinine", "CHEMICAL", 770, 780], ["troponine", "CHEMICAL", 782, 791], ["patient", "ORGANISM", 113, 120], ["patients", "ORGANISM", 381, 389], ["patients", "ORGANISM", 408, 416], ["chest", "ORGANISM_SUBDIVISION", 591, 596], ["white blood cell", "CELL", 669, 685], ["lymphocytes", "CELL", 693, 704], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 706, 724], ["procalcitonine", "SIMPLE_CHEMICAL", 726, 740], ["glomerular", "TISSUE", 742, 752], ["creatinine", "SIMPLE_CHEMICAL", 770, 780], ["troponine", "SIMPLE_CHEMICAL", 782, 791], ["D-dimers", "SIMPLE_CHEMICAL", 797, 805], ["lymphocytes", "CELL_TYPE", 693, 704], ["C-reactive protein", "PROTEIN", 706, 724], ["creatinine, troponine, and D-dimers", "PROTEIN", 770, 805], ["patient", "SPECIES", 113, 120], ["patients", "SPECIES", 381, 389], ["patients", "SPECIES", 408, 416], ["SARS-CoV", "SPECIES", 448, 456], ["pandemia", "PROBLEM", 18, 26], ["FFP3 masks", "TREATMENT", 73, 83], ["symptoms", "PROBLEM", 137, 145], ["COVID", "TEST", 161, 166], ["laboratory parameters", "TEST", 351, 372], ["SARS", "PROBLEM", 448, 452], ["CoV", "TEST", 453, 456], ["symptoms", "PROBLEM", 494, 502], ["dyspnea", "PROBLEM", 527, 534], ["sore throat", "PROBLEM", 536, 547], ["cough", "PROBLEM", 549, 554], ["fever", "PROBLEM", 556, 561], ["headache", "PROBLEM", 563, 571], ["fatigue", "PROBLEM", 573, 580], ["myalgia", "PROBLEM", 582, 589], ["chest pain", "PROBLEM", 591, 601], ["nausea", "PROBLEM", 603, 609], ["diarrhea", "PROBLEM", 611, 619], ["dysgeusia", "PROBLEM", 625, 634], ["white blood cell count", "TEST", 669, 691], ["lymphocytes", "TEST", 693, 704], ["C", "TEST", 706, 707], ["reactive protein", "TEST", 708, 724], ["procalcitonine", "TEST", 726, 740], ["glomerular filtration rate", "TEST", 742, 768], ["creatinine", "TEST", 770, 780], ["troponine", "TEST", 782, 791], ["sore throat", "ANATOMY", 536, 547], ["chest", "ANATOMY", 591, 596], ["nausea", "OBSERVATION", 603, 609], ["diarrhea", "OBSERVATION", 611, 619], ["dysgeusia", "OBSERVATION", 625, 634], ["reactive protein", "OBSERVATION", 708, 724]]], ["Patient data were obtained through the electronic medical record (ERPath, eHealth-Tec Innovations GmbH, Berlin, Germany; Medico, Cerner Health Services GmbH, Idstein, Germany).ParametersMissing data that could not be extracted from patients' records were excluded from statistical analysis.Statistical analysesWe used a t test to evaluate metric data.", [["patients", "ORGANISM", 232, 240], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 232, 240], ["statistical analysis", "TEST", 269, 289], ["a t test", "TEST", 318, 326], ["metric data", "TEST", 339, 350]]], ["Data were tested by Levene's test to assess the equality of variances.", [["Levene's test", "TEST", 20, 33]]], ["In case of unequal variances, Welch's t test was performed to analyze metric data.", [["unequal variances", "PROBLEM", 11, 28], ["Welch's t test", "TEST", 30, 44]]], ["Pearson's x 2 test or the Fisher's exact test was used to evaluate categorical data.", [["Pearson's x 2 test", "TEST", 0, 18], ["the Fisher's exact test", "TEST", 22, 45], ["categorical data", "TEST", 67, 83]]], ["Results for categorical variables were reported as percentages.", [["categorical variables", "TEST", 12, 33]]], ["All data were analyzed using SPSS, version 26 (IBM, Armonk, NY, USA).", [["All data", "TEST", 0, 8], ["SPSS", "TEST", 29, 33]]], ["Statistical significance was defined as two-tailed p < 0.05.ResultsA total of 314 patients (mean age 66 \u00b1 17.7 years; 118 female (37.6%)) were included in the analysis.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["the analysis", "TEST", 155, 167]]], ["According to the MTS, 52 patients were classified as \"red\" (16.6%), 28 patients as \"orange\" (8.9%), 118 patients as \"yellow\" (37.8%), 111 patients as \"green\" (35.4%), and 3 patients as \"blue\" (1.0%).ResultsForty-three patients (13.7%) were tested positive for SARS-Cov-2 by nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 274, 293], ["SARS", "DISEASE", 260, 264], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 173, 181], ["patients", "ORGANISM", 218, 226], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 260, 270], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 274, 293], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 218, 226], ["ResultsForty", "TEST", 199, 211], ["SARS", "PROBLEM", 260, 264], ["Cov", "TEST", 265, 268], ["nasopharyngeal swab", "TEST", 274, 293], ["nasopharyngeal swab", "ANATOMY", 274, 293]]], ["Results after comparison of the COVID-19 patients and the patients with negative swab are listed in Table 2 .ResultsOf the 271 with negative test results, 55 underwent repeated testing due to ongoing suspicion of COVID-19.", [["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 58, 66], ["the COVID", "TEST", 28, 37], ["repeated testing", "TEST", 168, 184], ["COVID", "TEST", 213, 218]]], ["Two of those 55 (3.6%) revealed to be positive in the course of clinical treatment but were not included in our primary analysis of COVID-19 positive patients.ResultsOf all COVID-19 patients, 14% (6/43) reported dysgeusia, while this clinical feature was only present in 1.5% (4/271) of non-COVID-19 patients (p = 0.001).", [["dysgeusia", "DISEASE", 212, 221], ["COVID-19", "GENE_OR_GENE_PRODUCT", 132, 140], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 182, 190], ["patients", "ORGANISM", 300, 308], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 182, 190], ["patients", "SPECIES", 300, 308], ["clinical treatment", "TREATMENT", 64, 82], ["COVID", "TEST", 132, 137], ["all COVID", "TEST", 169, 178], ["dysgeusia", "PROBLEM", 212, 221], ["non-COVID", "TEST", 287, 296], ["positive", "OBSERVATION", 38, 46]]], ["Significant differences between the two groups were not observed for other clinical features (Fig. 3) .ResultsPatients with COVID-19 had significantly less preexisting renal disorders (9.3% vs 27.0%; p value 0.012).", [["renal", "ANATOMY", 168, 173], ["renal disorders", "DISEASE", 168, 183], ["renal", "ORGAN", 168, 173], ["COVID", "TEST", 124, 129], ["significantly less preexisting renal disorders", "PROBLEM", 137, 183], ["value", "TEST", 202, 207], ["renal", "ANATOMY", 168, 173], ["disorders", "OBSERVATION", 174, 183]]], ["No significant differences were observed for the presence of a preexisting cardiac or pulmonary disorder, previous thrombosis, or pulmonary embolism and oncological diseases between COVID-19-positive and COVID-19-negative patients.ResultsThere were significantly more active smokers in the non-COVID-19 group than in the group with COVID-19-positive patients (13.7% vs 2.3%; p = 0.034).", [["cardiac", "ANATOMY", 75, 82], ["pulmonary", "ANATOMY", 86, 95], ["pulmonary", "ANATOMY", 130, 139], ["cardiac or pulmonary disorder", "DISEASE", 75, 104], ["thrombosis", "DISEASE", 115, 125], ["pulmonary embolism", "DISEASE", 130, 148], ["cardiac", "ORGAN", 75, 82], ["pulmonary", "ORGAN", 86, 95], ["pulmonary", "ORGAN", 130, 139], ["COVID-19", "GENE_OR_GENE_PRODUCT", 182, 190], ["COVID-19", "GENE_OR_GENE_PRODUCT", 204, 212], ["patients", "ORGANISM", 222, 230], ["COVID-19", "GENE_OR_GENE_PRODUCT", 332, 340], ["patients", "ORGANISM", 350, 358], ["patients", "SPECIES", 222, 230], ["patients", "SPECIES", 350, 358], ["a preexisting cardiac or pulmonary disorder", "PROBLEM", 61, 104], ["previous thrombosis", "PROBLEM", 106, 125], ["pulmonary embolism", "PROBLEM", 130, 148], ["oncological diseases", "PROBLEM", 153, 173], ["COVID", "TEST", 182, 187], ["COVID", "TEST", 204, 209], ["the non-COVID", "TEST", 286, 299], ["COVID", "TEST", 332, 337], ["p", "TEST", 375, 376], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["cardiac", "ANATOMY", 75, 82], ["pulmonary", "ANATOMY", 86, 95], ["disorder", "OBSERVATION", 96, 104], ["thrombosis", "OBSERVATION", 115, 125], ["pulmonary", "ANATOMY", 130, 139], ["embolism", "OBSERVATION", 140, 148], ["active", "OBSERVATION_MODIFIER", 268, 274], ["smokers", "OBSERVATION", 275, 282]]], ["However, the number of patients with an unknown smoking status was, although not significantly, also higher in the non-COVID-19 group than in the group tested positively (58.3% vs 16.0%; p = 0.154).ResultsThe mortality of COVID-19 patients admitted to our hospital via the ED was 18.6%, which was not significantly higher than patients admitted with similar symptoms but negative COVID-19 result (11.1%) (p = 0.159).ResultsIn the group of the COVID-19 patients, 18 patients (41.9%) were treated with oxygen upon admission in the emergency department.", [["oxygen", "CHEMICAL", 500, 506], ["oxygen", "CHEMICAL", 500, 506], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 231, 239], ["patients", "ORGANISM", 327, 335], ["patients", "ORGANISM", 452, 460], ["patients", "ORGANISM", 465, 473], ["oxygen", "SIMPLE_CHEMICAL", 500, 506], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 231, 239], ["patients", "SPECIES", 327, 335], ["patients", "SPECIES", 452, 460], ["patients", "SPECIES", 465, 473], ["p", "TEST", 187, 188], ["similar symptoms", "PROBLEM", 350, 366], ["COVID", "TEST", 380, 385], ["oxygen", "TREATMENT", 500, 506], ["higher", "OBSERVATION_MODIFIER", 101, 107]]], ["However, this was not significantly different to the 77 patients (28.5%) of the non-COVID-19 group who were supported with oxygen.ResultsWe could not find any significant differences regarding to vital parameters and laboratory values between the two groups ( Table 2) Discussion Forty-three patients (13.7%) of our 314 patients were tested positive for COVID-19 by pharyngeal swab.ResultsIn our study, dysgeusia was the only clinical finding that was significantly more frequent in COVID-19 patients.", [["pharyngeal swab", "ANATOMY", 366, 381], ["oxygen", "CHEMICAL", 123, 129], ["dysgeusia", "DISEASE", 403, 412], ["oxygen", "CHEMICAL", 123, 129], ["patients", "ORGANISM", 56, 64], ["oxygen", "SIMPLE_CHEMICAL", 123, 129], ["patients", "ORGANISM", 292, 300], ["patients", "ORGANISM", 320, 328], ["pharyngeal swab", "MULTI-TISSUE_STRUCTURE", 366, 381], ["patients", "ORGANISM", 492, 500], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 292, 300], ["patients", "SPECIES", 320, 328], ["patients", "SPECIES", 492, 500], ["oxygen", "TREATMENT", 123, 129], ["vital parameters", "TEST", 196, 212], ["laboratory values", "TEST", 217, 234], ["COVID", "TEST", 354, 359], ["pharyngeal swab", "TEST", 366, 381], ["our study", "TEST", 392, 401], ["dysgeusia", "PROBLEM", 403, 412], ["significantly different", "OBSERVATION_MODIFIER", 22, 45], ["pharyngeal swab", "ANATOMY", 366, 381]]], ["Unfortunately, we did not identify further clinical findings, laboratory parameters, or vital signs to distinguish between patients positive for COVID-19 and the negative tested ones.ResultsGao et al. showed significant differences in D-Dimer and C-reactive protein (CRP) between mild and severe cases of COVID-19 [12] .", [["COVID-19", "CHEMICAL", 305, 313], ["patients", "ORGANISM", 123, 131], ["D-Dimer", "SIMPLE_CHEMICAL", 235, 242], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 247, 265], ["CRP", "GENE_OR_GENE_PRODUCT", 267, 270], ["D-Dimer", "PROTEIN", 235, 242], ["C-reactive protein", "PROTEIN", 247, 265], ["CRP", "PROTEIN", 267, 270], ["patients", "SPECIES", 123, 131], ["laboratory parameters", "TEST", 62, 83], ["vital signs", "TEST", 88, 99], ["COVID", "TEST", 145, 150], ["significant differences in D-Dimer", "PROBLEM", 208, 242], ["C", "TEST", 247, 248], ["CRP", "TEST", 267, 270], ["mild and severe cases", "PROBLEM", 280, 301], ["COVID", "TEST", 305, 310], ["significant", "OBSERVATION_MODIFIER", 208, 219], ["differences", "OBSERVATION_MODIFIER", 220, 231], ["mild", "OBSERVATION_MODIFIER", 280, 284], ["severe", "OBSERVATION_MODIFIER", 289, 295]]], ["Also, lymphopenia and higher LDH values have been described to be associated with higher rate of ICU admissions in patients with COVID-19 [13] .", [["lymphopenia", "DISEASE", 6, 17], ["COVID-19", "CHEMICAL", 129, 137], ["LDH", "GENE_OR_GENE_PRODUCT", 29, 32], ["patients", "ORGANISM", 115, 123], ["LDH", "PROTEIN", 29, 32], ["patients", "SPECIES", 115, 123], ["lymphopenia", "PROBLEM", 6, 17], ["higher LDH values", "PROBLEM", 22, 39], ["COVID", "TEST", 129, 134], ["lymphopenia", "OBSERVATION", 6, 17], ["higher", "OBSERVATION_MODIFIER", 22, 28], ["LDH values", "OBSERVATION", 29, 39]]], ["Mardani et al. published a small study with 200 patients in which they suggest that level of LDH, CRP, ALT, and neutrophils could be used to predict the result of COVID-19 test [14] .", [["neutrophils", "ANATOMY", 112, 123], ["patients", "ORGANISM", 48, 56], ["LDH", "GENE_OR_GENE_PRODUCT", 93, 96], ["CRP", "GENE_OR_GENE_PRODUCT", 98, 101], ["ALT", "SIMPLE_CHEMICAL", 103, 106], ["neutrophils", "CELL", 112, 123], ["LDH", "PROTEIN", 93, 96], ["CRP", "PROTEIN", 98, 101], ["ALT", "PROTEIN", 103, 106], ["neutrophils", "CELL_TYPE", 112, 123], ["patients", "SPECIES", 48, 56], ["a small study", "TEST", 25, 38], ["LDH", "TEST", 93, 96], ["CRP", "TEST", 98, 101], ["ALT", "TEST", 103, 106], ["neutrophils", "TEST", 112, 123], ["COVID", "TEST", 163, 168], ["small", "OBSERVATION_MODIFIER", 27, 32]]], ["However, convincing data of larger studies that show the use of predicting laboratory parameters are sparse.ResultsIn our study, we observed three findings that seemed to be associated with COVID-19: [18] .", [["COVID-19", "CHEMICAL", 190, 198], ["larger studies", "TEST", 28, 42], ["predicting laboratory parameters", "TEST", 64, 96], ["our study", "TEST", 118, 127], ["COVID", "TEST", 190, 195]]], ["In their study, antihypertensive treatment seems to protect patients from severe COVID-19 infection.", [["COVID", "DISEASE", 81, 86], ["infection", "DISEASE", 90, 99], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["their study", "TEST", 3, 14], ["antihypertensive treatment", "TREATMENT", 16, 42], ["severe COVID-19 infection", "PROBLEM", 74, 99], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["infection", "OBSERVATION", 90, 99]]], ["Hypertension is associated with renal disorders [17] .", [["renal", "ANATOMY", 32, 37], ["Hypertension", "DISEASE", 0, 12], ["renal disorders", "DISEASE", 32, 47], ["renal", "ORGAN", 32, 37], ["Hypertension", "PROBLEM", 0, 12], ["renal disorders", "PROBLEM", 32, 47], ["renal", "ANATOMY", 32, 37], ["disorders", "OBSERVATION", 38, 47]]], ["In general, patients with renal failure may use more antihypertensive medication than patients without renal disorders.", [["renal", "ANATOMY", 26, 31], ["renal", "ANATOMY", 103, 108], ["renal failure", "DISEASE", 26, 39], ["renal disorders", "DISEASE", 103, 118], ["patients", "ORGANISM", 12, 20], ["renal", "ORGAN", 26, 31], ["patients", "ORGANISM", 86, 94], ["renal", "ORGAN", 103, 108], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 86, 94], ["renal failure", "PROBLEM", 26, 39], ["antihypertensive medication", "TREATMENT", 53, 80], ["renal disorders", "PROBLEM", 103, 118], ["renal", "ANATOMY", 26, 31], ["failure", "OBSERVATION", 32, 39], ["renal", "ANATOMY", 103, 108], ["disorders", "OBSERVATION", 109, 118]]], ["Therefore, this medication could protect them from severe COVID-19 infection needing hospital admission.", [["infection", "DISEASE", 67, 76], ["this medication", "TREATMENT", 11, 26], ["severe COVID-19 infection", "PROBLEM", 51, 76], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["infection", "OBSERVATION", 67, 76]]], ["However, we are aware that this is daring thesis and larger studies are needed to elucidate the complex interaction of renal function, antihypertensive medication, and COVID-19 infection. c.", [["renal", "ANATOMY", 119, 124], ["infection", "DISEASE", 177, 186], ["renal", "ORGAN", 119, 124], ["COVID-19", "ORGANISM", 168, 176], ["larger studies", "TEST", 53, 67], ["renal function", "TREATMENT", 119, 133], ["antihypertensive medication", "TREATMENT", 135, 162], ["COVID", "TREATMENT", 168, 173], ["infection", "PROBLEM", 177, 186], ["renal", "ANATOMY", 119, 124], ["infection", "OBSERVATION", 177, 186]]], ["In our study, there tended to be less active smokers in the COVID-19 group than in the non-COVID-19 group.", [["our study", "TEST", 3, 12], ["less", "OBSERVATION_MODIFIER", 33, 37], ["active", "OBSERVATION_MODIFIER", 38, 44], ["smokers", "OBSERVATION", 45, 52]]], ["Only one out of 43 positive patients reported to be a current smoker, while 13.7% of the non-COVID-19 patients announced to smoke regularly by the time of infection.", [["infection", "DISEASE", 155, 164], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 102, 110], ["infection", "PROBLEM", 155, 164], ["infection", "OBSERVATION", 155, 164]]], ["Smoking has been assumed to be possibly associated with adverse disease prognosis, as extensive evidence has highlighted the negative impact of tobacco use on lung health and previous studies have shown that smokers are more vulnerable to infectious diseases and were also noted to have higher mortality in the previous MERS-CoV outbreak [19, 20] .", [["lung", "ANATOMY", 159, 163], ["Smoking", "DISEASE", 0, 7], ["infectious diseases", "DISEASE", 239, 258], ["tobacco", "ORGANISM", 144, 151], ["lung", "ORGAN", 159, 163], ["tobacco", "SPECIES", 144, 151], ["MERS-CoV", "SPECIES", 320, 328], ["adverse disease prognosis", "PROBLEM", 56, 81], ["previous studies", "TEST", 175, 191], ["infectious diseases", "PROBLEM", 239, 258], ["higher mortality", "PROBLEM", 287, 303], ["lung", "ANATOMY", 159, 163]]], ["Most studies examining smoking on patients with COVID-19 assume that smoking is most likely associated with the negative progression and adverse outcomes of COVID-19 [6, 9, 21] .ResultsEven during the peak of local pandemia, the rate of proven COVID-19 did not exceed 13.7% among all patients presenting with suggestive symptoms.", [["smoking", "CHEMICAL", 23, 30], ["smoking", "CHEMICAL", 69, 76], ["pandemia", "DISEASE", 215, 223], ["COVID-19", "CHEMICAL", 157, 165], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 284, 292], ["COVID", "TEST", 157, 162], ["local pandemia", "TEST", 209, 223], ["the rate", "TEST", 225, 233], ["COVID", "TEST", 244, 249], ["suggestive symptoms", "PROBLEM", 309, 328], ["most likely", "UNCERTAINTY", 80, 91]]], ["We expect this rate to decrease further in the months to come.ResultsTypical ED diagnoses as decompensated heart failure, pneumonia, exacerbated chronic obstructive lung disease, or gastroenteritis present with symptoms suggestive for COVID-19 and can therefore be very misleading.", [["heart", "ANATOMY", 107, 112], ["lung", "ANATOMY", 165, 169], ["decompensated heart failure", "DISEASE", 93, 120], ["pneumonia", "DISEASE", 122, 131], ["chronic obstructive lung disease", "DISEASE", 145, 177], ["gastroenteritis", "DISEASE", 182, 197], ["heart", "ORGAN", 107, 112], ["lung", "ORGAN", 165, 169], ["decompensated heart failure", "PROBLEM", 93, 120], ["pneumonia", "PROBLEM", 122, 131], ["exacerbated chronic obstructive lung disease", "PROBLEM", 133, 177], ["gastroenteritis", "PROBLEM", 182, 197], ["symptoms", "PROBLEM", 211, 219], ["COVID", "TEST", 235, 240], ["decompensated", "OBSERVATION_MODIFIER", 93, 106], ["heart", "ANATOMY", 107, 112], ["failure", "OBSERVATION", 113, 120], ["pneumonia", "OBSERVATION", 122, 131], ["exacerbated", "OBSERVATION_MODIFIER", 133, 144], ["chronic", "OBSERVATION_MODIFIER", 145, 152], ["obstructive", "OBSERVATION_MODIFIER", 153, 164], ["lung", "ANATOMY", 165, 169], ["disease", "OBSERVATION", 170, 177], ["gastroenteritis", "OBSERVATION", 182, 197]]], ["COVID-19 is able to mimic many other common diseases and many unusual clinical presentations have been reported from all over the world [22] .ResultsThe established workflow of our hospital (Fig. 2 ) was able to prevent spreading of the virus and thereby protect ED staff and non-COVID-19 patients.", [["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 289, 297], ["COVID", "TEST", 0, 5], ["many other common diseases", "PROBLEM", 26, 52], ["the virus", "PROBLEM", 233, 242]]], ["Voluntary antibody testing of 316 employees of the university hospital during the peak of the pandemia in Essen revealed only three AB positive healthcare workers out of 244 exposed high-risk workers (1.2%) in ED, COVID-19 wards, and COVID-19 ICU as recently published from our institution [23] .ResultsFollowing the high number of patients presenting with possible symptoms of COVID-19 to the ED, only strict isolation and protection measures in line with a broad swab testing will prevent spreading of the virus and maintain safety of ED staff.", [["pandemia", "DISEASE", 94, 102], ["COVID", "DISEASE", 378, 383], ["patients", "ORGANISM", 332, 340], ["patients", "SPECIES", 332, 340], ["Voluntary antibody testing", "TEST", 0, 26], ["the pandemia", "TEST", 90, 102], ["COVID", "TEST", 214, 219], ["symptoms", "PROBLEM", 366, 374], ["COVID", "TEST", 378, 383], ["strict isolation", "TREATMENT", 403, 419], ["protection measures", "TREATMENT", 424, 443], ["a broad swab testing", "TEST", 457, 477], ["the virus", "PROBLEM", 504, 513]]], ["A validated fast SARS-Cov-2-PCR POCT would be extremely helpful to save health care resources.LimitationsOur study has few limitations.", [["A validated fast SARS", "TEST", 0, 21], ["PCR POCT", "TEST", 28, 36], ["Our study", "TEST", 105, 114]]], ["Data collection was retrospective.", [["Data collection", "TEST", 0, 15]]], ["Therefore, selection bias and errors in data entry could not be completely excluded.", [["selection bias", "TEST", 11, 25], ["errors in data entry", "TEST", 30, 50], ["could not be completely excluded", "UNCERTAINTY", 51, 83]]], ["Furthermore, this study is a single-center study, and for these reason, data should not be generalized.LimitationsAnother limitation is the single testing in SARS-Cov-2-negative patients, who mostly got no repeated testing, so there could have been some more SARS-Cov-2-positive patients than numbered.LimitationsWe often saw patients with advanced disease in our emergency department.", [["Cov-2", "GENE_OR_GENE_PRODUCT", 163, 168], ["patients", "ORGANISM", 178, 186], ["Cov-2", "GENE_OR_GENE_PRODUCT", 264, 269], ["patients", "ORGANISM", 279, 287], ["patients", "ORGANISM", 326, 334], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 279, 287], ["patients", "SPECIES", 326, 334], ["this study", "TEST", 13, 23], ["center study", "TEST", 36, 48], ["the single testing", "TEST", 136, 154], ["SARS", "TEST", 158, 162], ["repeated testing", "TEST", 206, 222], ["advanced disease", "PROBLEM", 340, 356]]], ["Severe disease of COVID-19 often starts in the second week after infection when the virus and antigen-antibody complexes affect the lungs and other parts of the body, and viral RNA often cannot be detected in the nasopharyngeal swab [24] .", [["lungs", "ANATOMY", 132, 137], ["body", "ANATOMY", 161, 165], ["nasopharyngeal swab", "ANATOMY", 213, 232], ["COVID-19", "CHEMICAL", 18, 26], ["infection", "DISEASE", 65, 74], ["COVID-19", "CHEMICAL", 18, 26], ["antigen-antibody complexes", "GENE_OR_GENE_PRODUCT", 94, 120], ["lungs", "ORGAN", 132, 137], ["body", "ORGANISM_SUBDIVISION", 161, 165], ["antigen-antibody complexes", "PROTEIN", 94, 120], ["viral RNA", "RNA", 171, 180], ["Severe disease of COVID", "PROBLEM", 0, 23], ["infection", "PROBLEM", 65, 74], ["the virus and antigen-antibody complexes", "TEST", 80, 120], ["viral RNA", "PROBLEM", 171, 180], ["the nasopharyngeal swab", "TEST", 209, 232], ["disease", "OBSERVATION", 7, 14], ["infection", "OBSERVATION", 65, 74], ["lungs", "ANATOMY", 132, 137], ["body", "ANATOMY", 161, 165], ["viral RNA", "OBSERVATION", 171, 180], ["cannot be detected", "UNCERTAINTY", 187, 205], ["nasopharyngeal", "ANATOMY", 213, 227], ["swab", "OBSERVATION", 228, 232]]], ["Therefore, a certain number of false negative tests should be taken into account.", [["false negative tests", "PROBLEM", 31, 51]]], ["Furthermore, we included only inpatient patients.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["As SARS-Cov-2 is often associated with minor symptoms or illness, the number of outpatient treatment could have been higher than in non-COVID-19 respiratory infections.LimitationsIn our cohort, the number of patients with unknown smoking status is very high (59.9%).", [["respiratory", "ANATOMY", 145, 156], ["illness", "DISEASE", 57, 64], ["respiratory infections", "DISEASE", 145, 167], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 3, 13], ["non-COVID-19 respiratory", "ORGANISM", 132, 156], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["minor symptoms", "PROBLEM", 39, 53], ["illness", "PROBLEM", 57, 64], ["outpatient treatment", "TREATMENT", 80, 100], ["respiratory infections", "PROBLEM", 145, 167], ["higher", "OBSERVATION_MODIFIER", 117, 123], ["respiratory", "ANATOMY", 145, 156], ["infections", "OBSERVATION", 157, 167]]], ["Therefore, in this study, it seems to be difficult to evaluate the exact number of current smokers.", [["this study", "TEST", 14, 24]]], ["We think that this might be the reason for the paradoxical finding that a history of smoking was more frequent in the non-COVID-19 group.ConclusionMany severely ill patients presenting to the ED show symptoms suggestive of COVID-19.", [["smoking", "CHEMICAL", 85, 92], ["COVID-19", "CHEMICAL", 223, 231], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["symptoms", "PROBLEM", 200, 208], ["COVID", "TEST", 223, 228]]], ["Even during the peak of pandemia, only 13.7% (43/314) of these patients proofed positive for COVID-19 in our study.", [["pandemia", "DISEASE", 24, 32], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["pandemia", "TEST", 24, 32], ["COVID", "TEST", 93, 98], ["our study", "TEST", 105, 114]]], ["Neither laboratory nor vital parameters nor clinical symptoms can be used to predict COVID-19-positive test results.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 85, 93], ["vital parameters", "TEST", 23, 39], ["clinical symptoms", "PROBLEM", 44, 61], ["COVID", "TEST", 85, 90]]], ["When present, dysgeusia should raise a high suspicion of COVID-19 during pandemia.", [["dysgeusia", "DISEASE", 14, 23], ["COVID-19", "CHEMICAL", 57, 65], ["pandemia", "DISEASE", 73, 81], ["pandemia", "CANCER", 73, 81], ["dysgeusia", "PROBLEM", 14, 23], ["COVID", "TEST", 57, 62], ["pandemia", "PROBLEM", 73, 81]]], ["Further studies with bigger numbers are needed to evaluate predictors for COVID-19 to help to optimize triaging patients in the ED.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["Further studies", "TEST", 0, 15], ["bigger numbers", "TEST", 21, 35], ["COVID", "TEST", 74, 79]]], ["Strict isolation and personal protection policy together with broad testing of patients under evaluation is needed for the months to come.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Strict isolation", "TREATMENT", 0, 16], ["personal protection policy", "TREATMENT", 21, 47], ["broad testing", "TEST", 62, 75], ["patients under evaluation", "TEST", 79, 104]]]], "5689f47a48a39326607ba4694d1ab76a3f119f99": [["ACE-I and ARBs have been shown to upregulate the expression of ACE-2 or to prevent the loss of ACE2 in the heart; they may have a similar effect in lung tissue.", [["heart", "ANATOMY", 107, 112], ["lung tissue", "ANATOMY", 148, 159], ["ACE-I", "CHEMICAL", 0, 5], ["ARBs", "CHEMICAL", 10, 14], ["ACE-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["ARBs", "GENE_OR_GENE_PRODUCT", 10, 14], ["ACE-2", "GENE_OR_GENE_PRODUCT", 63, 68], ["ACE2", "GENE_OR_GENE_PRODUCT", 95, 99], ["heart", "ORGAN", 107, 112], ["lung tissue", "TISSUE", 148, 159], ["ACE-2", "PROTEIN", 63, 68], ["ACE2", "PROTEIN", 95, 99], ["ACE-I", "TREATMENT", 0, 5], ["ARBs", "TREATMENT", 10, 14], ["ACE-2", "TREATMENT", 63, 68], ["the loss of ACE2 in the heart", "PROBLEM", 83, 112], ["a similar effect in lung tissue", "PROBLEM", 128, 159], ["loss", "OBSERVATION", 87, 91], ["heart", "ANATOMY", 107, 112], ["similar", "OBSERVATION_MODIFIER", 130, 137], ["effect", "OBSERVATION", 138, 144], ["lung", "ANATOMY", 148, 152], ["tissue", "OBSERVATION", 153, 159]]], ["15, 16 Thus, an ACE-I and ARB blocker prescription in COVID-19 patient may make the patient vulnerable due to additional virus entrance and replication in type II alveolar cells.", [["type II alveolar cells", "ANATOMY", 155, 177], ["ARB blocker", "CHEMICAL", 26, 37], ["ACE-I", "GENE_OR_GENE_PRODUCT", 16, 21], ["ARB blocker", "SIMPLE_CHEMICAL", 26, 37], ["COVID-19", "ORGANISM", 54, 62], ["patient", "ORGANISM", 63, 70], ["patient", "ORGANISM", 84, 91], ["type II alveolar cells", "CELL", 155, 177], ["type II alveolar cells", "CELL_TYPE", 155, 177], ["patient", "SPECIES", 63, 70], ["patient", "SPECIES", 84, 91], ["an ACE-I", "TREATMENT", 13, 21], ["ARB blocker prescription", "TREATMENT", 26, 50], ["additional virus entrance", "PROBLEM", 110, 135], ["type II alveolar cells", "PROBLEM", 155, 177], ["virus", "OBSERVATION", 121, 126], ["type II", "OBSERVATION_MODIFIER", 155, 162], ["alveolar cells", "OBSERVATION", 163, 177]]]], "PMC7503047": [["This study period corresponds with the local rise of the COVID-19 pandemic.", [["This study", "TEST", 0, 10], ["the COVID", "TEST", 53, 62], ["pandemic", "PROBLEM", 66, 74]]], ["ED 1 is a level 2 trauma center with an annual census of 25 000 patients, ED 2 is a level 2 trauma center with an annual census of 35 000 patients, and ED 3 is a level 3 trauma center with an annual census of 25 000 patients.", [["trauma", "DISEASE", 18, 24], ["trauma", "DISEASE", 92, 98], ["trauma", "DISEASE", 170, 176], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 216, 224]]], ["The combined adherence area of the 3 hospitals comprises 760 000 individuals.", [["combined", "OBSERVATION_MODIFIER", 4, 12], ["adherence", "OBSERVATION_MODIFIER", 13, 22], ["area", "OBSERVATION_MODIFIER", 23, 27]]], ["The hospitals are situated in regions with the highest prevalence of COVID-19 in the Netherlands, with COVID-19 admission rates (ARs) ranging from 90 to 330 per 100 000 inhabitants.4 Before and immediately upon arrival, patients were screened for possible COVID-19 in all 3 EDs, based on their symptoms, known COVID-19 contacts, and travel history.", [["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["COVID", "TEST", 69, 74], ["COVID", "TEST", 103, 108], ["COVID", "TEST", 256, 261], ["their symptoms", "PROBLEM", 288, 302]]], ["ED visits were subsequently labeled as COVID (defined as possible or suspected COVID-19) or non-COVID-related.", [["COVID", "TEST", 79, 84]]], ["We retrieved these data, as well as whether or not patients were admitted to the hospital.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["ARs were compared using chi-square tests, and the percentage of reduction in ED visits was assessed descriptively.", [["chi-square tests", "TEST", 24, 40], ["reduction", "OBSERVATION_MODIFIER", 64, 73]]], ["The study was approved by the medical ethical committee of Zuyderland Medical Center, Heerlen, the Netherlands (METCZ20200081).RESULTSFrom February 15 to April 16, 2020, 10 347 people visited 1 of the 3 EDs.", [["people", "ORGANISM", 177, 183], ["people", "SPECIES", 177, 183], ["The study", "TEST", 0, 9]]], ["The combined AR was 52%.", [["AR", "PROTEIN", 13, 15], ["The combined AR", "TEST", 0, 15]]], ["Of all ED visits, 2497 (AR 67%) were COVID-related and 7814 (AR 48%) non-COVID-related (Table 1).", [["AR", "TEST", 24, 26], ["COVID", "TEST", 37, 42], ["AR", "TEST", 61, 63]]], ["During the corresponding 60-day period in 2019, the total number of ED attendances was 12 626 (AR 50%).", [["AR", "TEST", 95, 97]]], ["The daily ED volume in 2020 was 18% lower than during the reference period (Figures 1\u20134).RESULTS", [["The daily ED volume", "TEST", 0, 19]]]]}